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Abstract
Proteoglycans (PGs) have important functions in a variety of tissues;
little is known, however, about PG expression and function in the nervous
system. This thesis assesses possible functions of PGs in the nervous
system by examining the neural expression of individual PG core proteins
(glypican, cerebroglycan, and decorin). Glypican mRNA and protein
expression was demonstrated in the nervous system. In situ hybridization
experiments showed that the expression of glypican in the nervous system
is regulated during development, and is expressed in a different pattern
than is the glypican homolog cerebroglycan. Immunohistochemistry
demonstrated that both glypican and cerebroglycan are expressed on
axons, and that cerebroglycan is polarized to axons in neurons of the
dentate gyrus. The pattern of glypican expression during development
suggests that it is involved in specific functions in the nervous system;
furthermore, the differences in expression between glypican and
cerebroglycan suggest different roles for the two core proteins in the
nervous system.
The expression and binding properties of the chondroitin sulfate PG
decorin were also studied. Decorin was shown to be expressed in the floor
plate of the developing mouse spinal cord, and was shown to bind netrin-1,
a floor-plate derived chemotropic factor for axon growth; the decorin core
protein was suggested to be involved in this interaction. The affinity of
netrin-1 for heparin was similar to that of netrin-1 for decorin. These data
indicate that decorin, and some heparan sulfate PGS, may interact with
netrin-1 in the developing spinal cord. The expression of decorin in the
floor plate at a time when netrin-1 may be promoting axon growth
suggests that decorin may play a role in nervous system development.
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Title: Associate Professor of Biology and Brain and Cognitive Sciences
Dedication
This thesis is dedicated to the memory of Joshua Lapin
Acknowledgments
This work would not have been possible without the support
and guidance of my thesis advisor, Arthur Lander. I have learned a
great deal from working with Arthur, and have enjoyed the
excitement and enthusiasm he brings to science.
I would also like to thank the other members of my thesis
committee, Frank Solomon, Bob Rosenberg, James San Antonio, and
Tyler Jacks, for their helpful suggestions and comments. Ralph
Sanderson, Renato Iozzo, Marc Tessier-Lavigne, Michael Galko, and
Brigid Hogan have collaborated with me on various aspects of this
work, and have been generous with their materials and their time.
In addition, I would like to thank Ann Graybiel, Sonal Jhaveri, and
Mriganka Sur for helpful advice on anatomy, Clive Wilson, Jerry
Yin, John J. Schwartz, and Nicholas Shworak, for advice on molecular
biology and biochemistry, and Rosario Moratalla, whose advice and
help on in situ hybridization has been invaluable.
I would like to acknowledge the past and present members of
the Lander lab, including Rachel Kindt, Lisa Plantefaber, Daniel
Emerling, and John Fesenko, and also Courtney Hunter, Gary
Gruberth, and Todd Grinnell, all of whom supplied excellent
assistance. I would particularly like to thank the "PG people": Chris
Stipp has worked in parallel with me during many of the
experiments done in this thesis, and I have enjoyed his camaraderie.
Mary Herndon has been a font of information about biochemistry,
and I greatly appreciate the time she has taken explaining things.
In addition, she has provided a really well-organized card file. Jon
Ivins and Scott Saunders have also given me much help and advice.
Above all, I would like to thank my baymate Asli Kumbasar; lab
would not have been the same without her.
I would like to thank my family, and in particular my parents,
Kenneth and Louise, for their enthusiasm and encouragement
throughout my education, and for their patience and support during
my years at MIT.
Finally, I wish to thank my partner, Kristen Fredricks, who has
made it all worthwhile.
Table of Contents
T itle p a g e ..................................................................................................................... 1
A b strac t.................................................... . . . ...... ..................................................... 2
D ed icatio n ........................................................................... .......................... 3
A cknow ledgm ents ........................................... ................................................... 4
T able of contents .................................................................... ..................... 5
List of figures and tables ...................................................... 7
Chapter 1: Proteoglycan expression and function in the nervous
sy stem .................................................................. .................................................. 9
Introduction........................... ............................. 10
Proteoglycan structure................................................................. 13
Expression of proteoglycan core proteins in the nervous
sy stem .......................... ........................................................................... 2 6
Functions of proteoglycans in developmental processes.........4 3
C onclusion ............................................................................................ 5 2
Chapter 2: Neuronal expression of glypican, a cell surface
glycosylphosphatidylinositol-linked heparan sulfate proteo-
glycan, in the adult rat nervous system................................. ........ 54
Introduction.... ....................................................................................... 5 5
Materials and Methods ..................................... ............. 57
R e su lts ............................................................................................................ 6 3
D iscussion............................................................................................... 8 0
Acknowledgments........................................................................... 86
Chapter 3: Determination of glypican expression and the
localization of glypican and cerebroglycan protein during
developm ent........................... ................................................................... 8 7
Introduction..... ...................................................................................... 8  8
Materials and Methods .................................................. 91
R e su lts ............................................................................................... .. . . 9 3
D iscussion............................................................................................. ....... 13 2
Acknowledgments......................................... ........................ 140
Chapter 4: Decorin in the developing nervous system: floor
plate expression and netrin-binding properties...................................1 4 1
Introduction.... ..................................................................................... 1 4 2
Materials and Methods ........................................ .............................. 147
R e su lts ............................................................ . . ...................................... 1 5 3
D iscussion.............................................................................................. 7 1
Chapter 5: The functions of proteoglycan core proteins in the
development of the nervous system .......................................... ...... 7 7
Introduction................................................................................... 178
Multiple PG core proteins as the basis for diverse
P G functions................................................................................... . .... 1 7 8
Functional implications of the restricted expression
o f P G s ..................................................................................................... . 1 8 0
Interactions of PG cores with other proteins ........................... 1 81
C o n c lu sio n ................................................................................................... 1 8 3
Appendix 1: Expression of glypican in myeloma cells leads to
loss of heparan sulfate synthesis on PG core proteins.............. 1 84
Introduction........................................................... ................................. 1 85
Materials and Methods ........................................ ........................... 187
R e su lts .......................................................................................................... 1 8 9
D iscussion .................................................................................................... 2 0 6
R eferences .......................................................................................................... 2 0 8
List of Figures and Tables
Chapter 1: Proteoglycan expression and function in the nervous
system.
Table 1. Some glycosaminoglycan-binding proteins of the
nervous system ..................................................................................................... 1 1
Figure 1. Glycosaminglycan structure....................................... 15
Figure 2. Protein binding sequences in glycosaminoglycans ............... 20
Table 2. PG core protein families ....................................... .................... 23
Chapter 2: Neuronal expression of glypican, a cell surface
glycosylphosphatidylinositol-linked heparan sulfate proteoglycan,
in the adult rat nervous system.
Table 1. Sequence of tryptic peptides of purified M12
compared with human glypican. ...................................... .......... 64
Figure 1. Detection of glypican message in rat brain, PC12 cells,
and fibroblasts....................................................................................................... 6 6
Figure 2. Comparison of rat and human glypican predicted
protein sequences. ..................................................................................... 6 8
Figure 3. Antibodies raised against glypican fusion protein
recognize adult rat brain HSPG M12.......................................... ......... 70
Figure 4. In situ hybridization of adult rat brain with rat
glyp ican . ................................................................................................................... 7 3
Figure 5. Neuronal expression of glypican................. .............. 7 6
Figure 6. Glypican expression in the cerebral cortex ........................... 7 9
Table 2. Relative levels of glypican hybridization in the adult
rat nervous system................................. 8..........................8 3
Chapter 3: Determination of glypican expression and
the localization of glypican and cerebroglycan protein during
development.
Figure 1. Glypican expression in E14 rat ..................................... . 95
Figure 2. Glypican expression in the ventricular zone of E14 rat
telencephalon. .................................................... 9 7
Figure 3. Glypican expression in the E18-P7 rat nervous system..... 99
Figure 4. Expression of glypican in developing bone ........................ 1....02
Figure 5. High magnification view of epiphyseal plate .................... 1.... 05
Figure 6. Expression of glypican in hair follicles and bone
m arrow ................................................................................................... . . 10 7
Figure 7. Western blot of PO rat brain membranes ............................ 11 0
Figure 8. Western blot of adult rat brain soluble fraction................... 11 3
Figure 9. Glypican and cerebroglycan protein in the E14 rat
telencep halon ............................................................................................. ........ 1 1 5
Figure 10. Glypican protein in the adult rat hippocampus ................ 117
Figure 11. Glypican protein in the adult rat cerebellum ..................... 1 20
Figure 12. Glypican protein in the adult rat forebrain............122
Figure 13. Glypican protein in the developing mouse nervous
sy stem ................................................................................................. . ....... 1 2 5
Figure 14. Localization of cerebroglycan on nerve fibers ................ 1 28
Figure 15. Axonal polarization of cerebroglycan..................................1 3 1
Chapter 4: Decorin in the developing nervous system:
floor plate expression and netrin-binding properties.
Figure 1. The role of the floor plate in the growth of spinal
com m issural axons...................................... ........................................ .. .... 14 4
Figure 2. Affinity coelectrophoresis........................ ................................... 1 5 2
Figure 3. Floor plate expression of decofin................................ ...... 5 5
Figure 4. BMP-6 expression in the developing spinal cord. ....... 7.....157
Figure 5. Western blot of r-netrin ...................................... 160
Figure 6. Affinity chromatography of r-netrin .................................... 1.... 62
Figure 7. ACE of r-netrin..................................................... ............................ 1 65
Figure 8. ACE of B-eliminated decorin ..................................................... 167
Figure 9. Measurement of Kd for decorin and GAGs .......................... 1 69
Figure 10. Interactions of decorin with proteins expressed
in the floor plate ................................................................................................. 74
Appendix 1: Expression of glypican in myeloma cells
leads to loss of heparan sulfate synthesis on PG core proteins.
Figure 1. Analysis of PGs from P3inf cells. ................................................ 1 9 1
Figure 2. FACS analysis of clones derived from P3inf cells............1 93
Figure 3. Analysis of PGs from F6 cells ..................................... . 195
Figure 4. Western blots of C3 and F6 extracts with 343-1 ........ 198
Figure 5. Two glypican isoforms are produced in P3 cells ......... 200
Figure 6. Effects of PIPLC on glypican in C3 cells ............... 203
Figure 7. Staining of F6 cells with 343-1 ................................................. 205
Chapter 1: Proteoglycan expression and function in the
nervous system.
1. Introduction.
During brain development, cells must respond to a wide range
of environmental cues in order to proliferate, differentiate, migrate
to correct locales in the nervous system, and extend axons to
appropriate targets, often over long distances. In vivo and in vitro
studies have shown these processes to be dependent on a number of
proteins.
The proteins underlying these processes are diverse, and fall
into several classes. These classes include extracellular matrix
molecules, growth factors, cell adhesion molecules, and proteases
and their inhibitors. Proteins within each of these classes interact
with distinct receptors: extracellular matrix molecules interact with
integrins, growth factors with receptor tyrosine kinases, cell
adhesion molecules with other cell adhesion molecules, and
proteases with protease inhibitors. Nevertheless, many of these
proteins possess a common property: they can bind to linear
polysaccharide polymers known as glycosaminoglycans (GAGs), and,
most frequently, to a type of GAG known as heparin or heparan
sulfate (Table 1) (for a review of heparin- or GAG-binding proteins,
see Jackson et al., 1991; Lander, 1994). For this reason,
proteoglycans (PGs), covalent complexes of protein cores and GAGs,
have the potential to participate in any process that involves one of
these molecules, and hence, in development of the brain.
PGs have in fact been shown to have a range of functions (for
review, see Lander, 1993). PGs can mediate cellular responses to
growth factors and other proteins by acting as coreceptors. In other
words, they can act as proteins whose binding to ligand is important
in the interaction of that ligand with distinct high affinity receptors
in order to produce a physiological response (Bernfield et al., 1992).
PGs can be thought of as coreceptors for ligands such as fibroblast
growth factors (FGFs); they can also act as coreceptors in reactions of
proteases with protease inhibitors, or in the homophilic binding of
NCAM. As components of cell surfaces, PGs can also directly mediate
cell adhesion, cell migration, and neurite outgrowth. As components
of extracellular matrix, they can participate in matrix organization,
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Extracellular matrix molecules
netrin- 1/netrin-2
laminin
fibronectin
thrombospondin
tenascin
vitronectin
p 3 0
amyloid B-protein
HB-GAM
Cell adhesion molecules
NCAM
L1
myelin-associated glycoprotein
Growth factors
FGF 1-9
PDGF
TGF-B
heregulins
Proteases and orotease inhibitors
protease nexin I
thrombin
tissue plasminogen activator
urokinase plasminogen activator
Proteins involved in lipoprotein metabolism
Apo-E
Table 1. Some glycosaminoglycan-binding proteins of the nervous
system.
and also provide cues for cell adhesion, cell migration, and neurite
outgrowth.
It is thus apparent that PGs have the potential to play
important roles in nervous system development. Many PGs have
been cloned, and studies of the expression of individual PGs are now
possible. It is apparent that most if not all of the major families of
PGs are represented in the brain. In fact, some PGs exhibit
remarkable spatial and temporal patterns of expression, suggesting
specific roles in nervous system development and function. Further
elucidation of the expression of individual PGs in the brain, and the
relationship of that expression to other PGs and GAG-binding
proteins, is necessary in order to deduce the functional roles of PGs.
Furthermore, as many of the functions of PGs can be related to GAG
structure, it is also important to understand the way in which
individual neural PGs are processed, and, in addition, the ways in
which the nervous system regulates GAG structure. Functional
studies of PGs in in vitro assays have supported the idea that PGs
are important for nervous system development and function, and
further studies will be important for understanding their roles in
vivo.
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2. Proteoglycan structure.
PGs are proteins which possess covalently attached GAGs.
Structural variability exists both at the level of the GAG and at the
level of the protein core; the variability at both levels play a part in
the diverse functions that PGs can have in nervous system
development. In this section, I shall first review GAG structure and
the role of GAG structure in protein-GAG interactions; I shall then
discuss some general features of PG core proteins.
Glycosaminoglycan (GAG) structure. GAGs are linear
polysaccharide chains that are composed of repeating disaccharide
units. These disaccharide units consist of alternating amino sugars
and hexuronic acids (or, in the case of keratan sulfate, alternating
amino sugars and galactose residues). The polysaccharide,
consisting of unbranched repeats of these disaccharides, is attached
to the serine of a PG core protein by a xylose-galactose-galactose
adaptor (with the xylose, sometimes phosphorylated, attached to the
serine via an O-glycosidic bond). The exception to this is keratan
sulfate, which, as discussed below, can be linked to proteins via N-
or O-linked sugars. Once formed, the GAG is chemically modified by
a series of deacetylations, N- and O-sulfations, and epimerizations.
Depending on the identity of the monosaccharides of the
disaccharide repeat, a GAG is defined as a heparin/heparan sulfate,
chondroitin sulfate/dermatan sulfate, keratan sulfate, or hyaluronic
acid (Fig. 1).
Heparin/heparan sulfate (HS) is defined as [D-glucuronic acid-
8(1--4)-D-N-acetylglucosamine-a((1- 4 )]n, and is usually composed
of 30-200 disaccharide units (for a review of heparin/heparan
sulfate structure, see Gallagher et al., 1992; Lindahl, 1987). Once
synthesized, HS chains can then be modified by N-deacetylation
followed by N-sulfation, O-sulfation, and epimerization of glucuronic
acid to iduronic acid. These modifications, however, are not evenly
distributed. N-sulfated hexosamines occur in clusters, so that there
13
Figure 1. Glycosaminoglycan structure. R = -H or -S03. R' = -Ac
(acetyl group) or -SO3 .
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Heparin/Heparan
Glucuronate N-acetylglucosamine Iduronate N-acetylglucosamine
Chondroitin Sulfate/Dermatan
Glucuronate N-acetylgalactosamine Iduronate N-acetylgalactosamine
Keratan Sulfate
Galactose N-acetylglucosamine Galactose N-acetylglucosamine
Hyaluronic Acid
Glucuronate N-acetylglucosamine
Sulfate
Sulfate
Glucuronate N-acetylglucosamine
are clusters of GlcNSO3 followed by stretches of GlcNAc 1. Both
epimerization and O-sulfation are associated with N-sulfation, so
both IdoA and IdoA(2S) are found in these clusters; GlcNAC(6S) is
also associated GlcNSO3. Hence, while there are potentially
thousands of sequences possible in HS based on the types of
modifications that can occur on monosaccharides, in reality the
clustering of these modifications results in constraints on sequences
present in HS.
Heparin is a highly sulfated version of HS synthesized by mast
cells. Unlike HS, GlcNS03 is predominant (composing over 80% of
hexosamines in the chain), and is present in clusters. Heparin is also
heavily O-sulfated, (containing at least one O-sulfate per
disaccharide) and has a higher percentage of di- and trisulfated
disaccharides than does HS. The high IdoA content of heparin
confers conformational flexibility on heparin, and may help explain
why more proteins bind to heparin than to other GAGs (Casu et al.,
1988).
Chondroitin sulfate/dermatan sulfate (CS/DS) is defined as [D-
glucuronic acid-B(1-- 3)-D-N-acetylgalactosamine-B( 1 -3)n.
Posttranslational modifications include 4- or 6-O-sulfation of N-
acetylgalactosamine, 2-O-sulfation of uronic acid, and epimerization
of the C-5 carbon of GlcA to form IdoA. DS is composed of the same
disaccharide as CS, but DS has a high iduronate content. DS is
defined empirically--a GAG is classified as DS if it can be degraded
by chondroitinase ABC (which cleaves at GlcA or IdoA) but not
chondroitinase AC (which cleaves at GlcA). CS can be degraded by
both enzymes. This high IdoA content of DS should make it a more
flexible polymer than CS (Casu et al., 1988). GAGs of this class may
also have a domain structure, as some work suggests that IdoA(2S)
and GalNAc(4S) occur in clusters (Maimone and Tollefson, 1990).
1Monosaccharides are abbreviated as follows: GlcA, glucuronic acid; IdoA,
iduronic acid; Gal, galactose; GalNAc, N-acetylgalactosamine; GalNSO3, N-
sulfated galactosamine; GlcNAc, N-acetylglucosamine; GIcNSO3, N-sulfated
glucosamine. O-sulfations are designated in parentheses. For instance,
iduronic acid sulfated on C-2 is abbreviated as IdoA(2S).
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Keratan sulfate (KS) is defined as [D-galactose-13(1--3)-D-N-
acetylgalactosamine-B(1--3)]n (for review, see Hounsell, 1989;
Stuhlsatz et al., 1989). KS is synthesized on preexisting N-or O-
linked sugars, and thus, unlike HS or CS which are only attached to
serine residues, KS can be potentially be attached to any amino acid
glycosylated with complex-type carbohydrates. KS is only modified
by O-sulfation, which can occur only the C-6 of Gal and GalNAc.
Furthermore, O-sulfation occurs in domains, so that, in order from
the linkage region, a nonsulphated stretch of disaccharides is found,
followed by a monosulfated stretch and then by a disulfated stretch.
These domains vary in length depending on the source of KS.
Hyaluronic acid (HA) is defined as [D-glucuronic acid-1(1--,3)-
D-N-acetylglucosamine-B(1--,4)]n. It is found unattached to protein,
and is unmodified after synthesis. Biophysical studies suggest that
hyaluronic acid is a relatively rigid structure, as a result of
intramolecular hydrogen bonding that can occur because hyaluronic
acid is unmodified (Scott, 1989).
GAG structure and GAG-protein interactions. Traditionally, it
has been assumed that most protein-GAG interactions have been
relatively nonselective. Affinity was thought to be the result of
nonspecific electrostatic interactions between highly negatively
charged GAGs and clusters of basic amino acids in GAG binding
proteins. While this may be true for certain proteins (see, for
example, Olson et al., 1991), much recent evidence makes clear that
most GAG-binding proteins bind different and specific carbohydrate
sequences in GAGs. Consequently, the modifications of the basic
polymeric structure of GAGs are crucial in determining which
protein-binding sequences will be present in particular GAGs, and
hence the functional abilities of that GAG.
Several lines of evidence support the idea that proteins bind
to specific sequences within GAGs. Within a sample of HS derived
from a given source, it is often possible to find a fraction of chains
that bind with high affinity to a given GAG-binding protein and a
fraction with low or no affinity. This is usually accomplished by
fractionating the GAG on the basis of affinity. Consequently,
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separate fractions of heparin have been isolated that have high
affinity for proteins such as antithrombin III, collagen, laminin, and
fibronectin (Lam et al., 1976; Lee and Lander, 1991; San Antonio et
al., 1993). Furthermore, heparin fractions which bind one protein
selectively do not necessarily bind a different protein selectively,
implying that proteins recognize distinct structural features of
heparin (San Antonio et al., 1993). For many proteins, high affinity
binding does not depend on chain length or levels of sulfation (as an
indicator of charge) (San Antonio, et al., 1993)2. For example, HS
with low affinity for collagen is sulfated to a similar extent as HS
with high affinity for collagen (Sanderson et al., 1994). This low
affinity HS, however, contains less N-sulfate and 2-O-sulfate and
more 6-O-sulfate than high affinity HS. Thus, collagen may
recognize a specific structural feature in HS that involves N-sulfate
and 2-0-sulfate.
The binding sites of GAG-derived oligosaccharides with high
affinity for certain GAG-binding proteins have been sequenced, and
in some cases the contributions of certain modifications to high
affinity binding have been determined. Antithrombin III (AT)
binds to a specific pentasaccharide sequence present in this
subfraction of heparin chains. This pentasaccharide consists of the
sequence GlcNAc(6S)-GlcA-GlcNSO3(3S6S)-IdoA(2S)-GlcNSO3(6S)
(Fig. 2A) (Atha et al., 1984; Lindahl et al., 1984; Atha et al., 1985).
While some structural variability within this sequence can be
tolerated, it has been shown that certain modifications are crucial
for high affinity AT binding. These include the 6-O-sulfate of
residue 1 and the 3-O-sulfate of residue 3. The 3-O-sulfate of
residue 3 is a rare modification in heparin, and accounts for the
small fraction of chains that possess the antithrombin-binding
pentasaccharide sequence. Removal of the 3-O-sulfate drastically
reduces affinity for antithrombin.
Recently, binding sequences in heparin for FGF-1 (aFGF) and
FGF-2 (bFGF) have been proposed (Fig. 2B,C). Fragments of HS that
2 High affinity binding may correlate with these parameters, however, as
longer or more highly modified chains are more likely to possess certain
binding sequences.
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Figure 2. Protein binding sequences in glycosaminoglycans, A,
Binding sequence in HS for antithrombin III (Atha et al., 1984;
Lindahl et al., 1984; Atha et al., 1985). The modifications important
for binding are in boxes. B, The structure of an HS disaccharide
required for FGF-2 binding (Habuchi et al., 1992; Turnbull et al.,
1992). C, The structure of an HS disaccharide required for FGF-1
binding (Mach et al., 1993). D, The structure of a DS disaccharide
required for heparin cofactor II binding (Maimone and Tollefson,
1990). The structures illustrated in B-D are found in the context of
longer sequences of the minimum length necessary for binding.
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Antithrombin
B) FGF-2
CH-OH
OS03 NHSO3
C) FGF-1
D) Heparin Cofactor II
I .. -
bind with high affinity to FGF-2 have a high content of IdoA(2S)-
GlcNSO3 (Habuchi et al., 1992; Turnbull et al., 1992). Fragments with
weaker affinities had lower percentages of this disaccharide, even
though they had the same levels of O-sulfation. The minimum size
of the FGF-2 binding sequence seems to be 5 sugars (Maccarana et
al., 1993). Consistent with these data, de-6-O-sulfated heparin
bound FGF-2, while de-2-O-sulfated heparin did not (Guimond et al.,
1993). The minimum heparin sequence needed to bind FGF-1 is a
tetrasaccharide that contains with IdoA(2S)-GlcNSO3(6S) (Mach et
al., 1993). Unlike FGF-2, FGF-1 requires both 6-0- and 2-0- sulfate,
while FGF-4 requires neither (Guimond et al., 1993). Thus, there
seems to be distinct structural requirements within heparin for
binding to FGF-1 and FGF-2, as well as other members of the FGF
family.
GAG binding sequences for other proteins have been
characterized. For example, heparin cofactor II has been shown to
recognize a hexasaccharide in dermatan sulfate with the sequence
IdoA(2S)-GalNAc(4S) (Maimone and Tollefson, 1990) (Fig. 2D). High
affinity for collagen type I is associated with the presence of 4-0-
sulfate (Sanderson et al., 1994).
Thus, the fact that a protein can bind a GAG does not mean
that a protein will bind to that GAG with a high affinity. High
affinity binding will depend on the presence of a particular binding
site within that GAG, and the numbers of binding sites found within
that GAG. A cell may regulate the types and numbers of particular
binding sites within its GAGs by adjusting the levels of modification
(such as sulfation or epimerization) of those GAGs. As a result of
such regulation, the affinities of GAGs for particular GAG-binding
proteins can depend on the synthetic source of the GAG. For
example, HS isolated from epithelial cells has a higher affinity for
collagen type I than does HS isolated from myeloma cells, and even
different myeloma cells synthesize HS with different affinities for
collagen type I (Sanderson et al., 1994). There is also heterogeneity
in GAGs from a single source. Heparin, for instance, can be
fractionated on the basis of affinity, as described above (Lee and
Lander, 1991; San Antonio et al., 1993). Endothelial cells synthesize
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both anticoagulantly active and inactive HS; the HS with high
affinity for AT accounts for this activity (Marcum and Rosenberg,
1989).
The existence of heterogeneous populations of GAGs in the
brain, which contains a multitude of cell types, is not unexpected.
Such heterogeneity has been borne out by biochemical fractionation
of HS from brain (Horner, 1991). In addition, immunostaining of
nervous system tissues with antibodies that recognize specific
structures on GAGs indicate that GAGs are nonuniformly distributed
in the brain (Fujita et al., 1989; Watanabe et al., 1989; David et al.,
1992b; Wang and Denburg, 1992; Fuxe et al., 1994; McAdams and
McLoon, 1995). GAG structure may be used to control the function
of proteins, such as FGFs, protease inhibitors, and extracellular
matrix molecules, in the brain. It may also be that the nervous
system uses GAG modification to allow cells in heterogeneous
populations to respond differently to particular signals, as different
cells in such a population may produce different GAGs which could
have different binding specificities.
Core protein structure. The core proteins to which GAGs are
attached are encoded by a variety of genes (Table 2). It is apparent
that there is no obvious domain or amino acid sequence that
specifies a PG, beyond those sequence determinants that direct GAG
attachment. I will discuss what is known about signals in PG core
proteins for attachment of HS and CS chains. All PGs (with the
exception of KSPGs) must contain these signals. The structure of
individual core proteins shall be discussed later in relation to PG
core protein families and their expression in the nervous system.
GAG Acceptor Sites. The determinants in a proteoglycan core
protein that initiate GAG synthesis have only been partially defined.
GAGs are attached on serines that are followed by adjacent glycines;
these sequences often occur in clusters. Nevertheless, other signals
must be present, as many proteins that possess such sequences do
not have attached GAGs, and not even all the serines in a PG core
protein that are found in such sequences are glycanated. The
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core protein size (kD) GAG
obs. r2red.
Aggregating PGs
Aggrecan 180-370 221 CS/KS
Versican 290-400 265 CS
Neurocan 220-245 136 CS
Brevican 145 99.5 CS
Cat-301 580 - CS (KS)
pgT1 300 - CS
DSD-1 350-400 - CS/DS
S103L 370 - CS (KS)
Small matrix PGs
Decorin 38 36 CS/DS
Biglycan 45 38 CS/DS
Lumican 51 39 KS
Fibromodulin 59 42 KS
Basement membrane PGs
Perlecan 400-700 396 HS
Agrin 250 - HS
6C4/1B11 180 HS
Synaptic vesicle PGs
SV2
Serglycin
Transmembrane PGs
100/250 83 KS
10-27 17-19 HS/CS
Phosphacan 300-400 173/185 CS (KS)
NG2 300 250 CS
Syndecan-1 69 33 HS/CS
Syndecan-2 49 23 HS
Syndecan-3 120 35 HS/CS
Syndecan-4 30-35 22 HS/CS
Drosophila syndecan 90 39 HS
GPI-linked PGs
Glypican 64 62 HS
Cerebroglycan 57 59 HS
OCI-5 - 69
K-glypican
Table 2. PG core protein families. The observed Mr's (by
SDS/PAGE), the calculated Mr's (based on primary sequence), and
the type of GAG substitution are listed. Dashes indicate when this
information has not been determined or reported.
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consensus sequence ser-gly-xaa-gly with nearby acidic residues can
act as an acceptor site, at least for chondroitin sulfate (Bourdon et
al., 1987), although other sequences can be glycanated as well.
Additionally, less closely situated acidic clusters have been shown to
affect heparan sulfate synthesis in sequences derived from the PG
betaglycan (Zhang and Esko, 1994). Tertiary structure is likely to
important as well. Modeling of the GAG acceptor region of decorin
shows that the ser-gly sequence may be part of a B-turn; amino
acids that affect acceptor efficiency in peptides have little effect in
the context of the entire protein (Mann et al., 1990).
It is apparent that, in addition to containing specific signals to
specify GAG attachment, there must also be elements that specify
the type of GAG attached, as some PGs exist as purely HS or CSPGs,
even though they are synthesized from the same source. It has
been reported that syndecan-1, a hybrid PG possessing both HS and
CS, contains sites that are preferentially glycanated with HS and CS
in the N-terminal domain of the protein, while the C-terminal
domain seems to exclusively contain CS (Kokenyesi and Bernfield,
1994). However, mutational analysis of syndecan-4 indicates that
all potential GAG attachment sites can accept either heparan sulfate
or chondroitin sulfate (Shworak et al., 1994a; Shworak et al., 1994b).
This discrepancy may be the result of differences in sequence
between the two core proteins. Furthermore, mutagenesis of one
GAG attachment site could change the preferences of other GAG
attachment sites. It also may be that overexpression of the
syndecan-4 protein alters the preferences of GAG attachment sites;
overexpression is known to affect other aspects of GAG synthesis,
such as the pattern of covalent modifications' on HS (Shworak et al.,
1994b).
Some studies suggest that nearby hydrophobic and possibly
aromatic amino acids play a role in heparan sulfate specificity. B-D-
xylosides, xylose analogs which can act as GAG acceptors, usually
prime CS but not HS synthesis. Xylosides can act as heparan sulfate
acceptors, however, if they have certain hydrophobic aglycone
structures attached (Fritz et al., 1994; Lugemwa and Esko, 1991).
Consistent with this, tryptophan-537 of betaglycan has been shown
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to be important for heparan sulfate synthesis at an adjacent
attachment site; mutation of this residue in a fragment of betaglycan
abolishes heparan sulfate attachment to serine-535 (Zhang and Esko,
1994). Interestingly, a phenylalanine sits next to the N-terminal
ser-gly cluster in syndecan-1 that is able to act as an acceptor for HS
(Kokenyesi and Bernfield, 1994). These studies have lead to the
suggestion that the GlcNAc transferase that initiates HS synthesis
may have a pocket that confers a preference for hydrophobic
regions. The GalNAc transferase that initiates CS synthesis may not
have this pocket, and thus not require hydrophobic determinants.
It should be noted however, that many HSPGs do not possess
obvious hydrophobic determinants adjacent to their potential GAG
attachment sites (e.g., glypican).
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3. Expression of proteoglycan core proteins in the nervous
system.
With the exception of their ability to bear GAGs, it is obvious
that no feature unites PG core proteins into a single group (Table 2).
PGs can exist extracellularly as matrix-associated, peripheral
membrane, or integral membrane proteins, and can also be found
intracellularly in vesicles. Some PGs bear HS, CS, or KS, and some
PGs exist as hybrids, able to bear more than one type of GAG.
Additionally, some core proteins are known as "part-time" PGs, as
they are only found to be glycanated in some instances.
This diversity is preserved in the nervous system, where it
has been found that at least 25 distinct PG core proteins are
expressed, often in a developmentally regulated fashion (Herndon
and Lander, 1990). Here, I discuss the some of the major PGs found
in the nervous system, and address their structures, patterns of
expression, and possible functions.
Large Aggregating CS/KSPGs. This class of PGs are referred to
as large, aggregating PGs as they were initially isolated from
cartilage and bone as aggregates of PG, HA, and link protein3. They
are modified with CS and, in some cases, KS. These aggregates are
thought to provide structural support; the large size and extensive
glycanation of the PG, complexed to the negatively charged
hyaluronate, can provide hydration, resist compressional forces, and
allow diffusion of ions. Studies of the expression of these PGs in the
brain, however, suggest a broader role.
To date, four distinct core proteins of this class have been
cloned. These are aggrecan, versican, neurocan, and brevican (Doege
et al., 1987; Zimmermann and Ruoslahti, 1989; Doege et al., 1991;
Rauch et al., 1992; Yamada et al., 1994) 4 . Sequencing reveals a
general, multidomain structure that is conserved between all family
3 Link protein is a HA-binding protein that stabilizes the interaction between
aggregating PGs and HA.
4 The core for the chicken aggregating PG PG-M found in condensing limb
bud mesenchyme has been cloned and is likely to be the chicken homolog of
versican (Shinomura et al., 1993). Like versican, it exhibits alternative
splicing of its GAG attachment domain.
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members, although there is much variation between individual
species. The N-terminal sequence consists of a globular domain that
contains an IgG-like domain and a HA-binding domain that has
homology to link protein. As expected, this region can bind HA.
Aggrecan contains two sets of link protein-related domains, while
other members contain a single set. This domain is followed by a
GAG-attachment domain containing multiple potential attachment
sites for CS and, in the case of aggrecan, KS. The C-terminal domain
contains an EGF-like repeat, a lectin-like domain, and a complement
regulatory protein-like domain (this C-terminal region as a whole is
referred to as a LEC-CAM domain). Some of these C-terminal
features are alternatively spliced in aggrecan (Doege et al., 1991).
Variability exists between members of this family, especially
in the GAG attachment domain. In aggrecan, there are predicted to
be roughly 30 KS attachment sites and over 100 CS attachment sites
(Doege et al., 1987; Doege et al., 1991). Versican contains 12-15
potential CS attachment sites (Zimmermann and Ruoslahti, 1989),
neurocan has a much shorter GAG attachment domain and contains
only 7 potential CS attachment sites (Rauch et al., 1992), while
brevican, which possesses the shortest GAG attachment site, contains
only 3 potential CS attachment sites (Yamada et al., 1994). In
addition, the GAG attachment domain of versican is alternatively
spliced (Dours-Zimmermann and Zimmermann, 1994). The
variability in the GAG attachment domain between family members,
as well as that introduced by alternative splicing, suggests that the
degree of glycanation is important for the function of these PGs.
There may also be proteolytic processing of the core proteins;
a 60 kD protein from adult brain is likely to be an N-terminal
fragment of versican (Perides et al., 1991; Perides et al., 1989;
Perides et al., 1992), and C-terminal fragments of neurocan and
brevican have been isolated from brain (Oohira et al., 1994; Rauch et
al., 1992; Yamada et al., 1994).
The identification of many forms of these aggregating PGs in
the brain is further evidence that there is in fact a definable ECM in
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the nervous system 5. The forms of these PGs do not include just
those described above, but also shorter fragments of these PGs, PGs
which bear antigenic relationship to previously cloned PGs, and
seemingly novel PGs. Furthermore, the distinct patterns of
expression of these PGs suggests that members of this family may
be required for different roles in nervous system development and
function.
Several lines of evidence suggest that both aggrecan and
versican are expressed in the nervous system. A CSPG purified from
human brain under denaturing conditions behaves identically to
versican both immunologically and biochemically (Perides et al.,
1992). Glia of the central and peripheral nervous systems are
stained by an anti-versican monoclonal antibody. In addition, the
60 kD protein, glial-hyaluronate binding protein (GHAP), has also
been purified from brain, and amino acid sequence indicates that it
is likely to be an N-terminal fragment of versican (Perides et al.,
1991; Perides et al., 1989). Studies in developing chick brain found
two PGs, one seemingly related to aggrecan (S103L) (Krueger et al.,
1992). This PG is aggrecan-like based on the possession of a
hyaluronic acid binding region, and its expression in cartilage as
well as in brain. S103L from brain, however, does not possess KS
chains, whereas S103L from cartilage, like aggrecan, does. Its
expression is regulated during development, and S103L not present
in the adult brain.
Neurocan was purified and cloned from brain based on its
crossreactivity with the monoclonal antibody 1D1 (Rauch et al.,
1991; Rauch et al., 1992). Like other members of this family,
neurocan aggregates with HA. Neurocan is reported to be expressed
by neurons (Margolis and Margolis, 1994). Antibodies stain the
cerebellum (Rauch et al., 1991) and the developing cerebral cortex,
where neurocan is found in the subplate (Miller et al., 1992; Oohira
et al., 1994). At later stages, neurocan staining demarcates the
5It has been previously suggested that there is little or no organized matrix in
the brain. More recent evidence suggests, however, that both extracellular
matrix molecules and some organized matrix are found in the central nervous
system (for discussion, see Sanes [1989]).
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boundaries of barrel fields in layer IV of the cerebral cortex (but is
not found in the barrel fields themselves until later) (Oohira et al.,
1994). Interestingly, neurocan is reported to interact with tenascin
(Grumet et al., 1994), which too is found in the borders of barrel
fields. Tenascin expression also overlaps with neurocan in the
cerebellum (Grumet et al., 1994), as does the expression of the cell
adhesion molecules N-CAM and Ng-CAM. Neurocan inhibits neurite
outgrowth and cell adhesion on these molecules in vitro (Grumet et
al., 1993; Friedlander et al., 1994).
Another CSPG, brevican, has recently been cloned from bovine
brain, and is similar to other members of the aggrecan family
(Yamada et al., 1994). Interestingly, both glycanated and
nonglycanated core proteins were identified in brain extracts,
indicating that brevican can exist as a "part-time" PG (although
there is no evidence that nonglycanated brevican is extracellular).
Brevican is expressed in brain, and by glia but not neurons in
culture.
The Cat-301 CSPG, present in the adult brain, is thought to be
related to aggrecan (Fryer et al., 1992), It is found in cartilage,
associates with HA, is substituted with both KS and CS, and exhibits
a high buoyant density in CsCl buoyant density gradient
centrifugation. In brain, however, Cat-301 exists in a somewhat
different form than in cartilage, as brain Cat-301 exhibits a lower
buoyant density than expected and contains no KS. As the chick PG
S103L, which is also thought to be related to aggrecan, does not
possess KS in brain (Krueger et al., 1992), it may be that in general
aggrecan(s) in the brain do not contain KS.
The expression of Cat-301 in the neri ,us system is
remarkably restricted (Hockfield et al., 1990). Appearing late in
development and present in the adult, Cat-301 is associated with
subsets of neurons. These subsets include spinal motoneurons and
neurons (both in the thalamus and visual cortex) involved in the
pathway of the visual system associated with processing motion. In
addition, its expression is activity-dependent; ablation of neuronal
activity during critical periods in development prevents Cat-301
expression (Hockfield et al., 1990; Kalb and Hockfield, 1990). It may
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be that, as a structural component, Cat-301 is involved in stabilizing
mature synaptic structures. The association of this antigen with
specific neural circuits, however, suggests that it may play more
than simply a structural role, and that there is some specificity in
the ECM surrounding synapses.
Another CSPG with similar biochemical properties to aggrecan
and its family members is pgTI (Iwata and Carlson, 1993; Iwata et
al., 1993). pgT1 was purified from rat based on its crossreactivity
with an antibody raised against PG1000, a large PG of elasmobranch
electric organ (Carlson et al., 1986; Carlson and Wight, 1987; Iwata
and Carlson, 1991). Like aggrecan, pgT1 forms aggregates with HA,
and these aggregates have morphology to aggrecan-HA aggregates.
However, the relationship between aggrecan or versican to pgTl is
unclear, as antibodies raised to a 15 amino acid epitope conserved in
aggrecan and versican do not recognize pgT1. pgTI is widely
expressed in the nervous system--both white and gray matter are
stained using the TI antibody.
A unique CS/DS hybrid epitope has been reported in mouse
brain, and has been used to isolate a single core protein, designated
the DSD-1 PG (Faissner et al., 1994). The biochemical data, in
particular the size, presence of CS chains, and extractability with
saline, suggest that the DSD-1 core may belong to the aggrecan
family. This core is expressed by glia in vitro (Faissner et al., 1994),
and immunohistochemistry suggests that it is present in the
boundaries of barrel fields in the somatosensory cortex (Steindler et
al., 1995).
Small, interstitial proteoglycans. This family of PGs include
two CS/DSPGs, decorin (Day et al., 1987; Krusius and Ruoslahti, 1986;
Li et al., 1992; Scholzen et al., 1994) and biglycan (Fisher et al.,
1989; Neame et al., 1989), and two KSPGs, fibromodulin (Oldberg et
al., 1989) and lumican (Blochberger et al., 1992a). Decorin, biglycan,
and fibromodulin are all abundant in tissues containing collagen,
such as tendon, bone, and/or cartilage, while lumican has been
characterized as "the" KSPG of cornea, although decorin is reported
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to contain KS chains in the adult chicken cornea (Blochberger et al.,
1992b).
The PGs of this family are relatively small, having core protein
sizes of 38-60 kD (see Table 2). Cloning and sequencing reveal that
members of this family have a common structure. The CS
attachment sites of decorin and biglycan are in the first few N-
terminal amino acids--decorin has one (serine-4) and biglycan has
two (serine-5 and serine-11). The N-terminal domain also consists
of four cysteines participating in two intrachain disulfide bonds,
while the C-terminal domain contains two cysteines that participate
in an intrachain disulfide bond. The central domain consists of a
leucine-rich repeat of the consensus sequence L-X-X-L-X-L-X-X-N-
X-L/I; these repeats, which vary in number between family
members, comprise 60% or more of the amino acid sequences of
these PGs. Leucine-rich repeats are likely to mediate protein-
protein interactions (Blochberger et al., 1992b; Kobe and
Deisenhofer, 1994), and have been implicated in the binding of
decorin to a variety of molecules (Schmidt et al., 1991; Spiro et al.,
1994).
Decorin is typically expressed in regions containing collagen,
and in fact its name derives from the observation that in electron
micrographs this PG can be seen to "decorate" collagen fibrils. With
the exception of biglycan, PGs of this family bind to fibrillar
collagens. Decorin has a Kd of 16 nM and fibromodulin a Kd of 35
nM for types I and II collagen in solid-phase binding assays
(Hedbom and Heinegfird, 1989; Hedbom and Heinegard, 1993); this
interaction is mediated by the core protein and not the GAG chain.
The binding sites on collagen for these PGs are different (Scott and
Haigh, 1988; Hedbom and Heinegard, 1993). Decorin has been
localized to the d and e bands and fibromodulin to the a and c bands
in the D period of collagen fibrils from tendon and cornea (Hedlund
et al., 1994; Pringle and Dodd, 1990; Scott and Haigh, 1988). This
binding decrease the rate of collagen fibril formation and the size of
the fibrils formed, and is thus thought to allow the formation of
small, regular arrays of collagen fibrils (Hedbom and Heinegard,
1989; Vogel et al., 1984). This function also contributes to the
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transparency of the cornea, where decorin and lumican are
expressed. Decorin has also been reported to bind to type VI
collagen (Bidanset et al., 1992; Spiro et al., 1994). Some data
suggests that the disulfide-bonded globular regions affect
fibrillogenesis, while it is the leucine-rich repeat region that
mediates collagen binding (Spiro et al., 1994).
Decorin has also been reported to bind to fibronectin (Kd = 20
nM) (Lewandowska et al., 1987; Schmidt et al., 1991; Winnemdller
et al., 1991) and thrombospondin (Kd = 5 nM) (Winnemiller et al.,
1992) in solid phase assays. In both cases this binding is mediated
by the core protein and can inhibit in vitro cell attachment to those
molecules. Decorin can bind to TGF-3 via its core protein, and this
binding can inhibit TGF-B function in vitro (Yamaguchi et al., 1990;
Yamaguchi and Ruoslahti, 1988). Decorin can also bind to netrin-1
and may modulate its neurite-outgrowth activity (see Chapter 4 of
this thesis).
Very little is known about the expression of these PGs in the
nervous system. Given the widespread association of decorin and
other family members with collagen, one might expect not to find
them present in the brain (it is unclear to what extent collagen
fibrils are present in the nervous system; see footnote 5). Indeed,
no lumican message has been detected in the brain (Blochberger et
al., 1992a). However, decorin has been detected in the mouse, in the
floor plate of the developing spinal cord and in the region of the
pons in the adult (Scholzen, et al., 1994), and has been reported also
in the human brain (Voss et al., 1986). Decorin has also been
reported in association with amyloid plaques related to Alzheimer's
disease (Snow et al., 1992). In situ hybridization in the adult rat
nervous system suggests that decorin is expressed by Schwann cells
in the PNS, and by neurons in the CNS (Hanemann et al., 1993).
NG2. NG2 is a large, membrane-associated CSPG with a core protein
of about 300 kD (Stallcup et al., 1983). It is widespread and
developmentally regulated in the nervous system, where it is
associated with glial progenitor cells (Levine and Card, 1987; Levine
and Stallcup, 1987; Stallcup and Beasley, 1987). NG2 is up-
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regulated in response to brain injury (Levine, 1994), which may
represent a proliferation of glial precursors. NG2 is also expressed
in a variety of tissues outside the nervous system.
NG2 does not fall into any known class of PG, or any other
protein. It is a transmembrane protein, with a large extracellular
domain and a relatively small cytoplasmic domain (Nishiyama et al.,
1991). The extracellular domain consists of a GAG attachment
domain bounded by two cysteine-containing regions, some of which
are disulfide-bonded. The GAG attachment domain possesses nine
potential GAG attachment sites, but not all of them seem to be used.
Recently, the NG2 core protein has been shown to inhibit
neurite outgrowth by cerebellar granule cells on substrates
consisting of laminin or L1; furthermore, these neurites will avoid
regions of a substrate possessing NG2 (Dou and Levine, 1994). As
NG2 is expressed in the deep regions of the cerebellar molecular
layer during development, it has been suggested that one role of
NG2 in the developing cerebellum is to repel developing axons of
granule neurons, hence keeping them parallel (Dou and Levine,
1994). This inhibitory effect would also explain the inability of
axons to grow in damaged regions, as these would be regions with
increased NG2 expression (Levine, 1994).
RPTPfl/Phosphacan. One CSPG identified in brain by the use of
monoclonal antibodies (Rauch et al., 1991; Yamada et al., 1994) has
recently been cloned and sequenced. The cDNA of the 3F8 epitope
from rat brain (Maurel et al., 1994) and that of a CSPG recognized by
a polyclonal antiserum (Shitara et al., 1994) encode a sequence
identical to that of a brain-specific receptor-type protein tyrosine
phosphatase, RPTPB (Krueger and Saito, 1992; Levy et al., 1993).
RPTPB possesses an extracellular domain with homology to carbonic
anhydrase (although this domain is not thought to be enzymatically
active), a transmembrane domain, and two C-terminal phosphatase
domains. Three alternatively spliced transcripts of RPTPB exist in
rat--two are transmembrane and one seems to be extracellular. The
3F8 proteoglycan (designated phosphacan) appears to be an
extracellular, soluble, alternatively spliced variant of RPTPB (Maurel
33
et al., 1994), while the clone from human may encode a
transmembrane variant (Shitara et al., 1994). There does not
appear be alternate splicing of the human gene.
RPTPB is brain-specific, and is expressed by glia (Canoll et al.,
1993; Milev et al., 1994). Within the brain, RPTPB is widespread,
being found on Bergmann glia of the developing and adult
cerebellum, radial glia of the cerebral cortex, the roof plate of spinal
cord, and several nerve fibers (where it is probably associated with
glia, and, in the periphery, with Schwann cells) (Canoll et al., 1993).
The 3F8 antigen has also been reported in the neocortical subplate
during development, becoming widespread as the cortex matures
(Miller et al., 1992). The relationship between these two studies
remains unclear. Interestingly, some phosphacan seems to be
substituted with both CS and KS chains (Maurel et al., 1994; Rauch et
al., 1991).
In vitro assays using purified phosphacan suggest that it
interacts with certain cell adhesion molecules (Ng-CAM, NILE/L1,
and N-CAM) and extracellular matrix molecules (tenascin) (Grumet
et al., 1993; Grumet et al., 1994; Milev et al., 1994). Most of the
observed binding seems to be mediated by the core protein.
Phosphacan can inhibit cell adhesion and neurite outgrowth on these
substrates, possibly, in the case of homophilic molecules such as N-
CAM, by binding to cell-surface N-CAM (Grumet et al., 1993). This
inhibition seems also to be due to the core protein and not to the CS
or KS GAG chains. As phosphacan expression in the brain overlaps
with that of some of these molecules, there is the possibility that
phosphacan may modulate their effects in vivo.
Synaptic vesicle PGs (SV2). One component of synaptic vesicles
is a KSPG designated SV2 (Scranton et al., 1993). SV2 was identified
and characterized in elasmobranch electric organ (Carlson and Kelly,
1983). SV2 is a transmembrane protein that has 12 predicted
transmembrane domains and possesses homology to both bacterial
sugar transporters and mammalian neurotransmitter transporters
(Bajjalieh et al., 1992; Feany et al., 1992). In rat there are two SV2
isoforms, with different patterns of expression in the brain
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(Bajjalieh et al., 1994). It may act as an acetylcholine transporter in
synaptic vesicles, as it is associated with the vesamicol receptor
(Bahr et al., 1992). Furthermore, the negatively charged GAG of
synaptic vesicle PGs could create a physical environment that can
regulate release of neurotransmitters and other components.
SV2 expression seems to be widespread throughout the brain
(Bajjalieh et al., 1994; Scranton et al., 1993). The KS chains attached
to it seem to be regulated, as certain KS epitopes, such as SV1, are
specific to electric organ synaptic vesicles (Scranton et al., 1993).
Furthermore, the KS in synaptic vesicle seems to have an unusual
structure--the inability to significantly degrade synaptic vesicle KS
with keratanase suggests that there may be other sugars, such as
fucose or sialic acid, covalently linked to the KS of SV2 in synaptic
vesicles (Scranton et al., 1993).
Basement membrane PGs.
i) Perlecan. Perlecan is a large, multidomain HSPG that is
typically associated with laminin and other components in the
basement membranes of all tissues (for review, see Iozzo et al.,
1994). While it has not been reported in the nervous system tissues
(it has only been found in the basement membranes of capillaries
within the brain [Kato et al., 1988; Lin, 1990]), it is present in the
basal lamina surrounding the neural tube and along which
peripheral nerves grow, and in the endoneurium surrounding
mature peripheral nerves (Halfter, 1993; Halfter and Schurer, 1994).
In this role, it is likely to help play a number of functions, including
organization of the extracellular matrix, localization of growth
factors, and support of axon growth. The ability of cells to adhere
via integrins to the perlecan core protein (Hayashi et al., 1992)
suggests that perlecan may directly mediate interactions with cells.
ii) Agrin. The neuromuscular junction is a specialized
synaptic structure possessing an organized basal lamina and clusters
of acetylcholinesterase and acetylcholine receptors (AChRs)
(McMahon, 1990). One component of this structure is agrin; agrin
was purified based on its ability to induce clustering of acetylcholine
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receptors, and is thus likely to play a key role in organizing the
neuromuscular junction.
Recently, it has been demonstrated that agrin is an HSPG (Tsen
et al., 1995); the core protein of an HSPG originally identified by the
monoclonal antibody 6D2 was cloned, and was found to have a
sequence identical to that of agrin 6 (Halfter, 1993; Tsen et al., 1995;
Tsim et al., 1992). The HSPG form of agrin has gone undetected up
to this point because a fraction of agrin isolated from brain is a
smaller molecular weight and does not seem to contain HS (Tsen et
al., 1995). It is unclear whether this smaller molecular weight form
of agrin is a truly unglycanated form, or whether it is a degradation
product. The existence of this agrin form may explain the fact that
the PG form of agrin has gone undetected up to this point.
It is likely that HS, either on agrin or on other PGs, plays a role
in organizing the neuromuscular junction. Exogenous HS can inhibit
AChR clustering, presumably by disrupting the binding of agrin to
other proteins (Hirano and Kidokoro, 1989; Wallace, 1990).
Myotubes deficient in HS synthesis exhibit defects in the clustering
of acetylcholine receptors, either spontaneously or in response to
purified agrin (Ferns et al., 1993; Gordon et al., 1993). However,
other PGs (possibly perlecan), at least as components of the basal
lamina, are present at the neuromuscular junction (Anderson and
Fambrough, 1983; Bayne et al., 1984). Hence, it is unclear whether
the HS involved in AChR clustering is required on agrin or on
another protein. Furthermore, it is not known if HS is involved
directly in AChR clustering or more generally in organization of the
basal lamina.
It is likely that AChR clustering is not agrin's sole function.
Alternatively spliced variants of agrin exist (Ferns and Hall, 1992),
with some variants having either reduced or no AChR clustering
activity (Ferns et al., 1993; Ruegg et al., 1992). No evidence exists
that the potential GAG attachment sites are spliced, and they are not
encoded in the exons encoding enhanced clustering activity.
6 The agrin gene possesses several EGF-like repeats, several domains with
homology to serine trypsin inhibitors, and a laminin-like domain (Rupp et
al., 1991; Tsim et al., 1992).
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Expression studies of agrin, which indicate that agrin is widespread
and found in areas not containing neuromuscular junctions, also
suggest other functions. During development, agrin is expressed by
neurons and Schwann cells during development in peripheral
nerves and ganglia (Halfter, 1993; Thomas et al., 1993), and is also
found in association with ventricular zones and, as expected, with
spinal motoneurons (Ma et al., 1994; Rupp et al., 1991). In the adult
nervous system, agrin expression, which is mostly neuronal, is
widespread (Ma et al., 1994; O'Connor et al., 1994). Agrin is also
present in muscle, and in basement membranes outside the nervous
system. Thus, agrin may also stabilize other synapses, or may
contribute to matrix structure. Its expression in nerve during
development suggests that it may play a role in axon outgrowth.
iii) 6C4/1B11. A 180 kD HSPG core protein from chick (total
MW 250 kD) recognized by the 6C4/1Bll monoclonal antibody is
distinct from perlecan and agrin. Like perlecan, it is found only in
basal lamina and not in brain parenchyma (Halfter and Schurer,
1994). This HSPG is expressed in the basal lamina surrounding
nerves; in vitro, however, it appears to be inhibitory for neurite
outgrowth, as neurites do not grow on 6C4/1B11 when spotted on
nitrocellulose alone or with extracts of basal lamina.
Syndecan. The syndecans are a family of four transmembrane HS
or HS/CSPGs (for review, see Bernfield et al., 1992). Their members
include syndecan-1 (Cizmeci-Smith et al., 1992; Kiefer et al., 1990;
Kojima et al., 1992; Mali et al., 1990; Saunders et al., 1989),
fibroglycan/syndecan-2 (David et al., 1993; Marynen et al., 1989;
Pierce et al., 1992), N-syndecan/syndecan-3 (Carey et al., 1992;
Gould et al., 1992), and ryudocan/amphiglycan/syndecan-4 (Baciu
et al., 1994; David et al., 1992a; Kojima et al., 1992). These proteins
are characterized by an extracellular domain with several GAG
attachment sites (syndecan-1 and syndecan-3 have longer
extracellular domains with more of these sites near the N-terminus),
a dibasic sequence in the extracellular domain proximal to the
membrane that is a site predicted for proteolysis, a transmembrane
domain, and a cytoplasmic domain that contains several tyrosine
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residues (of which only one fits the consensus sequence for tyrosine
phosphorylation). The transmembrane and cytoplasmic domains are
conserved both between members and between species, but the
extracellular domains are divergent (although the protease sites and
the GAG attachment sites are conserved). This suggests that the
transmembrane and cytoplasmic domains are likely to serve a
similar function in all cases, such as binding to the cytoskeleton
and/or participating in focal adhesions (Carey et al., 1994; Woods
and Couchman, 1992; Woods and Couchman, 1994).
Of all members of the syndecan family, syndecan-3 is the most
abundant in the nervous system (Kim et al., 1994). Syndecan-3
expression is developmentally regulated, being highest in the
neonatal rat brain, and is widespread throughout the nervous
system (Carey et al., 1992). Syndecan-3 is expressed by neurons in
culture, and is found on the cell body as well as on neurites (Raulo
et al., 1994). Syndecan-3 purified from brain has been reported to
bind FGF-2 and HB-GAM but not other heparin-binding proteins
(Chernousov and Carey, 1993; Raulo et al., 1994); as these studies
were carried out using solid phase binding assays, however, they
may not reflect the binding abilities of these proteins in solution.
It is unclear if other members of the syndecan family are
found in the nervous system. Both syndecan-2 and syndecan-4
messages have been detected in brain RNA (Kim et al., 1994; Pierce
et al., 1992). However, antibodies to syndecan-2 thus far have
yielded no staining of nervous tissue (David et al., 1993), suggesting
that the syndecan-2 message detected may be due to contaminating
endothelia (which express high levels of syndecan-2) from blood
vessels and meninges. Antibodies to syndecan-4 have been
reported to stain both central and peripheral nervous system (Baciu
et al., 1993). Syndecan-1 does not seem to be expressed in the
nervous system, although a mouse syndecan probe hybridizes to a
4.5 kb transcript from cerebrum (Saunders, et al., 1989).
Recently, a cDNA with homology to the syndecans has been
cloned from Drosophila, and has been shown biochemically to
encode an HSPG (Spring et al., 1994). As expected, this homology is
highest in the transmembrane and cytoplasmic domains. Analysis
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suggests that this gene is related to the evolutionary ancestor of the
four syndecan genes present in vertebrates. Interestingly,
Drosophila syndecan is expressed in both the central and peripheral
nervous systems in developing embryos. Its expression correlates
with that of FGF receptors in the Drosophila nervous system, further
suggesting that syndecan in the nervous system may act as a
coreceptor for FGF.
Glypican. Recently, many cell surface HSPGs have been identified
which associate with membranes via a glycosylphophatidylinositol
(GPI) lipid linkage. These include HSPGs from hepatocytes (Ishihara
et al., 1987), ovarian granulosa cells (Yanagishita and McQuillan,
1989), Schwann cells (Carey and Stahl, 1990), fibroblasts (David et
al., 1990), melanoma cells (Drake et al., 1992), and rat brain
(Herndon and Lander, 1990). The GPI-linked HSPG from human
fibroblasts was cloned, and named glypican (David et al., 1990).
Since that time, three other homologues have been identified--
cerebroglycan (Stipp et al., 1994), OCI-5 (Filmus et al., 1988), and K-
glypican (Watanabe and Yamaguchi, 1994).
These PGs seem to be, on the basis of sequence, a completely
novel class of proteins, as they contain no functional domains found
in other proteins or any homology to any other protein. All
members possess both putative N-terminal signal peptides and
short hydrophobic C-terminal stretches which form part of the
glypiation signal (i.e., the signal for attachment of the GPI-linkage).
While the number of potential GAG attachment sites vary between
members, they are all characterized by a cluster of serine-glycine
repeats (of varying size) roughly 40 amino ,cids upstream of the
predicted site of glypiation. They also contain other scattered Ser-
Gly sequences further upstream. The 14 extracellular cysteines,
which are conserved between family members, suggest that the
glypican is highly disulfide bonded and has a compact tertiary
structure. Indeed, the apparent molecular weights of glypican and
cerebroglycan increase upon reduction as measured by
electrophoresis (Herndon and Lander, 1990).
39
All glypican family members are expressed in the brain; their
patterns of neural expression, however, seem to be unique.
Glypican has been purified from rat brain (Litwack et al., 1994a; this
thesis), and the characterization of the neural expression of glypican
is the subject of this some of this work (for further discussion, see
Chapters 2 and 3 of this thesis; also, Karthikeyan et al., 1994;
Litwack et al., 1994a). In addition to the results presented here,
glypican has also been reported to be expressed in Schwann cells
(Carey et al., 1993); this shall be discussed in Chapter 3 of this
thesis.
Another core protein, cerebroglycan, has been purified from
rat brain. In situ hybridization experiments indicate that it is
nervous system specific, and is expressed by newly postmitotic
neurons as they begin migration or axon outgrowth (Stipp et al.,
1994). Its message, at least during early development, is expressed
in a complementary fashion to that of glypican (Lander, 1993;
Chapter 3, this thesis). OCI-5 was originally cloned from intestinal
cells, but OCI-5 message has been detected in the developing
nervous system (Watanabe and Yamaguchi, 1994). K-glypican,
named because of its expression in kidney, is also expressed in
developing brain; unlike glypican, however, the messages for both
OCI-5 and K-glypican decrease as the brain matures (Watanabe and
Yamaguchi, 1994).
The function of these PGs in the nervous system is unknown.
The spatial and temporal pattern of cerebroglycan expression
suggests that it may play a role in axon growth and cell migration
(Stipp et al., 1994); the localization of cerebroglycan to axons (see
Chapter 3 of this thesis) is consistent with this proposed role. The
high levels of glypican in the ventricular zones of the early
developing nervous system (Litwack, this thesis) at a time when
there is extensive proliferation and differentiation of cells imply
that it may act as growth factor receptors, mediating proliferation of
neuroepithelia and perhaps differentiation into neurons or glia. In
addition to ventricular zone expression, I shall show in this thesis
(Chapter 3) that glypican is widespread during later stages of
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development, suggesting that glypican may be involved in a
common function at those stages.
As a result of the GPI-linkage found on all glypican family
members, these HSPGs may confer different responses of cells in
response to heparin-binding proteins than transmembrane PGs (for
review of GPI-linked proteins, see Cross [1990]). The GPI-linkage is
thought to confer higher lateral mobilities on membrane proteins, as
the attached protein can potentially diffuse through the membrane
near the rates of lipid (Chan et al., 1991).
Transmembrane proteins are likely to be associated with
intracellular components via their cytoplasmic domains, and thus
may directly signal the cytoplasm or associate with the cytoskeleton.
GPI-linked proteins, however, are thought to often be associated
with specialized membrane structures known as cavaeolae, and are
often copurified with cavaeolar markers (Lisanti et al., 1994). Such
structures could provide a mechanism for GPI-linked proteins to
directly signal cells, as they could colocalize these proteins with
intracellular components. Intracellular tyrosine kinases have been
found to coimmunoprecipitate with GPI-linked proteins, suggesting
that they may be associated in cells (Rudd et al., 1993; Stefanova et
al., 1991; Thomas and Samelson, 1992). Such interactions could
occur via association of these proteins in membrane domains.
Alternatively, an "adaptor" protein, which spans the membrane and
binds to both extracellular and intracellular proteins, could mediate
such interactions (no such protein has yet been identified).
GPI-linked proteins are also likely to be processed differently
than transmembrane proteins. They can be shed from the cell
surface by phospholipase C or potentially by a protease, whereas
syndecan presumably must be shed by a protease (Bernfield, et al.,
1992). Some groups have suggested that GPI-linked PGs, once shed
by the cell, remain on the cell surface as peripheral membrane
(Carey and Evans, 1989; Ishihara, et al., 1987). GPI-anchored PGs
have also been reported to be metabolized by different intracellular
pathways than transmembrane PGs (Yanagishita, 1992).
The GPI-linkage may sometimes lead to differential sorting in
cells. In epithelial cells, GPI-linked proteins are often sorted to the
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apical surface as opposed to the basolateral surface (Lisanti et al.,
1989). The observation that some GPI-linked proteins in neurons
are sorted to axons lead to the proposal that the axon of a neuron is
equivalent to the apical surface of an epithelial cell, and the
dendrites and cell body to the basolateral surface with respect to
sorting of GPI-linked proteins (Dotti et al., 1991; Dotti and Simons,
1990). These studies were performed on neurons in vitro, however;
more extensive observation in vivo demonstrates in fact that GPI-
linked proteins are often not sorted to axons (Morris and Grosveld,
1989). The compartment in which a GPI-linked protein is found
may depend on the neuron in which it is being expressed, the time
during development when it is expressed, and also on the specific
GPI-linked protein being expressed (Faivre-Sarrailh et al., 1992; Xue
et al., 1990; Xue et al., 1991). Nevertheless, while generalizations
cannot be made about the relationship between GPI-linkage and
sorting, it is clear from these studies that GPI-linked proteins are
not always evenly distributed in neurons. Studies in this thesis will
demonstrate that glypican expression is consistent with axonal
polarization, and that cerebroglycan is polarized to axons in granule
cells of the hippocampus (see Chapter 3 of this thesis). The GPI-
linkage may allow a PG to be localized in cellular compartments
differently than if it were a transmembrane PG. The expression of
such PGs may represent one mechanism for cells to specifically
localize HS on the cell surface.
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4. Functions of proteoglycans in developmental processes.
PGs have been shown to modulate many processes important
in nervous system development, including cell adhesion, cell
migration, axon outgrowth, extracellular matrix organization, cell
proliferation, and differentiation. The modulation of these processes
can be ascribed partly to the GAG portion of the PG. The binding of
proteins to GAGs is often directly important for function despite the
existence of many non-PG signal-transducing receptors with high
affinity for those proteins. Functional studies have led to the
concept of PGs (especially cell surface PGs) as coreceptors, receptors
whose binding to ligand is important in the interaction of that ligand
with distinct high affinity receptors (Bernfield et al., 1992). The role
of PGs as coreceptors shall be illustrated below by examining the
functions of PGs, and particularly GAGs, in modulating the actions of
protease inhibitors, grow factors, and cell adhesion molecules.
In addition, PG core proteins can also directly interact with
these developmentally important proteins, or on their own can
directly modulate developmental events. Hence the existence of
multiple families of PG core proteins, with multiple members of each
family. Also, many cores are highly conserved between species. In
many cases, cores have already been shown to directly bind other
proteins. I will also note in this discussion the function of some PG
core proteins in developmental processes. 7
Proteases and Protease Inhibitors.
(i) Antithrombin III (AT), The anticoagulant properties of
heparin are well known. Heparin possesses this anticoagulant
activity as a result of its ability to bind AT, a protease inhibitor of
the serpin family 8 . This binding event accelerates the rate of
inactivation of thrombin and other proteases by AT. In reality, only
a fraction of heparin or HS chains possess AT binding activity; these
7 The evidence suggesting that heparin can regulate cell proliferation is not
discussed here (see Marcum et al., 1987; Karnovsky et al., 1989).
8 Serpin is an abbreviation of serine protease inhibitor,
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chains account for the anticoagulant activity in those samples
(Marcum and Rosenberg, 1989).9
The binding of AT by heparin increases rates of inactivation
by two basic mechanisms. In the case of inactivation of some
proteases, such as factor Xa, the conformational change induced in
AT upon binding to heparin is sufficient to account for this
acceleration (Evans et al., 1992). In this case, the AT-binding
pentasaccharide enhances inactivation to the same extent as full-
length heparin. In the case of proteases such as thrombin, heparin
also increases rates of inactivation by participating in a thrombin-
AT-heparin ternary complex (Evans et al., 1992; Olson and Bj6rk,
1991; Pratt et al., 1992). This process, known as surface
approximation, can take place because thrombin binds to heparin
(Olson et al., 1991). Consistent with the mechanism of surface
approximation, the rate of thrombin inactivation is dependent on
the size of the heparin fragment--heparin fragments longer than but
containing the pentasaccharide are required for maximal
acceleration (Evans et al., 1992; Pratt et al., 1992). Furthermore, the
enhancement of inactivation rate is abolished in the presence of
high concentrations of heparin, a result consistent with the binding
multiple factors on a single heparin chain. However, part of the
effect of heparin on AT inhibition of thrombin can additionally be
attributed to the conformational change of AT induced by heparin,
as the pentasaccharide sequence alone enhances the inactivation
rate, although not as much as do longer fragments (Evans et al.,
1992). It is likely that heparin's effect on thrombin inactivation by
AT results from both surface approximation and the allosteric
effects of heparin binding on AT.
(ii) Protease nexin-1 (PN-1). PN-1, which is identical to glia-
derived nexin, is a protease inhibitor of the serpin family. PN-1 is
abundant in the nervous system, where it is expressed by both glia
and neurons (Mansuy et al., 1993; Reinhard et al., 1994).
Widespread during development, it is retained in a number of adult
9 Such anticoagulantly active HS can be found on endothelial surfaces in vivo,
and can accelerate thrombin inactivation by AT (Marcum and Rosenberg,
1989).
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brain regions; it has also been localized to the neuromuscular
junction (Festoff et al., 1991).
The inactivation of proteases such as thrombin by PN-1 is
important in the regulation of neurite outgrowth, cell migration, and
astrocyte morphology in vitro (Cavanaugh et al., 1990; Lindner et al.,
1986; Monard, 1988). As the rate of inactivation of proteases by
PN-1 can be accelerated by heparin or HS (Evans et al., 1991; Farrell
and Cunningham, 1987)10 and to a lesser extent by CS (Farrell and
Cunningham, 1987), it is likely that nervous system HS and HSPGs
are important for the regulation of PN-1's effects. The interaction of
PN-1 with cell surface HS and inactivation by PN-1 can be
accelerated by cell surfaces (Farrell and Cunningham, 1986) implies
that cell surface HSPGs such as glypican or syndecan may be
involved. In addition, PN-1 can be found in extracellular matrix
(Halfter et al., 1990). Thus, HSPGs of basal lamina may also play a
role in regulating PN-1.
Fibroblast growth factors (FGFs). HSPGs are binding proteins,
distinct from the high affinity tyrosine kinase receptors FGFRs 1-4,
for members of the FGF family. They can bind FGFs because of the
high affinity the FGFs have for heparin and HS (FGFs have also been
referred to as the heparin-binding growth factors).
The affinity of FGFs for HS has been well characterized. In
many in vivo and in vitro situations FGF-2 has been shown to
associate with HS. HS can act as a reservoir for FGF-2 in the
extracellular matrix (Ishai-Michaeli et al., 1990), or as low affinity
binding sites on the surfaces of cells (Moscatelli, 1987). HSPGs
released from cell surfaces or the ECM are often found to be
complexed with FGF-2 (Bashkin et al., 1992; Brunner et al., 1991).
As a result, it is likely that HS acts as a reservoir for FGF-2, and in
fact little FGF-2 is found in the conditioned medium of FGF-2-
expressing cells (Vlodavsky et al., 1987).
10 Evans et al. (1991) suggest that heparin accelerates PN-1 inactivation of
thrombin by surface approximation.
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This binding has many consequences important for FGF
function. Heparin can affect the diffusion rate of FGF-2
(Flaumenhaft et al., 1990), and can protect both FGF-1 and FGF-2
from proteolytic degradation (Saksela et al., 1988). Heparin-FGF
binding has also been shown to be required for FGFs to signal
through their high affinity receptor tyrosine kinases. This
requirement has been demonstrated for FGF-2 signalling of cells
(Olwin and Rapraeger, 1992; Rapraeger et al., 1991; Yayon et al.,
1991) and for interaction with FGFR1 in solution (Ornitz and Leder,
1992). This requirement has also been demonstrated for FGF-1
signalling through FGFR1 and FGFR3 (Olwin and Rapraeger, 1992;
Ornitz and Leder, 1992) and also for FGF-4 (K-FGF) signalling (Olwin
and Rapraeger, 1992). Hence, cell surface HSPGs have been
proposed to be coreceptors for FGFs (Bernfield et al., 1992).
Heparin can function as a coreceptor in one of several ways.
Heparin can support the oligomerization of FGF-2 (Ornitz et al.,
1992) and FGF-1 (Spivak-Kroizman et al., 1994), thus assisting in
dimerization of FGF receptors. Heparin is also likely to participate in
the formation of a FGF-FGFR-heparin ternary complex and thus
stabilize the binding of FGF to its receptor. In support of this,
heparin has been shown to bind to a domain of FGFR1, and a
mutations in this domain affect both FGF-2 binding and heparin
binding (Kan et al., 1993)11. It thus seems likely that some sort of
heparin-bFGF-FGFR1 complex is formed 12. Kinetic studies suggest
that the role of heparin in this case is to stabilize the complex by
decreasing its dissociation rate (Moscatelli, 1992; Nugent and
Edelman, 1992).
Studies using oligosaccharides derived from heparin or
heparan sulfate are consistent the model of ternary complex
formation. An oligosaccharide consisting of five sugars is the
minimum length necessary to bind to FGF-2 (Maccarana et al.,
1993), while the minimum length of about 8-12 saccharides is
necessary for FGF-2 binding to its receptor and for mitogenic
11 Spivak-Kroizman et al. (1994]) report that heparin does not bind FGFR2.
12 For an opposing view, see Roghani et al. [1994].
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activity in response (Aviezer et al., 1994; Guimond et al., 1993;
Ishihara et al., 1993; Ornitz et al., 1992; Walker, 1994). Shorter
oligosaccharides can inhibit the binding of FGF-2 to its receptor
(Tyrell et al., 1993). Furthermore, selectively de-6-O-sulfated
heparin still binds to FGF-2 but blocks its mitogenic effect, implying
that a second site on heparin, not present in the FGF-2 binding
sequence is required for function. While consistent, these studies do
not rule out the possibility that the regions present in the longer,
activating heparin sequences, are also binding to different domains
in the same FGF-2 molecule or to different FGF-2 molecules (causing
oligomerization). These studies imply that there is a second binding
site on heparin, whether for FGF-2 or FGFR, that is necessary for
activity. 13
HSPGs are likely to be involved in FGF signalling in the
nervous system. FGFs and their high affinity receptors are widely
expressed throughout the nervous system, both during development
and in adulthood (Elde et al., 1991; Fu et al., 1991; G6mez-Pinilla and
Cotman, 1992; G6mez-Pinilla et al., 1992; Gonzalez et al., 1990;
Hughes et al., 1993; Peters et al., 1993; Stock et al., 1992; Wanaka et
al., 1991; Wilcox and Unnerstall, 1991; Woodward et al., 1992). FGFs
can affect neuronal proliferation, survival , and repair (G6mez-
Pinilla et al., 1992; Hughes et al., 1993; Walicke, 1988), and can also
promote mitogenesis and differentiation of neuroepithelia (Bartlett
et al., 1988; Murphy et al., 1990). Interestingly, a HSPG has been
characterized from neuroepithelia which has a high affinity for FGF-
2, but at a later stage developmental age switches to having an
apparent high affinity for FGF-1 (Nurcombe et al., 1993)--the timing
of this suggested switch correlates with the expression of these FGFs
in neuroepithelia.
Cell adhesion, migration, and axon outgrowth. The
interaction of cells with each other and to the extracellular matrix is
important in regulating processes such as cell migration and axon
1 3 Ornitz et al. (1995) report, however, that nonsulfated di- and trisaccharides
of heparin can activate signaling by FGF-1 and FGF-2, presumably by
oligomerization.
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growth, and influences the morphogenesis of the nervous system
(Hynes and Lander, 1992). PGs probably play a role here, as many
of these interactions are mediated by proteins that can bind GAGs.
Such proteins include NCAM, which is involved in cellcell adhesion,
and extracellular matrix molecules such as laminin or fibronectin,
which can bind integrins associated with cell membranes. These
proteins are widely distributed in the central and/or peripheral
nervous system during development.
PGs are likely to act as coreceptors in modulating cell-cell or
cell-substratum adhesion. HS is important in the homophilic binding
of NCAM, as exogenous heparin and antibodies to the heparin-
binding domain of NCAM inhibit NCAM-mediated cell adhesion;
peptides corresponding to the heparin-binding domain of NCAM
mutations in this domain also inhibit also inhibit adhesion via NCAM
(Cole et al., 1986; Reyes et al., 1990). Attachment of retinal cells to
thrombospondin can be blocked by the addition of heparin
(Neugebauer et al., 1991). Likewise, CHO cells deficient in HS and CS
adhere to fibronectin but poorly or not at all to the heparin-binding
domain of fibronectin (LeBaron et al., 1988). Even on intact
fibronectin, these cells do not form stress fibers or focal adhesions
as judged by localization of F-actin. This suggests that even when
adhesion is occurring in the absence of GAG, that adhesion is
somehow different or incomplete. These results also imply that
measurement of cell adhesion may be a poor way to assess the roles
of GAGs, as GAGs may be involved in responses that cannot be
detected by simply measuring the initial strength of cell adhesion.
In addition to acting as coreceptors, PGs can also directly
mediate adhesion. For instance, syndecan-1 directly mediates the
adhesion of myeloma cells to collagen type I (Sanderson et al.,
1992), and prevents migration of those cells into collagen gels
(Liebersbach and Sanderson, 1994) The ability of different
myeloma cell lines to adhere to collagen correlates with the affinity
of their HS for collagen. Melanoma and neuroblastoma cells can
adhere to a heparin-binding peptide derived from fibronectin; this
adhesion is heparin-dependent, and is likely to be mediated through
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a GPI-linked HSPG (Drake et al., 1992; Haugen et al., 1992a;
McCarthy et al., 1990).
Other studies have found that PGs can have inhibitory effects
on cell adhesion in vitro. While the effects of PGs on cell adhesion
mentioned above are likely due to cell surface PGs, the inhibitory
effects discussed below are usually due to the effects of PGs on the
substrates used. In some cases what is observed is likely to involve
the steric effects of the GAG. The inhibition of rat yolk sac tumor
cell attachment to fibronectin or collagen type I by a CSPG
(presumably serglycin) depends on the ability of that CSPG to bind
to the substrate (Brennan et al., 1983). Likewise, cell adhesion of
fibroblasts to substrates of fibronectin or other ECM molecules is
inhibited by substrate-bound PG-M, but not the core protein
(Yamagata et al., 1989). The inhibitory effect is due to the presence
of substrate-bound CS, as the effect could be reproduced with BSA-
conjugated CS but not soluble CS. A brain KSPG, when added to
substrates of laminin or NCAM, also inhibits cell adhesion in a KS-
specific manner (Cole and McCabe, 1991). That these effects are
steric is likely, as the inhibitions reported are generally seen with
large added concentrations of PG (furthermore, these studies usually
do not measure the amount of protein actually absorbed to
substrate). Further supporting the idea of steric hindrance is the
finding that integrins can bind to the core protein of perlecan, but
this binding is reduced with the intact PG (Hayashi et al., 1992). It
is also possible that inhibition is due to competition of GAG for
binding with cell surface GAG-binding receptors; however, no such
mechanism has ever been demonstrated.
Often, the inhibitory effects of PGs on --ell adhesion are due to
the specific effects of individual core proteins as opposed to the
actions of GAGs. Inhibitory effects of neurocan and phosphacan on
NCAM- and NgCAM-mediated cell-cell adhesion, as well as cell-
substratum adhesion to and neurite outgrowth on those proteins as
well as tenascin, have been observed (Friedlander et al., 1994;
Grumet et al., 1993; Grumet et al., 1994; Milev et al., 1994). These
effects are generally still observed, however, when PG core proteins
(prepared by enzymatic degradation of attached CS) are utilized in
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these assays. As with GAGs, these effects may also be due to the
steric effects of these cores, perhaps by the masking of functional
domains on the proteins used as substrates in these assays.
Less is known regarding the involvement of GAGs in axon
growth and guidance. Much of the focus of research involves the
reported inhibitory effects of CS and KS for axons. Some have
hypothesized that CS and KS are inherently inhibitory for axons, and
that these GAGs are used in brain to form barriers. This idea is
based on the localization of CS and KS to apparent barriers in vivo
(such as the roof plate of the spinal cord) and on the inhibitory
effects of some CS or KS on neurite outgrowth in vitro (Brittis et al.,
1992; Geisert and Bidanset, 1993; Snow et al., 1992; Snow et al.,
1991). One mechanism proposed for such inhibition involves the
interaction of CS or KS with a cell surface receptor for CS or KS. No
such receptor has yet been identified.
The effects of these GAGs on neurite outgrowth, as with their
effects on cell adhesion, could be explained by steric hindrance on
outgrowth-promoting substrates. For instance, an HSPG has been
purified from Schwannoma cells which inhibits neurite outgrowth
on laminin; in order for this inhibition to occur the PG must be
complexed to laminin on the substrate and HS must be attached
(Muir et al., 1989). While other interpretations are possible (such as
conformational effects of binding on laminin), these experiments are
consistent with a model of steric hindrance. In fact, as with cell
adhesion, other studies demonstrating inhibition of neurite
outgrowth have often used high relative concentrations of inhibitory
PG or GAG.
In some cases, however, the inhibition of neurite outgrowth
cannot be ascribed simply to a steric effect. The KSPG ABAKAN is an
inhibitor of cell adhesion and neurite outgrowth on laminin; this
inhibitory effect is masked by the addition of an antibody that binds
KS (Geisert and Bidanset, 1993). This result is difficult to explain by
a simple steric mechanism, as the GAG chain is still present on the
substrate, and in fact has additional size due to the presence of the
attached antibody. It may be that, in this case, KS is interacting
with a cell surface KS-binding protein important for cell adhesion
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neurite outgrowth. However, other effects, such as changes in the
substrate as a result of antibody binding, are also possible.
Further examination suggests that CS and KS are not in general
inhibitory molecules. While present in apparent axonal barriers, CS
and KS are also found in regions where axons grow, such as the
neocortical subplate or optic nerve, and at times when axons are
growing (Bicknese et al., 1994; McAdams and McLoon, 1995). In
addition, the CSPG DSD-1 has been reported to support, via its GAG,
neurite outgrowth in vitro (Faissner et al., 1994); neurites grow on
substrates of DSD-1 CSPG but fail to due so when the CS has been
enzymatically removed.
Often, inhibitory effects on neurite outgrowth are due not to
GAG but to the action of individual core protein. CSPGs purified
from brain inhibit PC12 cell neurite outgrowth, even when the CS
has been enzymatically removed (Oohira et al., 1991). Likewise, it
has been reported that neurocan and phosphacan core proteins
inhibit neurite outgrowth on NCAM, NgCAM, and tenascin
(Friedlander et al., 1994; Grumet et al., 1993). Individual core
proteins can have effects on cell migrations as well--the
hyaluronate-binding domain of a cartilage PG, presumably aggrecan,
has been suggested to inhibit neural crest cell migration on
fibronectin (Perris and Johansson, 1990).
Little is known about the role of HS in promoting axon growth
and guidance. The few studies done, however, suggest that HS can
influence these processes. Spinal cord neurons extend neurites on
heparin-binding peptides derived from fibronectin, and this
outgrowth can be reduced by soluble heparin (Haugen et al., 1992b).
Neurite outgrowth on HB-GAM is inhibited by heparitinase or added
heparin (Raulo et al., 1994). In addition, HS has been shown in
insects to be important for axon guidance, as exogenous heparin or
treatment with heparitinase causes axons to grow randomly or along
incorrect routes (Wang and Denburg, 1992). That HS is likely to
play a role is supported by the observation that many of the
proteins which promote axon growth and guidance bind to heparin.
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5. Conclusion.
PG structure and function can be regulated at many different
levels by cells. Cells can selectively regulate expression of PG cores.
They can also regulate the structure of the GAG that is attached. In
this way, cells may create an environment, both at the cell surface
and in the extracellular matrix, which with they and other cells can
interact.
It is apparent that this regulation at both levels occurs in the
nervous system. Most if not all of the major PG core protein families
are represented in the brain. The expression of these core proteins,
however, is both temporally and spatially regulated. GAG structure
is also temporally and spatially regulated in the nervous system,
and is likely to reflect in synthetic potentials of the various cell
types composing the nervous system.
This regulation is likely to reflect function. The GAG-binding
proteins to which cells respond will depend on the way in which
those cells regulate GAG synthesis, and hence which high affinity
binding sites they produce on their GAGs. The subsequent
responses to those selected GAG binding proteins may depend on
the particular core proteins expressed by those cells; such responses
could thus be controlled by regulation of core protein expression 14
In addition, the extracellular matrix will also be shaped by the
regulation of GAG synthesis and core protein expression. PG
expression thus is likely to reflect function; studying PG expression
during neural development will give insight into those functions.
This thesis addresses aspects of PG expression and function.
In Chapter 2, I present data showing that a particular PG, glypican,
is expressed in the rat brain, and that its expression is spatially
regulated in the adult nervous system. Chapter 3 addresses the
expression of glypican during neural development. In this chapter,
I also discuss the localization of both glypican and cerebroglycan
14 There is little evidence that core proteins direct the synthesis of specific
GAG structures beyond the specification of HS or CS chains. While some
groups have reported binding differences between core proteins from the
same source to certain GAG binding proteins (Aviezer et al., 1994; Mertens et
al., 1992), these differences have not been linked to differences in GAG
structure.
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protein products. In Chapter 4, I present data regarding the
expression of the small matrix CSPG decorin during spinal cord
development, and show that it binds netrin-1, a factor that
promotes axon growth and guidance. Appendix 1 discusses
preliminary results regarding the processing of glypican in myeloma
cells and its implications for mechanisms of GAG synthesis.
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Chapter 2: Neuronal expression of glypican, a cell surface
glycosylphosphatidylinositol-linked heparan sulfate
proteoglycan, in the adult rat nervous system.
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Introduction.
The interaction of cells with their environment is important
for the growth and function of the nervous system. These
interactions control processes such as cell adhesion, migration,
proliferation, axon growth and guidance, and responsiveness to
growth factors. Proteoglycans (PGs), proteins that contain one or
more covalently attached glycosaminoglycan (GAG) chains, are
thought to be involved in many such interactions. PGs are found
both in the extracellular matrix and on cell surfaces. Through their
GAG chains PGs have the ability to bind a number of important
nervous system proteins, including extracellular matrix proteins
(such as laminin, fibronectin, thrombospondin, and agrin), cell-
surface molecules (such as NCAM, myelin-associated glycoprotein,
the amyloid-B-protein precursor), synaptic enzymes
(acetylcholinesterase) and growth factors of the fibroblast growth
factor (FGF) family (for reviews, see Jackson et al. [1991]; Lander
and Calof, [1993]). In some cases it has been demonstrated that
GAGs--in particular GAGs of the heparan sulfate (HS) class--play an
essential role in the functions of these proteins. For example, cell-
surface HSPGs are apparently required for basic FGF (bFGF) to bind
to cells and exert its effects (Yayon et al, 1991; Rapraeger et al.,
1991; Kan et al., 1993), as well as for NCAM-mediated cell adhesion
(Cole et al., 1986; Reyes et al., 1990), and agrin-mediated clustering
of muscle acetylcholine receptors (Gordon et al., 1993).
Currently, it is not known which PGs in the nervous system
mediate these and other biological activities, nor where such PGs are
expressed. Up to 25 PG core proteins have been reported in the
developing and adult rat brain (Herndon and Lander, 1990),
including molecules bearing both HS and chondroitin sulfate (CS)
GAGs. Those PGs for which information exists on regional
distribution in the nervous system are mainly CSPGs: these include
the Cat-301 antigen (Hockfield et al., 1990), neurocan (Rauch et al.,
1992), versican (Perides et al., 1992), and the T1 antigen (Iwata and
Carlson, 1993)--all of which appear to be extracellular matrix-
associated--and one cell surface CSPG, NG2 (Stallcup et al., 1983;
Levine and Card, 1987; Nishiyama et al., 1991) In addition,
immunological studies have identified distinct CS epitopes on
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subsets of CNS neurons (Watanabe et al., 1989; Fujita et al., 1989;
Maeda et al., 1992).
In contrast, much less is known about the expression of PGs in
the brain that bear HS chains. One, known as N-syndecan or
syndecan-3 (for nomenclature, see Bernfield et al. [1992]), is an
integral membrane PG expressed mainly during perinatal
development, and appears to be associated with many cell bodies
(Carey et al., 1992). An HSPG has also been purified from mouse
neuroepithelium (Nurcombe et al., 1993). Other brain HSPGs have
been characterized biochemically, but their distributions have not
been elucidated (Margolis et al., 1975a; Margolis et al., 1975b;
Klinger et al., 1985; Herndon and Lander, 1990).
Two of the major HSPGs of the rat brain, known as M12 and
M13 (Herndon and Lander, 1990) associate with isolated
membranes, and exhibit detergent-partitioning properties indicative
of integral membrane proteins. These PGs lose their detergent-
partitioning properties when treated with phosphoinositide-specific
phospholipase C, indicating that they associate with membranes via
a covalent glycosylphosphatidyl-inositol (GPI) lipid linkage
(Herndon and Lander, 1990). Several other HSPGs have been
reported to possess GPI-anchors, including HSPGs isolated from rat
ovarian granulosa cells (Yanagashita and McQuillan, 1989), mouse
melanoma cells (Drake et al, 1992), rat Schwann cells (Carey and
Stahl, 1990), and human lung fibroblasts (David et al., 1990). The
latter molecule was cloned and given the name glypican (David et al,
1990).
In the present study we describe the purification and cDNA
cloning of M12 from rat brain and show that it is the rat homologue
of glypican. In situ hybridization studies are presented that indicate
that M12/glypican is regionally expressed in the adult brain.
Specifically, glypican is found to be expressed at high levels by
restricted populations of projection neurons. Some of these data
have been presented previously in abstract form (Litwack et al.,
1992).
56
Materials and Methods.
Purification of HSPG M12. A membrane fraction was isolated from
46.4 g wet weight of neonatal rat brains (roughly 165 animals), and
a detergent extract of this fraction was prepared (Herndon and
Lander, 1990). All further steps were done at 40 C except where
noted. PGs were purified by loading the detergent extract onto a
column (172 ml) of DEAE-Sephacel, washing sequentially in 50 mM
Tris-HCl (pH 8.0 at 40 C), 0.1% Triton X-100, and protease inhibitors
as in Herndon and Lander (1990) containing a) 0.15 M NaCl (starting
buffer), b) 0.25 M NaCI, c) 0.25 M NaCl, 6 M urea, and d) 0.25 M
NaCI, 6 M urea, with 50mM formate (pH 3.5) replacing the Tris-HCl.
The pH of the column was then restored to pH 8.0 with starting
buffer, and the PGs were eluted with starting buffer containing 0.75
M NaCI. This PG-enriched fraction was concentrated and exchanged
into starting buffer containing 0.15 M NaCl using a Centriprep-10
(Amicon), and was then digested with 0.09 units/ml chondroitinase
ABC (Sigma) for 2 hours at 37 0 C. This material was loaded on a 0.2
ml DEAE-Sephacel column, washed with starting buffer (without
protease inhibitors) and then 0.2 M NaCI, 6 M urea, 100 mM sodium
acetate (pH 3.5), 0.1% Triton X-100. The column was washed with
25 mM ammonium acetate (pH 7.0), 0.1% Triton X-100 and eluted
with a 20 ml 0.15 M - 0.75 M NaCI gradient in this buffer. The
fractions from 0.3 M to 0.75 M NaCl were pooled, and this PG-
enriched fraction, now depleted of chondroitin sulfate PGs; was
concentrated and exchanged into 25 mM ammonium acetate (pH
7.0), 0.1% Triton X-100, 0.15 M NaCl in a Centricon-10. This sample
was made 25 mM in Tris-HC1 (pH 7.1 at 370 C) and digested with 9
gg/ml heparitinase (prepared as in Herndon and Lander [1990]) for
3 hours at 370 C. The sample was concentrated in a Centricon-10,
subjected to electrophoresis in a 9% SDS-PAGE gel (Laemmli, 1970)
and electroblotted to nitrocellulose (Schleicher & Schuell). HSPG
core proteins were visualized by amido black staining (Schaffner
and Weissman, 1973). M12 and M13 were excised, and were
simultaneously eluted from the filters and digested with trypsin as
in Tempst et al. (1990). The tryptic peptides were separated by
reverse-phase HPLC (Tempst et al., 1990) and microsequenced by
automated Edman degradation (Biopolymers Lab, MIT).
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Cloning and sequencing of rat glypican. To obtain a human glypican
probe, cDNA was synthesized from 0.5 pig of human foreskin
fibroblast total RNA (purified as described by Chomczynski and
Sacchi [1987]) using MMLV-reverse transcriptase (Gibco BRL). This
cDNA was then amplified by PCR using 120 pmol each of
oligonucleotides GLA (5'-ggtccggaaagtggctcaggtc-3') and GLB (5'-
ggttgttgatctggttggccag-3'). These primers correspond respectively to
bases 920 to 941 (in the sense orientation) and 1539 to 1518 (in the
antisense orientation) of human glypican (David et al., 1990). PCR
was performed for 30 cycles: 940 C for 30 seconds, 55 0 C for 1
minute, and 72 0 C for 1.5 minutes. The resulting product was
digested with Xhol and Kpnl (human glypican contains an Xhol site
at base 690 and a Kpnl site at base 1494), isolated by agarose gel
electrophoresis, and cloned into pBluescript (Stratagene). The clone
was verified by partial sequencing.
A Lambda-Gem 2 cDNA library (gift of Dr. John Wagner,
Cornell University Medical School) constructed from A126 cells (a
PC12 rat pheochromacytoma cell variant) was screened with the
human glypican fragment labelled by the random primer method.
Twelve positive clones were obtained from an initial screen of
400,000 plaques. The inserts from positive phage were subcloned
into the EcoR1 site of pBluescript and both strands of the largest, a 3
kb clone designated 41a, were sequenced by the dideoxynucleotide
method using Sequenase (USB) or the fmol DNA Sequencing System
(Promega). Sequencing primers were synthesized based on internal
sequence (Biopolymers Lab, MIT), or restriction fragments were
subcloned into pBluescript and sequenced using T3 and T7 primers.
Clone 41a contains 3000 base pairs (bp) of the 3' end of rat glypican.
In order to obtain the 5' fragment of rat glypican, a primer-
extended cDNA library was constructed from 5 ptg of PC12 poly(A) +
RNA using the Time-Saver kit (Pharmacia). This poly(A) + RNA was
isolated over oligo-dT cellulose using the FastTrack kit (Invitrogen).
The oligonucleotide RG6 (5'-ccctgcacaaaggatcgt-3', situated 213 base
pairs downstream of the 5' end of clone 41a) was used to prime
first-strand synthesis. The final cDNA product was ligated into the
EcoR1 site of pBluescript and transformed into XL1-Blue cells. A
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clone of about 950 bp, designated 7a3, was obtained by colony
hybridization with probe 4EX (see below). Both strands of 7a3 were
sequenced as above, and assembled with 41a based on their
overlapping sequence. The assembled cDNA contains an open
reading frame that predicts the glypican amino acid sequence.
In order to obtain glypican cDNA fragments directly from rat
brain, PCR was performed as above from 0.5 plg rat brain total RNA
using the following sets of oligonucleotides: a) RG15 (5'-
tttgttgtctccgcctcctcg-3') and RG12 (5'-acgtcgctcaggctaaag-3'); b) RG11
(5'-cactgccgtcatcactgg-3') and RG10 (5'-tgctcaaaggctgccttg-3'); c)
RG11 and RG4 (5'-ctcatcactgacaagttc-3'); and d) RG5 (5'-
aggatgccagtgatgacg-3') and RG7b (5'-tggccaagacagtccttt-3'). The PCR
products were purified on a 2% Nusieve (FMC) agarose gel, and
sequenced with Taq polymerase using the fmol sequencing kit
(Promega) and oligonucleotides end-labelled with 32p-ATP.
Rat glypican probes. Probe 4X1 is a 162 bp EcoR1-Xhol fragment
from clone 41a inserted into pBluescript. Antisense RNA probes
were made by digesting the plasmid with EcoR1 and transcribing
with T7 RNA polymerase (Stratagene) in the presence of 35 S-UTP;
sense RNA probes were synthesized by digesting with Xhol and
transcribing with T3 RNA polymerase (Stratagene). Probe 4P1 is a
567 bp Pstl fragment subcloned from 41a into pBluescript.
Antisense RNA probes were made by digesting with EcoRI and
transcribing with T7 RNA polymerase. Probe 4P2 is a 332 bp Pstl
fragment subcloned from 41a into pBluescript. Antisense RNA
probes were made by digesting with BamH1 and transcribing with
T7 RNA polymerase. A rat glyceraldehyde -phosphate
dehydrogenase DNA probe was a gift of Dr. Timothy Hayes (N.I.H.).
Probes for Northern blots were labelled with 3 2 P-dCTP using the
Random Primer Labelling Kit (USB), and denatured at 1000C for 7
minutes before use.
Northern blotting. Total RNA, purified as described by Chomcyznski
and Sacchi (1987), was separated by electrophoresis in a 1.2%
agarose/6.4% formaldehyde gel and transferred to nitrocellulose by
capillary blotting. The filter was air dried for at least one hour, and
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then vacuum baked for 2 hours at 800 C. Prehybridization was
carried out at 42 0 C overnight in 50% formamide, 5X saline-sodium
phosphate-EDTA (SSPE), 5X Denhardt's, 0.1% SDS, 0.2 mg/ml yeast
RNA, and 0.1 mg/ml salmon sperm DNA. Hybridization was carried
out at 420 C for two days in 50% formamide, 5X SSPE, IX Denhardts,
0.1% SDS, and 0.1 mg/ml yeast RNA. Filters were washed once at
420 C in 50% formamide, 5X SSPE, 0.5% SDS for 30 minutes, twice at
420 C in 1X SSPE, 0.5% SDS for 15 minutes each, and twice at 65 0C in
0.1X SSPE, 0.5% SDS for 30 minutes each. Filters were exposed to
Kodak XAR-5 film at -80 0C and/or imaged using a phosphorimager
(Molecular Dynamics, Sunnyvale CA).
In situ Hybridization. Brains from 6-7 week old female Sprague-
Dawley rats were dissected and quick-frozen in isopentane chilled
on dry ice. 10 pm cryostat sections were thawed onto gelatin-coated
slides or Probe-On Plus slides (Fisher). Sections were stored at
-800 C until use.
In situ hybridization was performed as described by Simmons
et al. (1989). Briefly, sections were pretreated by fixation with 4%
paraformaldehyde in PBS for 5 minutes, washed in 2x saline-sodium
citrate (SSC), and treated with acetic anhydride to block positive
charges. Sections were then washed again in 2x SSC, dehydrated
stepwise in ascending alcohol concentrations, delipidated (in some
instances) in chloroform for 10 minutes, washed again in 100%
ethanol, and dried for at least one hour.
Sections were incubated overnight at 55-600 C in 50%
formamide, 10% dextran sulfate, 0.3 M NaCl, lx Denhardt's solution,
1 mM EDTA, 10 mM Tris (pH 8.0), 0.1 mg/ml yeast tRNA, 200 mM
DTT, 1% sarcosyl, and RNA probes at a concentration of 5x10 6-1x10 7
cpm/ml.
Sections were washed several times in 4x SSC, treated with
RNase A for 30-60 minutes, washed in descending salt
concentrations, and incubated in 0.1X SSC at 60 0 C for 30 minutes.
Sections were then dehydrated in ethanol and dried. Sections were
exposed to Hyperfilm-3Max (Amersham) or XAR-5 film (Kodak) for
10 to 14 days at -800 C. Sections were dipped in NTB-2 diluted 1:1
in water at -80 0 C for 15-30 days, developed in D-19 (Kodak),
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counterstained with either cresyl violet or bisbenzimid (Hoechst
33258) (Sigma), and studied with dark-field optics on a Zeiss
Axiophot or WILD microscope. Hybridized sections were compared
in some cases with nearby sections stained with cresyl violet, and
with sections illustrated in Paxinos and Watson (1986) and Swanson
(1992).
Production of glypican polyclonal antibodies. The EcoR1 fragment of
glypican clone 41a was cloned into the EcoR1 site of pMalc2 (New
England Biolabs), producing a construct that encoded a fusion
protein of glypican with the bacterial maltose-binding protein. The
construct was sequenced to verify that the junction was in-frame.
The fusion protein was induced by IPTG, and isolated by affinity
chromatography on an amylose column (New England Biolabs). The
fusion protein was then dialyzed into 150 mM NaC1, 20 mM Tris-HCl
(pH 7.5), 25 mM octyl-B-D-glucopyranoside. Antibodies were raised
at Pine Acre Rabbitry and Farms (Norton, MA). Rabbits were
injected intradermally with 0.5 mg of fusion protein in complete
Freund's adjuvant and boosted subcutaneously with 0.5 mg fusion
protein in incomplete Freund's adjuvant. After two boosts, sera
were collected and antibodies were purified over fusion protein
coupled to Affi-Gel 10 (Bio-Rad).
Immunoprecipitation. Embryonic day 18 and adult rat brain
membrane PGs were prepared and radioiodinated as described by
Herndon and Lander (1990) and boiled in 0.1% SDS to disrupt
aggregates of PGs that are present (cf. Herndon and Lander, 1990);
Triton X-100 was then added to a final concentration of 1%. This
material was incubated overnight at 40 C with 5 gLg of affinity
purified anti-glypican antibodies, and then absorbed to protein A-
Sepharose (Sigma) for 1 hour at 40C. The protein A-Sepharose was
then washed sequentially in 0.1 M Tris (pH 7.5), 2mM EDTA, 0.5% 3-
[(3-cholamidopropyl)dimethylammonio-]- 1-propanesulfate (CHAPS)
containing a) 150 mM NaCl, b) 0.5 M NaCl, and c) 150 mM NaCl; each
wash was done at 40C for 30 minutes. Antibody-antigen complexes
were dissociated by boiling the Sepharose in 0.5% SDS and diluting
into 1% Triton X-100, 50 mM Tris, 15 mM phosphoric acid (pH 7.3),
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and protease inhibitors. Aliquots were digested with heparitinase at
a concentration of 2 4g/ml at 430 C for 3 hours. Undigested and
heparitinase digested samples were separated by electrophoresis on
a 10% SDS-PAGE gel. The gel was dried and exposed to Kodak XAR-5
film at -800 C.
Western Blotting. Membrane and soluble fractions of rat brain were
prepared and 20 .tg aliquots were digested with heparitinase,
chondroitinase ABC, or simultaneously with both enzymes (Herndon
and Lander, 1990). Samples were subjected to electrophoresis in a
7% SDS/PAGE gel (Laemmli, 1970), and electroblotted to
nitrocellulose (Schleicher and Schuell). The nitrocellulose was
incubated at room temperature for one hour in 20% goat serum
(Sigma) in TBST (100 mM Tris-HCI [pH 8 at 40C], 150 mM NaCl, 0.1%
Tween-20), and then for one hour in 2.5 mg/ml 343-1 in 5% goat
serum/TBST. After washing several times in 5% goat serum/TBST,
the nitrocellulose was then incubated for one hour in a 1:5000
dilution of a horseradish peroxidase-linked goat anti-rabbit IgG
antibody (Amersham) in 5% goat serum/TBST. The filter was then
washed several times in TBST and then developed by ECL
(Amersham).
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Results
To determine the identities of two rat brain PGs that had
previously been shown to contain GPI anchors, HSPGs M12 (core
Mr-65 kD) and M13 (Mr-55 kD) (Herndon and Lander, 1990) were
purified from neonatal rat brain, and peptides derived from the two
core proteins were sequenced. Four M12-derived peptides were
obtained. These possessed a total of about 80% identity to regions of
the human glypican protein (Table 1), suggesting that M12 is rat
glypican. M13 peptides were not highly similar to human glypican,
and were used to isolate a cDNA clone encoding a novel PG core
protein (Stipp et al., 1994).
To obtain a rat glypican cDNA clone with which to compare the
M12 peptides, a human glypican probe was synthesized via PCR.
This probe detected a single 3.7 kb message in neonatal rat brain
total RNA (Fig. 1A). A message of the same size was detected in
human foreskin fibroblast RNA (Fig. lA), in agreement with the
previously reported human glypican message size from human lung
fibroblasts (David et al., 1990). A single message of this size was
also detected in PC12 cells, a rat pheochroma-cytoma cell line, and
was more abundant in RNA from these cells than in RNA from
neonatal rat brain (Fig. lA). This finding is consistent with previous
evidence that an M12-like proteoglycan is the major, if not only,
heparan sulfate proteoglycan found in PC12 cells (Herndon et al.,
1991).
A full-length rat glypican clone was obtained from PC12 cells
as described in Materials and Methods. The cDNA sequence predicts
a protein that is 89% identical to human glypican (the degree of
identity increases to 91% if GPI-attachment sequences, which should
not be present in the mature protein, are removed). The predicted
protein sequence also contains sequences identical to those of the
peptides derived from M12 (Fig. 2). Antibodies raised and purified
against a fusion protein synthesized from part of this cDNA detected
M12 in a Western blot of rat brain membranes (data not shown) and
also immunoprecipitated M12 from crude mixtures of PGs obtained
from both embryonic and adult rat brain (Fig. 3). Thus, we conclude
that M12 is the rat form of glypican.
While this work was in progress, peptide sequences from a rat
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PEPTIDE 15:
human glypican:
PEPTIDE 29:
human glypican:
PEPTIDE 15a:
human glypican:
PEPTIDE 26:
human glypican:
AEALRPFGDAPR
I II I I I I I I I I I
AEALRPFGDAPR
BXLPEVMGDGLANQGXNPEVD
I 111111111111 iii il:
RYLPEVMGDGLANQINNPEVE
MELETALHDSSR
:Iillll::111
AELETALRDSSR
BALQATLATQLHGIDDHFQ
1:111 11R1:::11111
RVLQAMLATQLRSFDDHFQ
Table:1. Seavence of tryptic peptides of purified
M12 com ared
with human glypican. Solid lines represent- identities; dotted lines
represent amino acids with similar properties. B refers to either K
or R.
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Figure 1. Detection of glypican message in rat brain. PCI2 cells, and
fibroblasts, A, Northern blot of 30 pg total RNA probed with a
human glypican cDNA. Lane 1, Rat fibroblast cell line F2408 RNA;
lane 2, PC12 cell RNA; lane 3, neonatal rat brain RNA; lane 4, human
foreskin fibroblast RNA. B, Northern blot of 20 Lg total RNA from
rat brain probed with rat glypican cDNA probe 4X1. Lane E,
emryonic day 18 rat brain RNA; lane N, neonatal rat brain RNA; lane
A, adult rat brain RNA. The filter was stripped and reprobed for rat
glyceraldehyde phosphate dehydrogenase (shown below), to
demonstrate the efficiency of loading and transfer of RNA. Levels of
glypican RNA relative to this control RNA are roughly equivalent at
the three developmental stages. Arrows in A and B point to position
of 18S and 28S ribosomal RNA bands.
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Figure 2. Comparison of rat and human glypican predicted protein
seauences. The rat sequence is listed on top; the human, on the
bottom. Amino acids in the human sequence identical to those in
the rat sequence are indicated with a dash; differences are listed.
Potential glycosaminoglycan attachment sites are indicated in
boldface; potential N-linked glycosylation sites are indicated by
asterisks; potential glypiation site is indicated by an arrow; putative
N- and C- terminal transmembrane hydrophobic stretches
(corresponding respectively to putative signal and glypiation
sequences) are indicated in italics; regions corresponding to
microsequenced peptides derived from purified M12 are
underlined. The nucleotide sequence of the full-length cDNA
extends about 70 bp past the 5' end and 200 bases beyond the 3'
end of the cDNA reported by Karthikeyan et al. (1992). Sequence
was assembled from clones 7a3 and 41a. The 3' end of clone 7a3
corresponds to base 883 and the 5' end of 41a corresponds to base
681 of the sequence in Karthikeyan et al. (1992).
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MELRRAR GWWLLCAAAAL VACARGDPASKSRSCSEVRQIYGAKGFSLSDVPQAEISGEHLRI 61 , rat
-------------------------------- G ------- ---------------- ----- uman;
- OGYTCCT SEMEENLANHSAMFLFTALRDSSRALOATLATOLG RTDmFoRLLNDSERTL 2
------------------ R-HA------R----V---M-----RSF----- H---------
QDAFPGAFGDLYTQNTRAFRDLYAELRLYYRGANLHLEETLAEFWARLLERLFKQLHPQLL 1 53
-AT------E---- A------ --------------------------------------
LPDDYLDCLGKQAEALR PFGUAPRELRLRATRAFVAARSFVQGLGVASDVVRKVAQVPLAP 2"
-------------------- E----------------- ---------------- G
ECSRAVMKLVYCAHCRGVPGARPCPDYCRNVLKGCLANQADLDAEWRNLLDSMVLITDKFW 30 5
-L------------------------------------------------
GPSGAENVIGSVHMWLAEAINALQDNKDTLTAKVIQGCGNPKVNPHGSGPEEKRRRGKLAL 366
-T--V-S------ T---------------R ------------------- Q-P------------ P
QEKSSTGTLEKLVSEAKAQLRDIQDYWISLPGTLCSEKMAMSPASDDRCWNGISKQBL 4 27
R-RPPS---------------- -------------- L-T---------MAR------
VMGDGLANOINNPEVEVDITKPDMTIRQQ IMQLKINTNRLRGAYGGNDVDFQDASDDG SGS4 8
---------------------------------------- S--N----------------
GSGGGCPDDACGRRVSKKSSSSRTPLTRALPGLSEQEGQKTSAATRPEPHYFFLLFLFTL V 49
---D--L--L---K--R--------------------------SC-Q-PT-L-PL-LF-A
LAAARPRWR558
-TV -----
Fig. 3. Antibodies raised against glypican fusion protein recognize
adult rat brain HSPG M12. 12 5 1-labelled adult rat brain PGs
(Herndon and Lander, 1990) were immunoprecipitated with 5 itg
rabbit IgG (lanes 2 and 6), or 5 ptg affinity purified anti-glypican
serum (lanes 3 and 7), or 5 gg anti-glypican serum containing 20 mg
glypican fusion protein. Lanes 1 and 5 show the starting material.
Samples were either subjected to SDS-PAGE without heparitinase
treatment (lanes 1-4) or treated with heparitinase before
electrophoresis (lanes 5-8). Arrowhead indicates the position of the
M12 core protein. Mr markers (in kD) are shown at right.
69
1 2 3 4 5 6 7 8
---- 220
.- 100
-- 68
-- 27
brain HSPG that were closely related to human glypican were
reported (Karthikeyan et al., 1992). This report also contained a
sequence for a rat glypican cDNA that contains four amino acid
differences (due to single base differences) from the sequence
presented here (Fig. 2): T instead of A at position 21, Y instead of N
at position 311, A instead of G at position 362, and I instead of T at
position 515. To address whether these differences represent
sequence polymorphisms between glypican from PC12 cells and
glypican from Sprague Dawley rats, we used PCR to obtain from
Sprague-Dawley rat brain RNA, cDNA fragments spanning three of
the four regions of sequence discrepancy. Sequenceable PCR
products were obtained that span three of the four regions
(positions 312, 362, and 515), and direct sequencing of these
fragments gave results that agreed in all cases with the sequence
reproted here for PC12 cells (data not shown). Consequently, the
data do not support the existence of glypican sequence
polymorphisms.
A northern blot using a probe from the rat glypican cDNA
confirmed that a single 3.7 kb glypican message is present in total
RNA from adult rat brain, and also detected a similarly sized
message in the embryonic (day 18) and neonatal rat brain (Fig. IB).
This is in agreement with expression of M12 protein, which was
detected at each of these stages (Herndon and Lander, 1990).
In situ hybridization experiments were undertaken to identify
the cell types that express glypican in the adult rat nervous system.
High levels of glypican expression were detected in several
structures in the adult rat brain. In the hippocampus, glypican was
expressed in high levels in the pyramidal cell layer (Fig. 4A).
Furthermore, the pyramidal cell layer in regions CA3 and CA4
expressed glypican mRNA at substantially higher levels than in
regions CAl and CA2. Some hybridization signal was also seen in
the dentate gyrus, although at lower levels than in regions CA3 and
CA4. High levels of expression were found throughout the dorsal
thalamus (Fig. 4A-C), including the ventrolateral, ventrobasal,
mediodorsal, lateral geniculate, and medial geniculate nuclei, but
expression was not seen in the medial and lateral habenula nor in
the ventral thalamus (e.g., the reticular nucleus and zona incerta).
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Figure 4. In situ hybridization of adult rat brain with rat glypican.
A, Coronal forebrain section probed with 4X1, viewed in dark field.
B, Coronal forebrain section at the level of the anterior thalamus
probed simultaneously with 4X1 and 4P2, viewed in dark field. C,
Coronal section through the posterior thalamus and anterior
midbrain, probed with 4X1, viewed in dark field. D, Coronal section
at the level of that in A probed with the sense (control) strand of
4X1, viewed in dark field. E, Coronal section through the anterior
forebrain probed simultaneously with 4X1 and 4P2; hyperfilm
image. F, Coronal section through the brainstem probed with 4X1,
viewed in dark field. G, A section approximately 30 gtm from that
in F stained with cresyl violet. H, Coronal section through the
brainstem probed with 4X1, viewed in dark field. I, Coronal section
through the brainstem probed with 4X1, viewed in dark field. J,
Section through a dorsal root ganglion probed with 4P1, viewed in
darkfield. Arrows point to silver grains clustered over sensory
neuron cell bodies. K, Same section as in J stained with cresyl violet.
L, High-magnification view of the septum and lateral ventricle from
a coronal section through the forebrain. M, Same section as in L
stained with cresyl violet. Asterisk in B indicates supraoptic nucleus
of the hypothalamus; arrow in B indicates the pyramidal layer of the
nucleus of the lateral olfactory tract. acc, nucleus accumbens; bla,
basolateral nucleus of the amygdala; cb, cerebellum; ct, cerebral
cortex; dg, dentate gyrus; dt, dorsal thalamus; e, ependyma; ha,
habenula; hi, hippocampus; Ic, locus coerulus; Iv, lateral ventricle;
me5, mesencephalic nucleus of the trigeminal (5th) nerve; mg,
medial geniculate nucleus of the thalamus; mo5, motor nucleus of
the trigeminal (5th) nerve; oc, Edinger-Westphal nucleus of the
oculomotor complex; p, piriform cortex; rn, red nucleus; s, septal
area; sc, superior colliculus; sn, sunstantia nigra; st, striatum; s5,
sensory nucleus of the trigeminal (5th) nerve; tu, olfactory tubercle;
7, nucleus of the 7th cranial nerve; 12, nucleus of the 12th cranial
nerve. In the sequence reported by Karthikeyan et al. (1992), 4X1
corresponds to bases 681-843, 4P1 corresponds to bases 1873-
2440, and 4P2 corresponds to bases 2435-2767. Scale bars: A-I,
500 4Lm; J and K, 200 gm; L and M, 20 plm.
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Strong hybridization was also seen to certain nuclei of the
amygdala (Fig. 4A,B), notably the pyramidal layer of the nucleus of
the lateral olfactory tract and the basolateral nucleus. Weaker
hybridization was seen to the lateral and basomedial nuclei, but no
hybridization to the anterior, medial, central, and cortical nuclei
were detected. The sense strand of glypican did not hybridize to
any of these or other structures (Fig. 4D). In addition, similar
results were obtained using several antisense probes synthesized
from different regions of glypican (see Materials and Methods) (data
not shown).
Other forebrain structures tended to show somewhat less
hybridization than that observed in the hippocampus, thalamus, and
amygdala. These included the piriform cortex (Fig. 4E), olfactory
tubercle (Fig. 4E), septal nuclei (data not shown), and the supraoptic
(Fig. 4B) and paraventricular nuclei (data not shown) of the
hypothalamus. Still weaker, but detectable hybridization was seen
to the cerebral neocortex (Fig. 4E; see also below) and nucleus
accumbens (Fig. 4E).
In the brainstem, relatively strong glypican hybridization was
seen to the red nucleus (Fig. 4C), locus coeruleus (Fig. 4F,G), and
several cranial nerve nuclei, including the motor nuclei of the 5th
(Fig 4F,G), 7th (Fig. 4H), and 12th (Fig. 41) nerves. Hybridization was
also seen to the oculomotor complex (Fig. 4C). In the spinal cord,
relatively strong hybridization was seen to the ventral horns (data
not shown), and to the dorsal root ganglia (Fig. 4J,K).
Many of the brain regions where glypican hybridization was
seen contain principal neurons with large, easily recognizable cell
bodies. When sections containing these re.-ons were examined at
higher magnification, it could frequently be established that
hybridization was localized to such neurons. For example, Figure 5A
shows glypican hybridization to cells in the nucleus of the 5th
cranial nerve. Figure 5B shows that clusters of silver grains are
present over large, lightly stained motoneuron cell bodies, but not
over smaller, more darkly stained cell bodies (i.e., glia and small
neurons). Similar results, that is, hybridization to large, lightly
stained cells, were obtained in other regions of the brain, such as the
thalamus and hippocampus (data not shown).
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Figure 5. Neuronal expression of glypican, A, Motor nucleus of the
trigeminal nerve. Arrows point to clusters of silver grains.
Arrowheads point to positions of small nuclei. Dark-field view. B,
Same field as in A. Arrows point to large, lightly stained nuclei
under the clusters of silver grains indicated in A. Arrowheads point
to small nuclei at positions indicated in A. C, Cerebellar cortex.
Arrows point to positions of Purkinje cells. Dark-field view. D,
Same field as in C. Arrowheads indicate the Purkinje cells marked
in C. Scale bars, 20 rtm.
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A characteristic of most of the neurons in regions that were
found to express glypican mRNA is that they are projection neurons.
In the cerebral neocortex, however, large numbers of local circuit
neurons are also present, and in layer 4 account for a large majority
of the neurons (Zilles et al., 1990). Interestingly, glypican
hybridization was not detected in layer 4 of the cortex, but was
readily detected in other cell body layers, that is, 2/3, 5, and 6 (Fig.
6A,B). In layer 2/3, hybridization was strongest in the superficial
part (Fig. 6B), and could be localized to a subpopulation of large cell
bodies (Fig. 6E,F). In layers 5 and 6, hybridization was present at all
levels, and was associated with most, but not all, large cell bodies
(Fig. 6C,D). Although cell body size and location alone are not
sufficient to establish the projection patterns of cortical neurons, the
data are at least consistent with the view that glypican is primarily
expressed by projection neurons.
Many types of projection neurons throughout the brain
expressed little or no glypican mRNA, however. These included
most neurons of the caudoputamen (Fig. 4E), the medial and lateral
habenula (Fig. 4A), the superior and inferior colliculi (Fig. 4C and
data not shown), the substantia nigra (Fig. 4C), and the cerebellum
(Fig. 4H,I). In the latter structure, individual Purkinje neurons are
readily visualized, and could be clearly shown to exhibit no glypican
hybridization over background (Fig. 5C,D). Although the possibility
remains that levels of glypican mRNA too low to detect are present
in these cells, the results emphasize the fact that levels of glypican
mRNA expression throughout the brain do no merely correlate with
cell body size.
In addition to being present in subsets of neurons, glypican
mRNA was also found in some supporting cell (stromal) elements of
the brain. For example, glypican hybridization could be seen
associated with some large blood vessels, although at weaker levels
than in many of the glypican-expressing neurons (data not shown).
Higher but variable levels of hybridization could also be seen
associated with ependymal zones (e.g., of the lateral ventricles) (Fig.
4E,L,M).
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Figure 6. Glypican expression in the cerebral cortex. A, Right,
coronal section at the level of the basal ganglia stained with cresyl
violet. Left, dark-field view of coronal section 30 ltm from that on
right hybridized simultaneously with 4X1 and 4P1. B, Magnified
views of corresponding regions from sections in A. Lines indicate
approximate divisions between cortical layers. C, High-
magnification view of layer 5, dark field. D, Same field as in C,
stained with Hoechst 33258. E, High-magnification view of layer 2,
dark field. F, Same field as in E, stained with Hoechst 33258. Solid
arrows in C-F indicated clusters of silver grains, and the cell nuclei
with which they are associated; open arrows indicate large cell
bodies lacking clusters of siver grains. Scale bars: A, 500 jim; B,
200 gim; F, 20 jim.
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Discussion
A major PG of the adult rat brain, HSPG M12, has been
identified as glypican based on the following observations: 1) M12
is a GPI-anchored PG with a core protein size (-65 kD) similar to that
observed for human fibroblast glypican (Herndon and Lander, 1990;
David et al., 1990); 2) peptides derived from M12 have amino acid
sequences identical to those predicted from a rat glypican cDNA
(this is in agreement with Karthikeyan et al., 1992, who also
identified peptide sequences in a rat brain HSPG core protein that
corresponded to sequences in a rat glypican cDNA); and 3)
antibodies raised against a rat glypican fusion protein specifically
immunoprecipitate M12 from a crude mixture of brain PGs and
recognize a PG core protein that comigrates with M12 on a Western
blot of heparitinase-digested brain membranes (data not shown). In
addition, the expression of glypican message parallels the
appearance of M12 core protein: we have found that glypican
message is expressed in the adult and developing rat brain, as is
M12, and that glypican mRNA can be detected by in situ
hybridization in many brain regions.
Neuronal expression of glypican.
The regional distribution of glypican mRNA in the adult brain,
as revealed by in situ hybridization, suggests the following general
features of glypican expression in the central nervous system:
Glypican is primarily a product of neurons. In many of the
regions where glypican mRNA is expressed, neuronal cell bodies can
be recognized by morphological criteria, e.g. location, nuclear size
and intensity of cresyl violet staining. In such regions (e.g.
hippocampus, motor nuclei, dorsal root ganglia), glypican
hybridization is found directly over such cell bodies. This suggests
that glial cells, which outnumber neurons in the brain, do not
express glypican, although low level expression, or expression by
small numbers of glia cannot be ruled out. Supporting and
connective tissue elements of the brain (e.g. linings of large blood
vessels, meninges, ependyma) also exhibit some glypican
hybridization, although at relatively low levels compared with
neuronal expression.
80
Glypican- expressing neurons are predominantly projection
neurons. Each of the neuronal populations that expresses glypican
appears to consist mainly of cells with axons that project to other
brain regions, or, in the case of motoneurons, to the periphery. Even
in the cerebral cortex, glypican expression is present in laminae
with corticocortical or corticofugal connections (e.g., layers 2/3, 5,
and 6), but absent from layer 4, which consists primarily of local
circuit neurons. Since projection neurons typically have long axons,
relatively high levels of glypican mRNA expression might be
required in some projection neurons, if it turns out that the
physiological processes that involve glypican require the molecule to
be present at the axonal surface. Indeed, glypican protein can be
localized in some regions of the adult brain to fiber tracts. This is
consistent with axonal expression and, in some cases, axonal
polarization of other GPI-anchored proteins (e.g. F3/Fll1 [Faivre-
Sarrailh, 1992], Tag-1 [Dodd et al., 1988; Furley et al., 1990], Thy-1
[Xue et al., 1990]).
Levels of glypican mRNA expression vary substantially among
different populations of neurons. Based on the autoradiographic
exposure times required to detect glypican expression in different
brain regions, we can estimate relative levels of glypican expression
(Table 2). High level expression does not bear a simple relationship
to neuronal cell body size or axon length. Indeed, some large and
medium-sized projection neurons do not express detectable glypican
(e.g. cerebellar Purkinje cells).
Although others have suggested that some PGs are localized to
neurons that form functional or anatomical systems (Hockfield et al.,
1990; Maeda et al., 1992), the types of neurons that express glypican
mRNA do not correspond to any single functional or transmitter-
specific subdivisions of the brain. Nevertheless, limbic structures--
hippocampus, amygdala, thalamus, cingulate and piriform cortex,
nucleus accumbens, and septal nuclei--are relatively prominent
among glypican-expressing structures. At least one other GPI-
anchored protein is known to be associated with limbic system
structures (LAMP [Levitt, 1984; Zacco et al., 1990; Zhukareva and
Levitt, 1993]). Also prominent among glypican-expressing neurons
are neurons whose axons contribute to peripheral nerves (spinal
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Table 2. Relative levels of glypican hybridization in the adult rat
nervous system. Intensity of hybridization is graded as +++ (very
strong), ++ (strong), + (moderate), +/- (weak), or - (absent), based in
part on autoradiographic exposure times. For example, structures,
such as CA3 and CA4 of the hippocampus were darkly exposed in
<15 d, while structures such as the cerebral cortex were usually only
detected in longer exposures (>25 d), or when two probes were used
simultaneously during hybridization. Structures graded as -
sometimes exhibited small clusters of siilver grains over rare large
cell bodies. Unlisted structures were not determined.
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Forebrain
Cerebral neocortex
Layers 2/3, 5. 6
Layers 1,4
Hippocampus
CA1, CA2
CA3, CA4
Dentate gyrus
Caudoputamen
Dorsal thalamus
Ventral anterior-lateral nucelus
Ventral posterolateral nucleus
Mediodorsal nucleus
Nucleus reuniens
Lateral geniculate nucleus
Medial geniculate nucleus
Anterodorsal
Anteromedial
Lateral dorsal
Anteroventral nucleus
Ventral thalamus
Reticular nucleus
Zona Incerta
Epithalamus
Medial habenula
Lateral hdbenula
Amygdaloid nuclei
Basolateral
Nucleus of the lat. olfhrtory tract-
Lateral and basomedial
Anterior, medial, central,cortical
Hypothalamus
Supraoptic nucleus
+ Paraventricular nucleus
Arcuate nucleus
Piriform cortex
++ Olfactory Tubercle
+++ Septum
+ Nucleus accumbens
+/. Endopiriform nucleus
Ependyma
++ Large meningeal blood vessels
Brainstem
Superior colliculus
Inferior colliculus
Red nucleus
Substantia nigra
Locus coeruleus
Cerebellum
Granule cell layer
Purkinje cell layer
Cranial nerve nuclei
Edinger-Westphal
Motor V
Motor VII
Motor XII
Mesencephalic V
Sensory V
Spinal cord
Ventral horn motoneurons
Dorsal horn neurons
Dorsal root ganglion neurons
4
+
++
++
++
4+
+4+
+4+
4++
++
4+
and cranial motoneurons; dorsal root ganglion neurons).
Functional roles of glypican in the adult rat nervous system,
Although glypican is only one of many PGs in the mammalian
brain, there are reasons to believe that whatever roles it plays there
may be unique. In adult brain, glypican is a major HSPG, and it is
the only HSPG that exhibits detergent partitioning properties
indicative of an integral membrane protein (Herndon and Lander,
1990). This suggests that the bulk of the HS borne by integral
membrane proteins in the adult brain may be found on glypican.
Since glypican is only expressed by certain populations of neurons,
this suggestion raises the interesting possibility that CNS glia and
some neurons may be relatively or entirely deficient in cell-surface
HS. If so, expression patterns of glypican might play an important
role in restricting the sites of action of molecules that normally
interact with cell-surface HS.
Among such molecules that are found in the adult brain,
members of the FGF family of polypeptide growth factors are
present in many locations where glypican-expressing neurons are
found. Acidic FGF, for instance, is highly expressed in spinal and
cranial motoneurons, as well as neurons of the dorsal root ganglia,
thalamus, septum, and red nucleus, but differs from glypican in
being largely absent from the cerebral cortex and hippocampus
(Elde et al., 1991; Stock et al., 1992). However, hippocampal
pyramidal neurons do express basic FGF (primarily in subfield CA2
[G6mez-Pinilla et al., 1992; Woodward et al., 1992]), and FGF-5 (in
subfields CA2 and CA3 [G6mez-Pinilla and Cotman, 1992]). Basic FGF
is also found in some cranial motor nuclei (G6mez-Pinilla et al.,
1992), and FGF-5 is present in skeletal muscle (Hughes et al., 1993).
Although the functions of these growth factors in the adult nervous
system are not known, evidence suggests that they may be involved
in facilitating neuronal repair and/or neuronal survival (G6mez-
Pinilla et al., 1992; Hughes et al., 1993). Since the actions of growth
factors of the FGF family apparently require the participation of the
HS chains of HSPGs (Yayon, et al., 1991; Rapraeger et al., 1991),
glypican may play an important role in the trophic and injury
responses of neurons.
84
Glypican could also play a role in neuronal injury responses by
virtue of interactions with HS-binding extracellular matrix
molecules. For example, laminin, a strongly neurite outgrowth-
promoting molecule, becomes exposed in the endoneurial sheaths of
peripheral nerves during nerve regeneration (Bignami et al., 1984;
Longo et al., 1984); both motoneurons and primary sensory neurons
express glypican, which could then be involved in the recognition of
and response to endoneurial laminin. Alternatively, it is known that
at least one HSPG that is released by cells strongly inhibits the
neurite outgrowth effects of laminin (Muir et al., 1989); neuronal
glypican might be released under some circumstances and thereby
interfere with regeneration. Significantly, GPI-anchored molecules,
including some GPI-anchored PGs, are known to be shed by cells,
presumably through the action of endogenous surface
phospholipases (Ishihara et al., 1987; Carey and Evans, 1989; Low,
1989). This could account for the existence of an HSPG with
biochemical properties very similar to those of glypican in the adult
rat brain soluble (non-membrane associated) fraction ("S9"; Herndon
and Lander, 1990).
It is possible that glypican mediates different effects
depending on its cellular source. Several heparin-binding proteins
bind specifically to subfractions of heparin, suggesting that these
proteins recognize aspects of GAG structure that may be found only
on some HS chains (Marcum and Rosenberg, 1989; Lee and Lander,
1991; Nurcombe et al., 1993; San Antonio et al, 1993). Purification
of glypican from specific neural sources, followed by binding studies
with heparin-binding proteins of the brain, should indicate whether
heterogeneity in the HS borne by the glypican core protein
influences the kinds of molecules for which glypican, in different
types of neurons, may act as a receptor.
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Chapter 3: Determination of glypican expression and the
localization of glypican and cerebroglycan protein during
development.
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Introduction.
Many processes in the development of the nervous system
involve cell surface heparan sulfate proteoglycans (HSPGs). Cell
surface HSPGs can participate in NCAM-mediated cell adhesion (Cole
et al., 1986; Reyes et al., 1990), as well as cell-substratum adhesion
and neurite outgrowth (LeBaron et al., 1988; Sanderson et al., 1992;
Wang and Denburg, 1992). HS on the cell surface can also affect
neurite outgrowth by regulating the inactivation of proteases by
their inhibitors (Monard, 1988). Furthermore, HSPGs are required
for the action of some growth factors, in particular fibroblast growth
factors (FGFs) (Rapraeger et al., 1991; Yayon et al., 1991); thus
HSPGs are likely to play a role in FGF-mediated cell survival,
proliferation, and differentiation. Consistent with these roles, many
HSPGs have been identified from brain membranes, and the
expression of these PGs has been found to be developmentally
regulated (Herndon and Lander, 1990).
Cell surface HS can be provided by two classes of integral
membrane HSPGs, each of which define a gene family. Syndecans 1-
4 are hybrid chondroitin sulfate (CS)/HSPGs (for review, see
Bernfield et al., 1992). They are composed of an extracellular
domain containing several potential attachment sites for HS and CS,
a hydrophobic transmembrane domain, and a highly conserved
cytoplasmic domain that has been suggested to interact with
cytoskeletal elements. Of all members, only syndecan-3 (N-
syndecan) has been shown to be expressed by nervous tissue.
Regulated during development, syndecan-3 is expressed highly and
widely in neonatal rat brain, with lower levels in embryonic and
adult brain (Carey et al., 1992).
The other family of integral membrane HSPGs consists of
glypican and its homologs. Glypican is a roughly 60-70 kD
glycosylphosphatidylinositol (GPI)-linked HSPG first cloned in
fibroblasts (David et al., 1990), but later shown to also be expressed
in brain (Karthikeyan et al., 1992; Karthikeyan et al., 1994; Litwack
et al., 1994a). In the brain, glypican has been shown to be
expressed by subpopulations of projection neurons (Litwack et al.,
1994a). Other family members include K-glypican and OCI-5
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(Filmus et al., 1988; Watanabe and Yamaguchi, 1994), both of which
are found in brain, and cerebroglycan, which is expressed
specifically in the nervous system by postmitotic neurons during
periods of initial migration or axon growth (Stipp et al., 1994). Thus,
while all members seem to be represented in the brain, at least
some of them are expressed in distinct fashions.
Based on their modes of insertion in cell membranes, these
two classes of cell surface HSPGs are likely to mediate different
cellular responses upon binding heparin-binding proteins, and thus
may serve different functions in the nervous system. Syndecan, for
instance, possesses a cytoplasmic domain that is thought to interact
with the cytoskeleton, and syndecans have in fact been found in
focal adhesions (Woods and Couchman, 1992; Carey et al., 1994;
Woods and Couchman, 1994). Thus, heparin-binding proteins could
be linked to the cytoskeleton upon binding syndecan. Glypican, on
the other hand, is inserted into the membrane via covalently
attached lipids (for a review of GPI-anchored proteins and their
properties, see Cross, 1990). This mode of insertion could confer
higher lateral mobilities in the cell membrane with respect to
transmembrane proteins (Chan et al., 1991). Such a mode of
insertion could also allow glypicans to be shed from the cell surface
by phospholipases C or D (as contrasted with syndecan, which must
be released by proteases). The GPI-linkage might also localize
glypicans to specialized domains in the cell membrane (Lisanti et al.,
1994); this could be a mechanism of association of glypican with
particular membrane proteins. GPI-linked proteins have also been
shown to be associated with intracellular tyrosine kinases
(Stefanova et al., 1991; Thomas and Samelson, 1992; Rudd et al.,
1993), and might therefore be able to transduce signals.
Interactions of heparin-binding proteins with different PGs may
thus lead to different functional consequences.
In an effort to understand the function of HSPGs in the
development of the nervous system, we have begun to characterize
the expression of glypican and its homologs in the brain. Previous
studies have shown that glypican is expressed by subpopulations of
neurons in the adult rat nervous system (Litwack et al., 1994a). The
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studies presented here characterize the expression of glypican
during neural development, as well as in other developing tissues.
Immunohistochemistry indicates that both glypican and
cerebroglycan are expressed on axons; in some neurons,
cerebroglycan is polarized to axons and not to dendrites or cell
bodies. Some of this data has been presented previously in abstract
form (Kumbasar et al., 1994; Litwack et al., 1994b).
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Materials and Methods.
Rat glypican probes. RNA probes from rat glypican clones 4X1 and
4P1 were synthesized as previously described (Litwack et al.,
1994a; Chapter 2, this thesis).
In situ hybridization. Embryos were dissected from timed pregnant
Sprague-Dawley rats, with plug date considered embryonic day 0
(EO). E14 embryos were fixed overnight with 4% paraformaldehyde
in PBS, and then equilibrated in sequentially in 5% and then 15%
sucrose in PBS. Rats of all other embryonic ages and postnatal rats
were frozen in isopentane chilled on dry ice. 20 gm cryostat
sections were collected on Probe-On Plus microscope slides (Fisher).
In situ hybridization experiments were performed as previously
described (Litwack et al., 1994a).
Anti-peptide antibodies. A peptide designated 343
(CGNPKVNPHGSHPEEKRR) was synthesized and purified by reverse-
phase HPLC (Biopolymers Lab, M.I.T.). This peptide corresponds to
amino acids 343-360 of rat glypican (Litwack et al., 1994a). 20 mg
of keyhole limpet hemocyanin (KLH) (Pierce) was reacted with 2 mg
sulfo-SMCC (Pierce) at room temperature with stirring for 30
minutes. Activated KLH was purified over a Sephadex G-25 column
(Pharmacia) in 0.1 M sodium phosphate (pH6). 22 mg 343 was
dissolved in the same buffer, and reacted overnight at room
temperature with the activated KLH. KLH-343 complexes were
purified over a Sephadex G-25 column. Antibodies were raised at
Pine Acres Rabbitry and Farms (Norton, MA). Rabbits were injected
intradermally with 2.5 mg KLH-343 in complete Freund's adjuvant
and boosted four times intramuscularly with 2.5 mg KLH-343 in
incomplete Freund's adjuvant. Antibodies were collected and
purified over 343 coupled to Sulfo-Link (Pierce). This antiserum
was designated 343-1.
A rabbit polyclonal antiserum was also raised as described
above to a peptide designated 521 (CRPPRPPRPPRRDGL). This
peptide corresponds to amino acids 521-535 of cerebroglycan. The
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antiserum was designated 521-2, and was used after two
intramuscular boosts.
Western blots. GAG lyase digestions and Western blots were
performed as described in Chapter 2.
Immunohistochemistry. E13.5 CD-1 mouse embryos, E13 rat
embryos, E19 rat heads, and PO rat brains were dissected and fixed
by overnight immersion in 4% paraformaldehyde in PBS at 40 C.
Tissue was equilibrated sequentially in 5% and 15% sucrose in PBS.
were treated similarly. E14 rat embryos, P21 rat brains, and adult
rat brains were quick-frozen on isopentane. 20 ýtm cryostat sections
of all samples were collected on Probe-On Plus slides (Fisher) and
stored at -80oC until further use. For immunohistochemistry,
sections were incubated in block (2% BSA, 100 mM Tris [pH 8 at
4oC], 150 mM NaCl, 0.3% Triton X-100). Sections were washed in
TBS (100 mM Tris [pH 8 at 40 C], 150 mM NaCl) and, when sections
were to be developed with horseradish peroxidase, treated twice for
30 minutes each in 0.3% H202 and washed again in TBS. Affinity
purified 343-1 was applied at 2.5-5 ýtg/ml in block; affinity purified
521-2 was applied at 2.5 pLg/ml. For immunofluorescence, a 1:100
dilution of Cy3 (Jackson Immunoresearch) was used as a secondary
antibody, and sections were coverslipped using GelMount (Biomeda).
For horseradish peroxidase, sections were incubated in biotin-
conjugated goat anti-rabbit antibody (Vector) diluted 1:300 in block
as a secondary antibody. Sections were washed in TBS and then
incubated in ABC reagent (Vector) diluted in block. Sections were
washed again in TBS and developed in 50 gg/ml DAB/0.3% H20 2/50
mM Tris. Sections were washed in H20, dehydrated, cleared in
xylenes, and coverslipped using Permount. In some cases, sections
were counterstained with methyl green before dehydration and
mounting.
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Results.
Glypican expression in the developing nervous system. In the adult
rat nervous system, glypican is expressed by subpopulations of
neurons (Litwack et al., 1994a). In situ hybridization experiments
were undertaken in a series of embryonic and postnatal rats in
order to determine how glypican expression is regulated during
development.
At E14, glypican is associated primarily with the nervous
system (Fig. 1A). In particular, glypican expression is associated
with ventricular zones (Fig. 1A,B,D,2), regions of proliferating
neuroepithelia that give rise to both neurons and glia. Only
background levels of hybridization are seen in the preplate (Fig. 2),
which contains the earliest-born neurons of the cerebral cortex. At
this age, the pattern of glypican expression is complementary to the
expression of cerebroglycan, a member of the glypican family of
lipid-linked HSPGs (Fig ID,E; Stipp et al., 1994). Cerebroglycan
expression is associated with the preplate and with other zones of
differentiated neurons (Fig. 1E).
During later stages of development, glypican expression in the
nervous system is widespread. In the E18 rat brain, glypican
expression is associated with the ventricular zone, intermediate
zone, and cortical plate of the cerebral cortex in a pattern that
correlates with the distribution of cell bodies (Fig. 3A). Only the
marginal zone, which contains relatively few cell bodies, has
background levels of glypican hybridization.
Glypican is expressed in other regions of the nervous system,
including the corpus striatum (Fig. 3A), which does not express
glypican in the adult (Litwack et al., 1994a r . Glypican expression is
also associated with the thalamus and hippocampus (Fig. 3A).
The pattern of glypican expression in the PO rat brain is
virtually identical to that observed in the E18 rat brain (Fig. 3B);
widespread expression is seen in the thalamus, corpus striatum, and
cerebral cortex. The low levels of hybridization in the intermediate
zone of the cerebral cortex is consistent with the lower density of
cells in this area in the PO rat. High levels of expression continue to
be observed in the corpus striatum, thalamus, and all layers of the
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Figure 1. Glypican expression in E14 rat. A, Hyperfilm image of a
sagittal section through E14 rat, probed with 4X1. B, Darkfield view
of a sagittal section through E14 rat, probed with 4X1. C, Darkfield
view of a section nearby to that in B, probed with sense (control)
strand of 4X1. D, Hyperfilm image of a sagittal section through E14
rat, probed with 4X1. E, Hyperfilm image of a section nearby to that
in D, probed with a cerebroglycan antisense RNA probe.
Abbreviations: f, forebrain; h, hindbrain; m, midbrain; t,
tegmentum. Scale bars: A, 1 mm; B-C, 250 itm; D-E, 1 mm.
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Figure 2. Glypican expression in the ventricular zone of E14 rat
telencephalon, A, Darkfield view of a sagittal section through E14
rat forebrain, probed with 4X1. B, Same section as that in A,
counterstained with Hoechst and viewed by fluorescence. C,
Darkfield view of a sagittal section nearby that in A, probed with
the sense (control) strand of 4X1. D, Same section as that in A,
counterstained with Hoechst and viewed by fluorescence. In all
panels, rostral is to the left, dorsal is up. Dashed lines indicate the
approximate boundary between the ventricular zone and preplate.
Abbreviations: p, preplate; v, ventricular zone. Scale bar: A-D, 100
Rm.
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Figure 3. Glypican expression in the E18-P7 rat nervous system. A,
Darkfield view of a sagittal section through E18 head, probed with
4P2. B, Darkfield view of a sagittal section through PO head, probed
with 4P2. C, Darkfield view of a sagittal section through P7 brain,
probed with 4X1. D, Same section as in C. E, Same section as in C. F,
Darkfield view of a coronal section through P7 brain, probed with
4P2. G, Darkfield view of a coronal section through P7 brain, probed
simultaneously with 4X1 and 4P2. H, Darkfield view of a coronal
section through P14 brain, probed with 4P2. In A-E, anterior is to
the left, dorsal is up. Abbreviations: a, nucleus accumbens; b, bone;
c, cerebral cortex; cb, cerebellum; cp, cortical plate; dg, dentate
gyrus; egl, external granule cell layer; h, hippocampus; hf, hair
follicles; i, intermediate zone of the cerebral cortex; igl, internal
granule cell layer; Iv, lateral ventricle; ml, molecular layer; o,
olfactory bulb; p, piriform cortex; pl, pyramidal cell layer of the
hippocampus; s, striatum; t, thalamus; v, ventricular zone. Scale
bars: A-E, 250 ptm; F-H, 1.5 mm.
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hippocampus, including proliferative cells in the hilar region of the
dentate gyrus that give rise to granule neurons.
In the P7 rat brain, glypican expression continues to be
widespread (Fig. 3C-G). All regions observed express glypican,
including the external and internal granule cell layers of the
cerebellum (Fig. 3E); as with the corpus striatum, this expression
must be transient, as no glypican expression is seen in the adult rat
cerebellum (Litwack et al., 1994a).
Despite the widespread expression of glypican at this age,
some regional differences can be observed. In the hippocampus, the
pyramidal cell layer has higher levels of expression than the dentate
gyrus (Fig. 3D), similar to the adult pattern of expression in the
hippocampus (Litwack et al., 1994a). In addition, the anterior
thalamus has lower levels of expression than the posterior thalamus
(Fig. 3D). Expression in the cerebral cortex is still relatively uniform,
however, and significant glypican expression persists in the corpus
striatum (Fig. 3F,G).
By P14, the pattern of expression more closely resembles the
adult pattern of expression (Fig. 3H). In the hippocampus, high
levels of expression are seen in the CA3 region of the pyramidal cell
layer, whereas lower levels are seen in the rest of the pyramidal cell
layer and in the dentate gyrus. The dorsal thalamus expresses
glypican, while the ventral thalamus generally does not (although
there is a small amount of hybridization in the most ventrolateral
regions of the ventral thalamus). Very low levels of cortical
expression are observed.
In all cases, sections hybridized to sense (control) strands of
glypican showed no specific hybridization to any region of the
nervous system (Fig. 1C,2C,D; data not shown).
Nonneural expression of glypican. Outside the nervous system,
particularly high levels of glypican message were detected in
developing bone. During endochondral ossification in an E18 rat
humerus, hybridization is seen in the periosteum and also in the
trabeculae (Fig. 4A-D). In a section through E18 trunk,
hybridization is likewise observed in association with periosteum
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Figure 4. Expression of glypican in developing bone. A, Section
through E18 forearm probed with 4P2, viewed in dark field. B,
Section adjacent to that in A, stained with hematoxylin and eosin. C,
Section through E18 vertebral column probed with 4X1, viewed in
dark field. D, Section 40 ýtm from that in C, stained with
hematoxylin and eosin. E, Section through P7 limb probed with 4X1,
viewed in dark field. F, Same section as in E, stained with Hoechst.
G, Section through P7 limb probed with the sense (control) strand of
4X1, viewed in dark field. G, Same section as in G stained with
Hoechst. The hypertrophying chondrocytes in F-G were lost during
sectioning. In C-D, rostral is to the left, and dorsal is to the top.
Abbreviations: c, chondrocytes; d, dorsal root ganglion; ep,
epiphyseal plate; hc, hypertrophying chondrocytes; o, osteoblasts; p,
periosteum; t, trabeculae. Scale bars: A-D, 250 kim; E-H, 100 Lnm.
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and trabeculae in vertebral bodies and ribs (Fig. 4C,D). However, no
expression is observed in the resting, proliferating, or hypertrophic
chondrocytes (Fig. 4A-F).
The pattern of expression in developing bone is consistent
with expression by populations of differentiated osteoblasts.
Osteoblasts differentiate in the periosteum and then migrate into
the trabeculae, both regions that express glypican. Consistent with
this interpretation, vertebral bodies at different stages of
development show hybridization that appears in a spatial and
temporal progression that is consistent with osteoblast
differentiation. Development of vertebral bodies proceeds In a
rostral-to-caudal fashion. In the younger, more caudal vertebral
bodies expression appears in the periosteum (Fig. 4C,D). The
periosteal expression extends completely around the older, more
rostral vertebral bodies. In these older vertebral bodies, expression
also appears in the trabeculae. The caudal-to-rostral pattern of
glypican expression parallels the development and differentiation of
osteoblasts.
In situ hybridization experiments in P7 bone provide results
consistent with the hypothesis that glypican is expressed by
differentiated osteoblasts. In the epiphyseal plate of a long bone In
P7 limb, hybridization is seen in association with cells near bony
spicules (Fig. 4E,F,5), i.e., the same area where osteoblasts are
located. However, osteoclasts may also be present as well in these
regions, and these experiments do not distinguish between the two
populations. Association of glypican with differentiated osteoblasts
is also observed in intramembranous bone formation (which, for
example is the mechanism of formation of skull bones) (Fig. 3A).
Hybridization to the sense strand only shows signal associated
with the bony spicules in the trabeculae (Fig. 4G,H,5C,D), an artifact
seen in all hybridization experiments performed on bone. In these
controls no hybridization is seen over cell bodies.
At this stage hybridization is also seen in the bone marrow in
clusters (Fig. 6C,D). Glypican could be expressed by subpopulations
of hematopoietic cells or stromal cells of the marrow. In P7 limb,
glypican expression is also associated with hair follicles (Fig. 6A,B);
103
Figure 5. High magnification view of epiphyseal plate, A, Darkfield
view of a section through epiphyseal plate in P7 limb, probed with
4X1. B, Same section as in A, stained with Hoechst. C, Darkfield
view of a section nearby to that in A, probed with sense (control)
strand. D, Same section as in C, stained with Hoechst. Scale bar: A-
D, 25 pLm.
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Figure 6. Expression of glypican in hair follicles and bone ma-row.
A, Darkfield view of hair follicles in P7 limb, probed with 4X1. B,
Same section as in A, stained with Hoechst. C, Darkfield view of
bone marrow in long bone of P7 limb, probed with 4X1. D, Same
section as in C, stained with Hoechst. Scale bar: A-D, 100 jim.
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expression of glypican in hair follicles was also noted in E18 rat
head (Fig. 3A). While some variation in the levels of glypican
expression between individual hair follicles can be observed,
comparison with a Hoechst-stained section indicates that these
variations are likely due to the region of the particular hair follicle
present in the section (Fig. 6A,B). The expression of glypican in hair
follicles is consistent with results previously obtained via
immunostaining (David et al., 1992a).
Localization of glypican to nerve fibers. In order to determine the
distribution of the glypican protein product, an antiserum was
raised to a glypican-derived peptide. This antiserum was then
purified by affinity chromatography using the peptide antigen;
these affinity-purified antibodies, designated 343-1, were used in
all experiments described below.
By Western blotting of PO rat brain membranes treated with
heparitinase, 343-1 recognizes a single band of about 66 kD (Fig.
7A) 1. No higher molecular weight smear, typical of intact PG, was
detected in untreated brain membranes; it is likely that the intact
PG, which contains a high level of negative charge due to attached
GAG, failed to bind to the relatively hydrophobic nitrocellulose
membrane (Rapraeger et al., 1985). 343-1 also recognizes a protein
of the correct molecular weight in extracts of myeloma cells
expressing a rat glypican transgene, but not in control myeloma cells
(Appendix 1).
1No core protein was observed by western blot when PO membranes were
treated with chondroitinase ABC, but the intensity of the glypican signal was
higher when membranes were treated with chondroitinase and heparitinase
together than when membranes were treated with heparitinase alone. This
could reflect a population of glypican that possesses CS as well as HS.
However, no CS has previously been observed on glypican. Furthermore,
comparisons of relative intensities between treatments are sometimes
misleading. For instance, in adult rat brain soluble fraction, the intensity of
the immunoreactive band is higher with heparitinase treatment alone than
with heparitinase and chondroitinase treatment (Fig. 8). It would be
necessary to purify GAGs from glypican that had been purified from brain in
order to definitively say that some glypican possesses CS chains.
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Figure 7. Western blot of PO rat brain membranes, A, Western blot
of 18 p~g of PO membranes using 343-1. B, Western blot as in A
using 521-2. Lane 1, heparitinase- and chondroitinase-treated; lane
2, chondroitinase-treated; lane 3, heparitinase-treated; lane 4,
untreated.
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No specific bands corresponding to intact glypican were
observed in Western blots of adult membranes using 343-1. A
broad smear of about 47-58 kD was observed in adult soluble
fractions that had been treated with heparitinase (Fig. 8A). The
apparent Mr of this protein increased to 62 kD upon reduction, a
property that has been observed with glypican (Fig. 8B). This band
is likely to represent a proteolytic fragment of glypican. It is
unclear whether this is an endogenous proteolytic product or
whether proteolysis occurred during purification. The
immunoreactive band in the soluble fraction was observed with two
separate purifications of soluble fraction from adult brain (data not
shown).
Immunostaining using 343-1 generally gave results consistent
with the data obtained from in situ hybridization experiments. In
the E14 rat, for example, high levels of glypican mRNA message are
expressed in the ventricular zone of the developing nervous system
(Fig. 1,2). Likewise, high levels of staining with 343-1 were
observed in the ventricular zone (Fig. 9A), while, as described
below, no specific pattern of staining was observed with control
antibodies (data not shown). 343-1 staining near the pial surface
appeared to be at or just slightly above background, consistent with
the low levels of signal observed with in situ hybridization.
Staining of the adult rat nervous system with 343-1 indicated
that the glypican protein product is expressed on fibers, and is
likely to be associated with axons. High levels of immunoreactivity
were seen in the hippocampus (Fig. 10A,C). The associational and
commissural fiber layer, containing axons arising from hippocampal
pyramidal cells, was heavily stained, and cell bodies within the
pyramidal cell layer were also detected. Consistent with the relative
levels of glypican expression observed by in situ hybridization,
lower levels of glypican were seen in the cell bodies of the dentate
gyrus than in the pyramidal cell layer. Less immunoreactivity was
observed in the mossy fibers projecting from the dentate gyrus to
the pyramidal cell layer. In addition to axons arising from the
dentate gyrus, pyramidal cell dendrites are also located in the
mossy fiber layer. An evenly distributed membrane protein might
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Figure 8. Western blot of adult rat brain soluble fraction. A,
Western blot of 20 jtg of adult rat brain soluble fraction with 343-1.
SDS/PAGE was performed in nonreducing conditions. B, As in A, but
SDS/PAGE was performed under reducing conditions. Lane 1,
heparitinase- and chondroitinase-treated; lane 2, chondroitinase-
treated; lane 3, heparitinase-treated; lane 4, untreated.
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Figure 9. Glypican and cerebroglycan protein in the E14 rat
telencephalon. A, Sagittal section through E14 rat telencephalon
stained with 343-1. B, Sagittal section adjacent to that in A, stained
with 521-2. In both section, rostral is down and dorsal is to the left.
Abbreviations: p, preplate; v, ventricular zone. Scale bar: 100 gLm.
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Figure 10. Glypican protein in the adult rat hippocampus. A,
Coronal section through adult rat cerebellum stained with 343-1;
view of CA3 area of the pyramidal cell layer. B, Coronal section
adjacent to that in A, stained with antibodies to KLH (control); view
of CA3 area of the pyramidal cell layer. C, Same section as in A;
view of dentate gyrus. D, Same section as in B; view of dentate
gyrus. Abbreviations: ac, associational and commissural axons; dg,
dentate gyrus; m, mossy fibers; p, pyramidal cell layer. Scale bar:
50 gim.
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be expected to found in layers containing axons and dendrites, while
a membrane polarized to axons would be expected to be localized
only to those layers containing axons. These data suggest that
glypican might be polarized in pyramidal cells of the hippocampus.
Staining of other regions of the adult brain further
demonstrates the localization of glypican to fibers. A high level of
staining was observed in the granule cell layer of the cerebellum
(Fig. 11). As cerebellar granule cells do not express glypican mRNA
(see Fig. 4 in Chapter 2), glypican is likely being supplied by
afferents projecting into the granule layer from cells that do express
glypican. These afferents, known as cerebellar mossy fibers, consist
mainly of axons of the deep cerebellar nuclei (the expression of
glypican mRNA in the deep cerebellar nuclei has not been
determined). Neurons from the locus coeruleus also project to the
cerebellum.
Glypican staining was also observed in the cerebral cortex (Fig.
12A). Scattered staining was seen in the deep layers of the cortex,
where neurons express relatively low levels of glypican. High levels
of staining were observed, however, in layer IV of the cortex, the
cells of which does not express glypican. Afferent projections to
layer IV derive largely from the dorsal thalamus, which expresses
high levels of glypican mRNA; the immunoreactivity in layer IV is
likely to be of thalamic origin.
In the ventrolateral region of forebrain, 343-1 staining was
observed in piriform cortex (Fig. 12B), a region that was found by in
situ hybridization to express glypican. The fiber layer of the
piriform cortex, as well as the cell body layer was stained. The
lateral olfactory tract showed no immunoreactivity for 343-1, which
might be expected as the olfactory bulb, from which the lateral
olfactory tract projects, expresses little glypican (data not shown).
However, the glypican epitope may be undetectable in this region
with our current staining protocol. It has been found that different
procedures, such as different fixations, are required to visualize
Thy-1, another GPI-linked protein, in different regions of the
nervous system (Morris and Grosveld, 1989).
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Figure 11. Glypican protein in the adult rat cerebellum. A, Sagittal
section through adult rat cerebellum stained with 343-1. B,
Adjacent section to that in C, stained with antibodies to KLH
(control). C, Adjacent section to that in A, stained with 343-1 in the
presence of a tenfold molar excess of the peptide antigen.
Abbreviations: g, granule cell layer; m, molecular layer; p, Purkinje
cell layer; w, white matter. Scale bar: 100 ptm.
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Figure 12. Glypican protein in adult rat forebrain. A, Coronal
section through adult rat cerebral cortex at the level of the striatum
stained with 343-1. The cortical layers II-VI are indicated on the
left. B, Coronal section through adult rat piriform cortex at the level
of the striatum stained with 343-1. Open arrow indicates the cell
bodies of the piriform cortex; closed arrow indicates the fiber layer
of the piriform cortex; asterisk indicates the lateral olfactory tract.
Abbreviations: s, striatum; w, white matter. Scale bar: 135 -tm.
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E13.5 mouse embryos were also stained with 343-1. These
experiments demonstrate association of glypican with fibers during
neural development. In the E13.5 mouse embryonic nervous
system, glypican immunostaining is observed in the brainstem (Fig.
13A). This staining has a "tract-like" appearance, and is presumably
associated with ascending and descending fibers that project
through the brainstem. In addition, glypican appeared to be
expressed on spinal commissural axons (data not shown).
Glypican immunostaining was observed in the peripheral and
central roots of E13.5 mouse dorsal root ganglia (Fig. 13B), with
much less staining in the cell body region. This staining pattern is
consistent with polarization of glypican to axons (as opposed to cell
bodies and dendrites). This staining pattern may not be
representative, however, as these experiments were performed with
affinity-purified antibodies from an earlier test bleed than those
used on rat tissue. These antibodies, when used to stain adult rat
hippocampus, did not stain cell bodies as intensely as did the
antibodies from the later test bleed. Furthermore, even if the
pattern is an accurate representation of glypican distribution, the
evidence for polarization is not conclusive. The concentration of
membranes in axons is much greater than in cell bodies; hence, even
a uniformly distributed membrane protein would be stained more
intensely in axons as opposed to cell bodies (Morris and Grosveld,
1989).
Unfortunately, due to the widespread distribution of glypican
in the nervous system, I was unable to address the question of the
axonal polarization of glypican in vivo. Hippocampal neurons
cultured for several day expressed glypican but did not polarize it to
axons; instead, glypican was expressed in an apparently uniform
fashion on cell bodies, dendrites, and axons (Litwack et al., 1994b).
In addition, the staining experiments shown here do not rule out the
possibility that glypican in the roots of dorsal root ganglia is
expressed by Schwann cells; Schwann cells in vitro express a GPI-
linked HSPG that is reported to be glypican (Carey et al., 1993).
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Figure 13. Glypican protein in the developing mouse nervous
system. A, Sagittal section through E13.5 mouse brainstem stained
with 343-1. Rostral is to the right, dorsal is to the top. B, Sagittal
section through E13.5 mouse dorsal root ganglia stained with 343-1.
Abbreviations: cr, central root; d, dorsal root ganglion; pr,
peripheral root. Scale bar: 50 plm.
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Control sections in all staining experiments were stained with
an antiserum to KLH, which was prepared by affinity purification on
a KLH column using the same serum used to purify 343-1. In all
cases no specific pattern of staining was observed (Fig. 10B,D,11B;
data not shown). Furthermore, addition of a tenfold molar excess of
the peptide antigen with respect to antibody concentration
abolished almost all specific staining in adult hippocampus and
cerebellum (Fig. 11C; data not shown). With both controls a low
level of signal was observed in hippocampal cell bodies (e.g., Fig.
10B).
Polarization of cerebroglycan to axons. The axonal polarization of
GPI-linked HSPGs could be addressed more directly by
immunostaining for cerebroglycan, which is more restricted than
glypican in its expression (Stipp et al., 1994). In order to perform
these experiments, an anti-cerebroglycan antiserum, designated
521-2, was prepared as described in Materials and Methods. In
immunoblots of PO rat brain membranes treated with heparitinase,
this antiserum detected a single band at the size previously
observed for the cerebroglycan core protein (Fig. 7B) (Herndon and
Lander, 1990; Stipp et al., 1994)2. As with glypican, the failure of
521-2 to detect a high molecular weight smear (cerebroglycan core
protein with attached HS) is likely due to poor retention of PGs by
nitrocellulose.
Like 343-1, 521-2 gave staining results that were consistent
with the pattern of message expression obtained from in situ
hybridization experiments. First, 521-2 specifically stained nervous
system (Fig. 14A). Second, in E14 rat high levels of staining were
associated with the layer of postmitotic neurons, with little staining
observed in the ventricular zone (Fig. 9B). As with in situ
hybridization experiments, the patterns of glypican and
cerebroglycan staining were complementary, and suggest that at
2 As with glypican, more signal was detected in membranes treated with
heparitinase and chondroitinase than with heparitinase alone. See footnote 1
for discussion.
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Figure 14. Localization of cerebroglycan on nerve fibers. A, Sagittal
section through E19 rat head stained with 521-2. B, Coronal section
through PO rat brain stained with 521-2. C, Transverse section
through E13 rat spinal cord stained with 521-2. Open arrow
indicates spinal commissural axons. Abbreviations: c, hippocampal
commissural fibers; d, dorsal root ganglion; h, hippocampus; i,
internal capsule; iz, intermediate zone; m, motoneurons; o, optic
tract; vr, ventral root. Scale bars: A-B, 200 rpm; C, 50 pm.
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this stage cells may turn off glypican expression as they turn on
cerebroglycan expression.
Like glypican, cerebroglycan is expressed on fibers. In the
developing cerebral cortex, cerebroglycan is associated most heavily
with the intermediate zone (Fig. 14A), which contains developing
cortical and thalamic axons, as well as migrating cortical neurons.
Cerebroglycan is also associated with hippocampal fibers (Fig. 14B)
and the internal capsule (Fig. 14B), which consists of cortical and
thalamic axons. In the developing spinal cord, cerebroglycan is
expressed on commissural axons, axons of motoneurons, and is also
found in the dorsal root ganglia (Fig. 14C).
Like glypican, the pattern of cerebroglycan staining suggests
that it is polarized to axons. In dorsal root ganglia, high levels of
cerebroglycan are found on the peripheral roots, while the cell
bodies express little or no cerebroglycan (Fig. 15A). In order to
conclusively address the polarization of cerebroglycan, the
expression of cerebroglycan in the P21 rat dentate gyrus was
examined. In the dentate gyrus, granule cell axons project through
the hilar region to area CA3 of the pyramidal cell layer (Bayer,
1980; Gaarskjaer, 1986). Granule cell dendrites, however, project in
the opposite direction. As the membrane density of axons and
dendrites are likely to be relatively similar, an antibody that
recognizes a uniformly distributed membrane protein should stain
with similar intensity in both regions. Cerebroglycan staining,
however, was localized to the hilar region; in this region, individual
axons are apparent (Fig. 15B). No significant staining is seen,
however, in the region containing granule cell dendrites. While
occasional fibers in this region expressed cerebroglycan, they did
not appear to be dendritic, and are likely to be the axons of
hippocampal afferents.
In all experiments involving 521-2, control sections stained
with equivalent concentrations of the KLH-specific antibodies
(described above) or commercially obtained nonimmune rabbit IgG
showed no specific pattern of staining.
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Figure 15. Axonal polarization of cerebroglycan, A, Sagittal section
through E14 rat dorsal root ganglia, stained with 521-2. B, Sagittal
section through P21 rat hippocampus, stained with 521-2. Asterisk
indicates hilar region of the dentate gyrus. Abbreviations: d, dorsal
root ganglion; pr, peripheral root. Scale bars, A, 50 Lrm; B, 30 pm.
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Discussion.
A major fraction of cell surface HS in the developing and adult
rat nervous system can be accounted for by GPI-anchored HSPG core
proteins (Herndon and Lander, 1990). The two GPI-anchored core
proteins identified by Herndon and Lander (1990) have been
cloned; one (previously designated M12) is glypican (David et al.,
1990; Karthikeyan et al., 1992; Litwack et al., 1994a), while the
other (previously designated M13) is a related PG, cerebroglycan
(Stipp et al., 1994). The patterns of expression of both cores are
restricted, and suggest that they may have important functions in
brain development and function. In this Chapter, I have further
characterized glypican expression during embryogenesis, and have
localized the protein products via immunohistochemistry, as a
means of further deducing their roles in nervous system
development.
Glypican and cerebroglycan are expressed by different populations
of cells in the early developing nervous system.
In situ hybridization experiments indicate that glypican
expression in the early nervous system is restricted. In the
telencephalon of E14 rat, glypican is found at high levels in the
ventricular zone, a region consisting of proliferating neuroepithelia;
much lower levels of expression are seen elsewhere in the embryo.
The ventricular zone expression of glypican contrasts with the
expression of a related HSPG, cerebroglycan. Little or no expression
of glypican is found in the preplate, a layer of differentiated
neurons lying pial to the ventricular zone, of the developing cerebral
cortex. Cerebroglycan, however, is highly expressed in the preplate
as well as in other layers of differentiated neurons, while little is
expressed in ventricular zones. These patterns of expression are
confirmed by antibody staining experiments, which additionally
demonstrate that glypican is not significantly retained by cells that
have migrated into the preplate.
These complementary patterns of expression suggest that
neurons switch HSPG expression during development.
Neuroepithelial cells may express glypican, and upon differentiation,
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down-regulate glypican and up-regulate cerebroglycan. Switching
between two homologous versions of GPI-anchored HSPGs suggests
that there may be some functional differences between these two
proteins, despite their structural similarity. Glypican, for instance,
may function to act as a receptor for members of the fibroblast
growth factor (FGF) family. Members of the FGF family are
expressed in the ventricular zone, and have been shown to support
survival, proliferation, and differentiation of cultured
neuroepithelial cells (Murphy et al., 1990). Interestingly, the
binding specificity for particular FGFs of at least one HSPG from
cultured neuroepithelial cells of different ages correlates with the
expression of those FGFs in the ventricular zone at those ages
(Nurcombe et al., 1993). As HS is necessary for FGF action (see
Chapter 1 for discussion), HSPGs have been suggested to act as
coreceptors for FGFs (Bernfield et al., 1992). Glypican could act as
such a coreceptor. Furthermore, glypican is associated with other
regions of proliferating cells, such as the hilar region of the dentate
gyrus, which contains precursors to hippocampal granule cells, the
ganglionic eminence, which contains the precursors of striatal
neurons, and the external granule cell layer of the cerebellum,
which gives rise to granule cells. It may be that there is a general
requirement for glypican in neural precursor cells, and that glypican
is so required in order to assist in FGF function in those cells.
While glypican expression suggests a role in FGF function, the
expression of cerebroglycan in newly differentiated neurons
suggests a role in axon outgrowth (Stipp et al., 1994). Cell surface
HS is likely to affect axon outgrowth. Many proteins that promote
axon outgrowth, such as laminin and fibronectin, bind HS. Cell
surface HS has been suggested to mediate neurite outgrowth on
heparin-binding peptides derived from fibronectin (Haugen et al.,
1992a). Furthermore, exogenously added heparin can disrupt axon
guidance in some systems (Wang and Denburg, 1992). Consistent
with the idea that cerebroglycan is important for axon growth is the
finding that it is localized to fibers and, in at least some cells, is
polarized to axons.
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It is unclear if a glypican-cerebroglycan switch is occurring at
other times or locations during neural development. In some
regions, such as the developing cortex, it is likely that at least some
cells are expressing both PGs, as both glypican and cerebroglycan
are expressed in the ventricular zone and the cortical plate.
However, in the absence of double-labeling it is unclear if the same
cells in both regions are expressing both PGs.
Glypican expression is widespread during later stages of neural
development.
At later stages of neural development (E18-P7), glypican
expression is widespread. Glypican is expressed in regions such as
the hippocampus, cerebral cortex, and thalamus, which express
glypican in the adult. In other regions, such as the cerebellum
(granule cell layer) and the corpus striatum, glypican expression is
transient, as these areas express glypican during development but
not in adulthood. While glypican expression is neuronal in the adult,
this study did not distinguish between glial and neuronal expression
during development (most glial cells, however, appear after birth).
The widespread expression of glypican implies that glypican may be
involved in a common process that all neural cells undergo.
One such function may again be the interaction of glypican
with FGFs. As in earlier embryos, glypican at this stage is
coexpressed with members of the FGF family (Gonzalez et al., 1990;
Fu et al., 1991; Wilcox and Unnerstall, 1991) and FGF receptors
(Wanaka et al., 1991; Peters et al., 1993). In addition to their effects
on neuroepithelial cells, FGFs have been shown to have trophic
effects on neuronal survival (Unsicker et al., 1987; Walicke, 1988).
Such correlations can be made in the adult nervous system as well;
glypican is highly expressed in motoneurons, which are dependent
on FGF-5 for survival (Hughes et al., 1993). The loss of glypican
expression during the maturation of some regions may reflect
changes in the requirements of neurons in those regions for trophic
factors.
Glypican may also be important for other functions as well.
Taking the cerebral cortex as an example, glypican expression
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correlates with both stem cells and with postmitotic cells3 .
Furthermore, glypican expression remains on in all layers of P7
cortex, when most cell migration is completed and much axon
growth has occurred (while it is off in layer IV in the adult).
Glypican expression may correlate with other phenomena, however;
changes in neuronal soma, synaptogenesis, and dendritogenesis, for
instance, occur into the fourth week of postnatal life (Miller, 1988).
It may be that glypican, at least in some regions, correlates with
plasticity, as it is expressed by both the cerebral cortex and the
hippocampus.
Axonal expression and polarization of GPI-anchored HSPGs.
The idea that GPI-anchored HSPGs are important for axonal
growth is supported by the expression of glypican and
cerebroglycan on axons4 . In the hippocampus, glypican is found on
the axons of pyramidal cells; glypican is also found in the fiber
tracts of the piriform cortex. In the developing mouse nervous
system, glypican was also observed to be on fibers in the brainstem,
spinal cord (data not shown), and dorsal root ganglia. The
localization of glypican described by Karthikeyan et al. (1994) is
generally consistent with the data presented here.
Other regions gave results which, interpreted in the light of in
situ hybridization experiments, are consistent with axonal
localization of glypican. For instance, glypican was observed in the
fiber layer of the piriform cortex. Glypican immunoreactivity was
also observed in the granule cell layer of the cerebellum. As
granule cells do not express glypican (Litwack et al., 1994a; Chapter
2, this thesis), it is likely that glypican is ;':ovided by mossy fibers,
which consist of axons arising mainly from the deep cerebellar
nuclei, that synapse on granule cells; it is not known, however, if
neurons of the deep cerebellar nuclei express glypican. Glypican in
3 Karthikeyan et al. (1994) suggest that glypican is not found in the cortical
plate during development. It is likely that this interpretation results from
the levels of background observed in their in situ hybridization experiments.
4 Glypican and cerebroglycan can also be detected in membrane preparations
enriched in growth cones or synaptosomes (Kumbasar et al., 1994; Litwack et
al., 1994b).
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the granule cell layer could also be derived from the locus coeruleus,
which does express glypican (Litwack et al., 1992a; see Fig. 4 in
Chapter 2). A similar interpretation can explain the
immunoreactivity observed in the cerebral cortex. While glypican
was observed in the deep and the superficial layers of the cortex,
both of which express glypican, it was also, however, observed in
layer IV, which does not express significant glypican in the adult.
Glypican in layer IV is likely to be provided by thalamic neurons;
the thalamus expresses glypican in the adult, and thalamic neurons
synapse on layer IV cortical neurons. In both the cerebellum and
the cerebral cortex, glypican was not observed in white matter,
contrary to what might be expected if afferents are providing axonal
glypican. This may be due to myelination, which could either
exclude glypican or mask the glypican epitope. It should also be
noted that the immunoreactivity in cerebellum and cerebral cortex
could be the result of glypican remaining from development, when
both these regions expressed glypican. Turnover rates measured for
GPI-linked PGs in vitro suggest that this is probably not the case.
Turnover rates of GPI-linked PGs in vivo are not known, however.
The patterns of immunoreactivity observed suggested that
glypican may be polarized at least to some extent to axons. In the
adult hippocampus, for instance, glypican was observed in the
associational and commissural fibers, with lower levels in the mossy
fiber layer. As pyramidal cells, which are the source of associational
and commissural axons, project dendrites into the mossy fiber layer
(Bayer, 1980), the lower levels of immunoreactivity there suggests
that glypican could be polarized to axons and not dendrites.
However, hippocampal cell bodies, both in the pyramidal cell layer
and in the dentate gyrus, also contained significant
immunoreactivity. This was observed in other regions, such as the
piriform cortex, where both the fiber layer and the cell bodies were
immunoreactive.
Results in developing mouse were also consistent with axonal
polarization of glypican. In dorsal root ganglia, glypican was seen at
high levels in central and peripheral roots, but at much lower levels
in cell bodies. While consistent with axonal localization, this pattern
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could also be explained by Schwann cell expression of glypican.
Some work suggests that glypican may be expressed in Schwann
cells. It should be noted however, that much of this work was done
in cultured Schwann cells. As most, if not all, adherent cells in vitro
express glypican (Lories et al., 1992), it may be that glypican
expression is induced in cultured cells. In addition, Carey et al.
(1993) use an antibody that was raised to a full length glypican
fusion protein. Unlike the anti-peptide antibody used here, which
was raised to an epitope not conserved among family members, the
anti-fusion protein antibody may recognize a glypican homolog.
Unfortunately, the widespread distribution of glypican made it
difficult to design an experiment to definitively test the idea that
glypican is polarized to axons. Cerebroglycan, however, is much
more restricted in development, and is also observed on fibers.
Staining of P21 dentate gyrus shows that cerebroglycan is in fact
polarized in those cells.
The GPI-anchor may be a signal in some cells for axonal
polarization. Many GPI-anchored proteins are expressed on axons.
In epithelial cells, the GPI-anchor has been shown to target proteins
to the apical surface (Lisanti et al., 1989). While it has been
proposed that a similar mechanism occurs in neurons, with the axon
being the equivalent of the apical surface, analysis of the expression
of several GPI-linked proteins demonstrates that such a
generalization is not possible. While as noted above, some proteins
(such as F3/Fll1 and TAG-1 [Dodd et al., 1988; Furley et al., 1990;
Faivre-Sarrailh et al., 1992]) are found on axons, some are found on
dendrites and cell bodies, such as Thy-1 (Xue et al., 1990; Xue et al.,
1991). In fact, the compartmentalization of Thy-i changes during
neuronal differentiation. The present study indicates that some
cells can polarize cerebroglycan, and some cells may also polarize
glypican. Furthermore, some cells, such as cultured hippocampal
neurons, do not polarize cerebroglycan and glypican (Kumbasar et
al., 1994; Litwack et al., 1994b). In vitro studies, however, often
give results different from those obtained in vivo. Hippocampal
neurons in culture polarize Thy-1 to axons (Dotti and Simons, 1990;
Dotti et al., 1991), while hippocampal neurons in vivo do not (Xue et
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al., 1990; Xue et al., 1991). It has been proposed that, as in
epithelial cells (Lisanti et al., 1989), the GPI-linkage is a signal that
allows neuronal cells to sort the proteins to axons (Dotti and Simons,
1989; Dotti et al., 1990). It may be that the GPI-linkage acts as a
sorting signal in those neurons that do polarize glypican and
cerebroglycan. However, it is possible that these two proteins are
selectively stabilized on axons, perhaps by binding to other proteins
or by being less susceptible to degradation.
The polarization of GPI-anchored HSPGs to axons may serve
several functions. As discussed above, cell surface HS is likely to
play a role in axon outgrowth. In addition, neuronal response to
growth factors may require localized cell surface HSPGs. The trophic
factors to which neurons respond, as well as the signals which
influence axon growth and guidance, are often target-derived. For
instance, motoneuron survival is likely to depend on muscle-derived
FGF-5 (Hughes, et al., 1993). The expression of glypican on axons
would thus be necessary in order for motoneurons to receive FGF-5
induced signals.
Nonneural expression of glypican.
Glypican is widely expressed in tissues outside the nervous
system. Particularly high levels of glypican expression are
associated with differentiated osteoblasts, although it is unclear at
what stage of differentiation glypican is turned on. No glypican
expression was observed in chondrocytes at any stage. As in the
brain, glypican might bind growth factors. Several heparin binding
growth factors have been purified from bone which act as mitogens
for osteoblasts (Hauschka et al., 1986).
Clusters of glypican-expressing cells were observed in bone
marrow. These could be bone marrow stroma or hematopoietic cells
(either stem cells or differentiated cells). The clustered pattern of
expression might be suggestive of hematopoietic cells, possibly
clones. HS in the stroma compartmentalizes factors such as GM-CSF
and IL-3 (Gordon et al., 1987; Roberts et al., 1988). These factors
support the proliferation of hematopoietic cells, which must actually
contact stroma in order to respond to them. HS in this case is
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thought to localize these factors and present them to responsive
cells. Glypican could function in the stroma to compartmentalize
these factors, or, on the surfaces of hematopoietic cells, it could
influence the action of these factors.
Glypican is also expressed in hair follicles. Due to the single
time point observed, it is unclear if expression is regulated during
the hair follicle growth cycle. Interestingly, glypican in hair follicle
to is a potential regulator of FGF action. FGF-5 is expressed in hair
follicles and is likely to regulate the transition of the hair follicle
from anagen (hair growth) to catagen (hair follicle regression), as a
targeted mutation in the FGF-5 gene results in delayed progression
into catagen (Hebert et al., 1994).
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Chapter 4. Decorin in the developing nervous system:
floor plate expression and netrin-binding properties.
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Introduction
Decorin is a chondroitin sulfate/dermatan sulfate proteoglycan
(CS/DSPG) with a core protein of about 38 kD (Krusius and Ruoslahti,
1986; Day et al., 1987; Li et al., 1992; Scholzen et al., 1994). It
belongs to a family of small interstitial proteoglycans whose other
members include another CSPG, biglycan (Fisher et al., 1989; Neame
et al., 1989), and two keratan sulfate (KS) PGs, fibromodulin
(Oldberg et al., 1989) and lumican (Blochberger et al., 1992a). The
core proteins of all these PGs are characterized by a leucine-rich
repeat sequence, a motif that is thought to be involved in mediating
protein-protein interactions (Kobe and Deisenhofer, 1994). Decorin
binds via its core protein to a variety of molecules, including
fibrillar collagens (Hedbom and Heinegard, 1989; Bidanset et al.,
1992; Hedbom and Heinegard, 1993), fibronectin (Lewandowska et
al., 1987; Schmidt et al., 1991; Winnemoller et al., 1991),
thrombospondin (Winnemoller et al., 1992), and TGF-B (Yamaguchi
et al., 1990).
Decorin is usually found in regions containing collagen, such as
skin, tendon, and bone, and decorin is typically associated with
collagen fibrils in those regions. The binding of decorin to collagen
decreases the rate of collagen fibril formation, and results in smaller
fibrils (Vogel et al., 1984; Hedbom and Heinegird, 1989). Recent
results suggest, however, that decorin is also expressed in the
developing mouse nervous system along the ventral midline of the
spinal cord (Scholzen, et al., 1994). This pattern suggests that
decorin may be expressed by floor plate. Interestingly, there is
little evident pericellular matrix in floor plate, and no obvious
collagen fibrils.
The floor plate of developing spinal cord plays an important
role in axon growth and guidance (Fig. 1). Commissural neurons,
which are located in the dorsal spinal cord, extend axons toward the
floor plate. Commissural axons at this stage are thought to be
growing in response to diffusible factors released by the floor plate,
as axons from dorsal spinal cord explants grow towards floor plate
explants in culture (Tessier-Lavigne et al., 1988; Placzek et al.,
1990). In addition, commissural exons will grow towards ectopic
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Figure 1. The role of the floor plate in the growth of spinal
commissural axons. A, Commissural axons originate from neurons in
the dorsal spinal cord and project along the circumference of the
spinal cord. B, At approximately the level of the ventral
motoneurons, commissural axons grow directly towards the floor
plate, likely in response to diffusible signals released by the floor
plate (Tessier-Lavigne et al., 1988; Placzek et al., 1990). C, Once at
the midline, axons grow underneath the floor plate; this growth
might be influenced by contact-mediated guidance cues from the
floor plate or the basement membrane (Chang and Lagenaur, 1990;
Klar et al., 1991; Yaginuma et al., 1993). On the contralateral side of
the floor plate, axons turn perpendicularly and grow in the direction
of the head.
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floor plate (Yaginuma and Oppenheim, 1991), and commissural
axons in are misguided when floor plate is disrupted (Bovolenta and
Dodd, 1991). Once at the floor plate, commissural axons pass just
underneath it, and might at this point be guided by contact-
mediated interactions with the floor plate (Chang and Lagenaur,
1990; Klar et al., 1991; Yaginuma et al., 1993). After passing
underneath the floor plate the axons then turn and extend along the
rostrocaudal axis of the spinal cord.
Recently, a protein that can act as a chemotropic factor for
spinal commissural axons in vitro has been purified from brain
(Kennedy et al., 1994; Serafini et al., 1994). This protein, netrin-1, is
expressed in the floor plate at a time when commissural axons are
believed to be responding to floor plate-derived signals in vivo.
While it has been argued that netrin-l acts as a diffusible factor,
this protein is found in association with membrane fractions of
homogenized brain, and little netrin-1 is found in the conditioned
medium of cells expressing exogenous netrin-1 cDNA (although
netrin-1 can be removed from cultures of all such cells with high
salt washes). These data, along with the homology that has been
observed between netrin-1 and laminin, suggest that netrin-1 may
be part of the extracellular matrix. Given this possibility, the
mechanism by which gradients of netrin-1 are established in vivo--
if such gradients exist--may not be simple.
Netrin-1 can promote in vitro neurite outgrowth from explants
of dorsal spinal cord on its own (Kennedy et al., 1994; Serafini et al.,
1994). However, its activity is increased in the presence of netrin
synergizing activity (NSA), a fraction obtained during the
purification of netrin-1. The existence of NSA implies that other
factors may play a role in netrin-mediated neurite outgrowth, and
that netrin-1 is likely to interact with these factors in the nervous
system.
The expression of decorin along the ventral spinal cord
suggests that netrin-1 could be one of several proteins, including
other proteins of the extracellular matrix, whose expression
overlaps with that of decorin. Further characterization of decorin
expression shows that the decorin message and protein product are
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expressed in the floor plate at a time when netrin-1 mediated
chemotropic growth of commissural axons is occurring. Binding
studies indicate that decorin binds to netrin-1 and that this binding
is likely to involve the core protein. These data suggest that decorin
interacts with netrin-1 in vivo, and raise the possibility that decorin
plays a role in netrin-1 mediated neurite outgrowth.
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Materials and Methods.
Materials. Bovine skin decorin was the gift of Dr. L. Rosenberg
(Montefiore Medical School). The mouse decorin cDNA and rabbit
anti-mouse decorin antiserum were provided by Dr. R. lozzo
(Thomas Jefferson University). The mouse bone morphogenetic
protein (BMP)-6 cDNA was provided by Dr. B. Hogan (Vanderbilt
University). Extracts of COS cells expressing the netrin-1 transgene
and 9E10 supernatant were provided Dr. M. Tessier-Lavigne (UCSF).
125 I-labelled urokinase was provided by M. Herndon (MIT).
Heparin, chondroitin sulfate A, and chondroitin sulfate B (dermatan
sulfate) were obtained from Sigma.
RNA probes. A full length mouse decorin cDNA (Scholzen et al.,
1994) in pT7/T3al9 (Gibco) was digested with AccI, and
digoxigenin-labelled antisense RNA (correspond to bases 1105-1372
of mouse decorin) was synthesized by transcription with T7 RNA
polymerase (Genius 4 Kit; Boehringer Mannheim). A digoxigenin-
labelled RNA probe corresponding to BMP-6 was produced by EcoRI
digestion of mouse BMP-6 in pBluescript (Stratagene) followed by
transcription with T7 RNA polymerase (this probe corresponds to
bases 395-0 of mouse BMP-6).. A digoxigenin-labelled sense RNA
(control) was produced by BssHII digestion of mouse BMP-6 in
pGEM-3 (Promega), and transcription with T7 RNA polymerase (this
probe corresponds to bases 0-395).
In situ hybridization. CD-1 mouse embryos were dissected and
fixed overnight with 4% paraformaldehyde/PBS. Embryos were
then cryoprotected by incubating overnight at 40 C in 5%
sucrose/PBS, and then 15% sucrose/PBS. 20 4m cryostat sections
were collected onto Probe-On Plus slides (Fisher).
As a pretreatment for hybridization, sections were fixed in 4%
paraformaldehyde/PBS for one hour on ice. Sections were washed
three times 5 minutes each in PBT (PBS/0.1% Tween-20). After
bleaching twice for 45 minutes each in 5:1 (v/v) methanol:30% H202,
sections were rehydrated stepwise into PBT. Sections were treated
with 10 mg/ml proteinase K in PBT for 10 minutes at room
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temperature, and fixed for 5 minutes at room temperature with 4%
paraformaldehyde/0.2% glutaraldehyde/PBS. Sections were washed
twice in PBT, treated with 0.1% sodium borohydride, and washed
twice again in PBT.
Sections were incubated in hybridization buffer (50%
deionized formamide, 5X SSC [pH 4.5], 50 pag/ml yeast RNA, 50 jtg/ml
heparin, 1% SDS) for one hour at 58 0 C. Sections were then
hybridized overnight at 58 0 C in hybridization buffer containing 1
gg/ml digoxigenin-labelled RNA probes.
After hybridization, sections were washed twice 15 minutes
each at 60 0 C in WI (50% formamide, 5X SSC [pH 4.5], 1% SDS) and
twice for 5 minutes at room temperature in W2 (0.5 M NaC1, 10 mM
Tris-HCI [pH 7.5], 0.1% Tween-20). RNase treatment was for 30
minutes at 37 0 C with 20 m g/ml RNase A in W2. Sections then were
washed once for five minutes at room temperature in W2, once for
five minutes at room temperature in W3 (50% formamide, 2X SSC
[pH 4.5]), and twice for 30 minutes at 600 C in W3.
For antibody binding, sections were washed three times five
minutes each at room temperature in TBST (0.14 M NaCI, 2.7 mM
KC1, 25 mM Tris-HCI [pH 7.5], 0.1 % Tween-20, 5 mM levamisole),
and then blocked for one hour at room temperature with 10% heat-
inactivated sheep serum (Sigma) in TBST. Sections were incubated
overnight at 40 C in a 1:2500 dilution of alkaline phosphatase-
conjugated anti-digoxigenin antibody (Genius 3 Kit; Boehringer
Mannheim) (preabsorbed to mouse brain acetone powder [Sigma]) in
1% sheep serum. The next day, sections were washed extensively in
TBST, and then several times in NTMT (0.1 M NaC1, 0.1 M Tris-HCI
[pH 9.5], 50 mM MgCl2, 0.1% Tween-20, 5 mM levamisole). Sections
were developed with 4.5 ml NBT and 3.5 ml X-phosphate each
(Genius 3 Kit; Boehringer Mannheim) per ml of NTMT. Reactions
were stopped by washing in PBT, and slides were coverslipped using
Gelmount (Biomeda).
Immunohistochemistry. Immunohistochemistry for decorin was
performed as described in Chapter Three, using a 1:100 dilution of a
rabbit anti-decorin polyclonal antibody. Staining was developed
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using horseradish peroxidase. Control sections were stained only
with secondary antibody, and failed to give any specific pattern of
immunoreactivity (data not shown).
Affinity chromatography. 1 mg of decorin was dialyzed into 0.1 M
Hepes (pH 8.0) and coupled to Affigel-15 (Biorad) as per
manufacturer's instructions. 1 mg crystalline BSA (Calbiochem) was
resuspended in the same buffer and coupled to a separate sample of
Affigel-15 as above. Columns were washed extensively in 20 mM
Tris-HCI (pH 7.4 @ 40C) containing a) 0.14 M NaCi, b) 0.14 M NaCI, 1
mg/ml BSA (Calbiochem), c) 1 M NaC1, and then in 0.1 M sodium
acetate (pH 4). Columns were reequilibrated in 20 mM Tris-HCI (pH
7.4 @ 4°C), 0.14 M NaC1.
1 M NaCi extracts of COS cells which express a netrin-1
transgene fused to a myc epitope (Serafini et al., 1994) were diluted
into 0.14 M NaCI and passed over the columns. After washing with
20 mM Tris-HCI (pH 7.4 @ 40 C), 0.14 M NaCI, columns were eluted
with 20 mM Tris-HCI (pH 7.4 @ 40 C), 1 M NaCI. NaCI was added to
samples to IM, and samples, including a series of dilutions of the
original cell extract, were applied to Immobilon-P (Millipore) using a
dot blot apparatus (Biorad).
Filters were blocked with 5% nonfat dry milk in TBST (50 mM
Tris-HCl [pH 7.5], 0.15 M NaCl, 0.2% Tween-20) for one hour, and
then incubated with 9E10 supernatant (an anti-myc monoclonal
antibody) including 1% milk for about 1-2 hours at room
temperature. Filters were then incubated in a 1:5000 dilution of a
horseradish-peroxidase conjugated anti-mouse Ig antibody
(Amersham), developed by enhanced cheri'iluminescence
(Amersham), and exposed to XAR-5 film (Kodak). Film images were
scanned and pixel intensity calculated over defined areas (specified
to include individual samples), with background calculated for the
same areas subtracted.
Western blotting. COS cell extracts were diluted into 0.2 M NaCI, and
separated by 7.5% SDS/PAGE. Samples were then
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electrophoretically transferred to Immobilon-P (Millipore). Filters
were probed with 9E10 as described above.
Affinity coelectrophoresis (ACE). ACE was performed as previously
described (Lee and Lander, 1991) with the following modifications.
Lanes and well were placed as shown in Fig. 2. All experiments
were done in the absence of CHAPS. 1% low melting point agarose
(Gibco BRL) was cast onto GelBond (FMC). Descending concentrations
of decorin or glycosaminoglycans were cast with agarose into the
lanes, and 1 M NaCI extracts containing netrin-1 were diluted to
NaCi concentrations below 0.2 M, and cast in 1% agarose into the
well. After electrophoresis, the gel was removed from the gelbond
and equilibrated in 20 mM Tris-HCI (pH 7.4 @ 40 C), IM NaCl for 15
minutes. The gel was blotted to Immobilon-P by capillary transfer
in the same buffer and probed with 9E10 as described above.
For ACE experiments using commercial GAG preparations,
those GAGs were resuspended in ACE running buffer, diluted, and
cast into lanes. Decorin-derived DS was prepared by treating
decorin with 0.1 N NaOH/0.1M NaBH 4 for 90 minutes at 44 0 C to
cleave the dermatan sulfate chain from the decorin core protein.
The reaction was stopped with 0.5 M ammonium formate/50 mM
HC1, and the entire mixture was then diluted and cast into lanes. For
ACE of decorin-derived DS versus 125 1-labelled urokinase, the
urokinase was embedded in the long well and the DS in the lanes;
after electrophoresis, the gel was dried and exposed on a
phosphorimager (Molecular Dynamics).
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Figure 2. Affinity coelectrophoresis. A, A horizontal 1% agarose gel
is cast with 9 lanes and 1 well perpendicular to the lanes.
Descending concentrations of a test sample, in these experiments
decorin of GAGs, are cast into the lanes with agarose. COS cell
extracts containing netrin-1 are cast into the well with agarose. B,
Netrin-1 migrates towards the anode during electrophoresis.
However, the test samples in these experiments migrate towards the
anode with much greater rates than does netrin-1. Hence, during
electrophoresis the test samples encounter netrin-1. At
concentrations of the test sample above its Kd for netrin-1, binding
occurs, and the mobility of netrin-1 is increased. At concentrations
below Kd, no binding occurs, and thus there is no change in the
mobility of netrin-1. The mobilities of netrin-l at the various
concentrations of test sample can be used to calculate the Kd of the
test sample for netrin-1 (Lee and Lander, 1991; Lim et al., 1991).
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Results.
Expression of decorin in the floor plate.
In situ hybridization experiments were performed in order to
determine the pattern of decorin expression in the developing spinal
cord. In the embryonic day 11 (Ell) mouse spinal cord, high levels
of expression were observed in the floor plate (Fig. 3A), consistent
with an earlier report of decorin expression (Scholzen et al., 1994).
Lower levels of decorin expression could be observed in the
developing connective tissue surrounding the spinal cord.
Immunostaining with anti-decorin antibodies demonstrated that the
decorin protein product is also present in the floor plate (Fig. 3B).
No signal above background was observed in any other tissue (with
the exception of the surrounding connective tissue), suggesting that
there is little: diffusion of decorin away from the floor plate.
In the E13 spinal cord, high levels of decorin expression
persisted (Fig. 3C). Expression was limited, however, to the lateral
margins of the floor plate; the medial floor plate was negative for
decorin expression. As younger floor plate cells are found more
laterally and older cells more medially (M. Tessier-Lavigne, personal
communication), these results suggest that decorin expression might
be transient in cells of the floor plate. In addition, at E13 higher
levels of expression could be observed in the surrounding
connective tissue, and in the skin, than at Ell. This pattern of
expression persisted in the E15 spinal cord (Fig. 3D). The decorin-
expressing cells appear at E15 to have moved dorsally with respect
to cells in earlier spinal cord; this is the result of continual
accumulation of axons beneath the floor plate.
In situ hybridization experiments were also done using a RNA
probe for bone morphogenetic protein (BMP)-6 (also known as Vgr-
1), a member of the TGF-B family of proteins. BMP-6 expression in
the floor plate has previously been reported (Jones et al., 1991); in
that study, BMP-6 expression was localized to the cells adjacent to
the floor plate. In this study, BMP-6 expression was observed
directly in the floor plate, and, like decorin, seemed to be transient
(Fig. 4A-C). While BMP-6 expression was observed in the medial
floor plate, the lateral margins had higher levels of signal. It may
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Figure 3. Floor plate expression of decorin. A, Transverse section
through Ell mouse spinal cord hybridized with an antisense decorin
RNA probe. Arrow indicates floor plate. B, Transverse section
through Ell mouse spinal cord stained with an anti-decorin
polyclonal antibody. C, Transverse section through E13 mouse
spinal cord hybridized as in A. D, Transverse section through E15
mouse spinal cord hybridized as in A. Scale bar: 100 ptm.
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Figure 4. BMP-6 expression in the developing spinal cord., A,
Transverse section through Ell mouse spinal cord hybridized with a
BMP-6 antisense RNA probe. B, Transverse section through E13
mouse spinal cord hybridized with a BMP-6 antisense RNA probe. C,
Transverse section through E15 mouse spinal cord hybridized with a
BMP-6 antisense RNA probe. Abbreviations: f, floor plate; r, roof
plate. Scale bar: 100 grm.
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be that the previously reported pattern of BMP-6 expression was
due to the use of younger mice than those used in the experiments
presented here. As in the previous report, BMP-6 expression was
observed in the roof plate at all developmental stages checked (Fig.
4A-C).
Comparison of BMP-6 and decorin expression in the floor plate
suggests that BMP-6 is expressed slightly earlier. At Ell, when
decorin is expressed in the middle of the floor plate, BMP-6
expression appears to be more lateral (Fig. 4A). At E13 and E15,
ventral BMP-6 expression has significantly declined, and is confined
to the medial floor plate (Fig. 4B,C). In all cases, the sense (control)
strand of BMP-6 gave no signal anywhere in the spinal cord. As
BMP-6 is similar to TGF-f3, a protein which binds decorin (Yamaguchi
and Ruoslahti, 1988), it may be that BMP-6 in the floor plate binds
decorin. This hypothesis is currently being tested in collaboration
with A. Yang (UROP).
Binding of decorin to netrin-1.
As decorin expression is coincident with that of netrin-1, a
floor plate-derived chemoattractant for spinal commissural axons
(Serafini et al., 1994; Kennedy et al., 1994), we tested decorin for its
ability to bind to netrin-1. High salt extracts of COS cells expressing
recombinant netrin-1 fused to a myc epitope (r-netrin) were used
for these experiments. One band of the molecular weight previously
observed for netrin-1 (Serafini et al., 1994) was observed in
Western blots of the extract probed with the monoclonal
supernatant 9E10 (which recognizes the myc epitope) (Fig. 5). A
small amount of high molecular weight material was observed at the
interface between the stacking and separating gel; this is likely to be
aggregated r-netrin. When these extracts were passed over decorin
conjugated to Affigel, approximately 10-20% of the recoverable r-
netrin was eluted with 1 M NaCl (as measured by immunoreactivity
to the myc epitope) (Fig. 6). In contrast, no r-netrin could be eluted
with 1 M NaCl from a similar column prepared with BSA. These
data show that r-netrin can bind to decorin.
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Figure 5. Western blot of r-netrin. A Western blot of a 1 M NaCI
extract of COS cells which express a netrin-1 transgene. N=r-netrin.
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Figure 6. Affinity chromatography of r-netrin, COS cell extracts
containing r-netrin were passed over decorin-Affigel or BSA-Affigel
columns; the columns were then eluted with 1 M NaCi and collected
into five fractions. R-netrin eluted with 1 M NaCI is expressed as
the percentage of total r-netrin recovered. Roughly 50% of the r-
netrin applied to each column was recovered (likely due to
nonspecific and irreversible absorption of netrin-1 to both columns).
The dot blot of the 1 M NaCl fractions is shown for each column; no
signal was detected in the eluates from BSA-Affigel columns, even
after long exposures. ND, not detectable.
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In order to further characterize this binding, the affinity of r-
netrin for decorin was measured by ACE. Horizontal agarose gels
were cast, and samples embedded, as indicated in Fig. 2. While r-
netrin migrates towards the anode, the mobility of decorin towards
the anode is greater. Thus, decorin will encounter r-netrin during
electrophoresis. At concentrations of decorin near or above the Kd
of r-netrin for decorin, a shift in the mobility of r-netrin occurs (Fig.
7A). The Kd calculated from a plot of R versus decorin concentration
is 91.5 nM (Fig. 9A).
Binding of netrin-1 to glycosaminoglycans (GAGs).
Netrin-1 is known to bind heparin, as heparin affinity
chromatography was one of the methods used to purify netrin-1
(Serafini et al., 1994). It thus seemed likely that Kd measured for r-
netrin and decorin reflected an interaction between r-netrin and the
DS chain present on decorin. The affinities of r-netrin for various
commercial GAGs were measured. R-netrin had a Kd of 85 nM for
heparin (Fig. 7B,9B), 1.4 jtM for CS B (porcine skin DS) (Fig. 9B; data
not shown), and 2.8 pM for CS A (Fig. 9B; data not shown). While
heparin bound well to r-netrin, the affinities of CS, and particularly
of DS, were lower than expected.
As the decorin-derived DS in our particular sample could have
had a different fine structure than the DS obtained commercially, we
measured the affinity of the DS from decorin for r-netrin. The DS
chain was detached from decorin by B-elimination, and the mixture
of DS and decorin core protein was loaded into the ACE gel. This
procedure allowed for the measurement of the affinity of r-netrin
for decorin-derived DS, and not for the decorin core protein, as the
core protein has a low mobility and thus would not encounter r-
netrin during electrophoresis (data not shown). No shift in r-netrin
was observed below DS concentrations below 1 pM DS (Fig. 8A).
Above this concentration, the r-netrin mobility was retarded in the
gel; this is in contrast with results obtained both with intact decorin
and with commercially available DS (see below), which caused an
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Figure 7. ACE of r-netrin. Decorin (A) and heparin (B) vs. r-netrin.
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Figure 8. ACE of B-eliminated decorin, A, B-eliminated decorin vs.
r-netrin. B, B-eliminated decorin vs. urokinase.
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Figure 9. Measurement of K_ of r-netrin for decorin and GAGs. A,
Plot of R vs. decorin concentration. --_ - decorin; --- A- B-
eliminated decorin. In this case, R is displayed as the absolute value
of R, as R has negative values due to the retardation of netrin-1 with
6-eliminated decorin. B, Plot of R vs. GAG concentration. --- *---
heparin; --- A--- chondroitin sulfate; -- U- dermatan sulfate. Kd's
for GAGs were calculated using the following Mr's: heparin, 10,000;
chondroitin sulfate, 17,500; dermatan sulfate, 25,000.
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increase in the mobility of netrin-11. Using this shift as a
measurement of binding, the Kd of 1-eliminated DS was about 1.4
iLM (Fig. 8A,9B). The same sample had a Kd of about 1.2 tM for
urokinase (Fig. 8B; data not shown); as this is similar to previously
measured Kd's for CS and urokinase (M. E. Herndon and A. D. Lander,
unpublished results), it is unlikely that the DS was damaged during
8-elimination. The affinity of r-netrin for commercial DS is
consistent with that measured for decorin-derived DS; in fact, it is
likely that commercial DS, being derived from skin, was originally a
component of decorin. These data imply that the affinity of the DS
chain of decorin for r-netrin does not account for the affinity of
intact decorin for r-netrin, and suggests that the decorin core
protein is involved in the interaction of decorin with r-netrin.
11t is unclear why r-netrin in this experiment was retarded. It may be that
there is something inherently different about the DS chain derived from this
sample of decorin and the other GAGs tested. For instance, it may be that
decorin-derived DS is longer, and thus can bind multiple r-netrin molecules,
decreasing the mobility. It may also be, however, that the decrease in
mobility was an artifact of the experiment. Since the reagents used to
perform the B-elimination were not removed before ACE, it may be that those
reagents were able to encounter r-netrin and affect its mobility. In a
previous experiment where the concentration of decorin-derived DS was
below 1 ltM, no shift of r-netrin was observed (data not shown), consistent
with the interpretation that decorin-derived DS has a significantly lower
affinity for r-netrin than intact decorin.
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Discussion.
Decorin expression is transient in the floor plate. It has recently
been shown that decorin, a small matrix PG usually associated with
collagen fibrils, is expressed along the ventral developing nervous
system; this data suggested that decorin might be expressed by the
floor plate (Scholzen et al., 1994). In situ hybridization experiments
on transverse sections through developing spinal cord confirm these
results. Furthermore, these experiments suggest that decorin
expression in the floor plate may be transient. As the spinal cord
develops (E13 and E15), decorin expression is confined to the lateral
margins of the floor plate. The medial floor plate expresses high
levels of decorin at Ell, but is negative at E13 and 15. As newer
floor plate cells are added to the lateral margins, it may be that the
older floor plate cells which, after a period, have down-regulated
decorin expression.
Interestingly, BMP-6, a member of the TGF-B family, is
expressed in the floor plate at the same time as decorin (Jones et al.,
1991). This expression is also apparently transient, as it is has
virtually disappeared by E15. BMP-6 colocalizes well with decorin
at Ell, when both messages overlap in floor plate expression.
Compared to decorin, BMP-6 at this time seems to be more highly
expressed along the lateral margins of the floor plate; earlier studies
in younger mice found that BMP-6 expression was confined to cells
on either side of the floor plate (Jones et al., 1991).
By analogy to TGF-B, this pattern of expression suggests a
possible mode of regulation of decorin expression in the floor plate.
TGF-B has been shown to induce decorin expression in some cells
(Bassols and Massagu6, 1990). It is possible that BMP-6, a member
of the TGF-B family, may perform such a function in the floor plate.
In addition, decorin can bind TGF-B and inhibit the effects of TGF-1
on growth (Yamaguchi and Ruoslahti, 1988; Yamaguchi et al., 1990),
Hence, it is also possible, by analogy, that decorin in turn regulates
BMP-6 action in the floor plate. As a first step in testing these
hypotheses, I am currently attempting in collaboration with A. Yang
(UROP) to measure the binding of decorin to BMP-6.
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Decorin and the extracellular matrix of floor plate.
As predicted by in situ hybridization, immunohistochemistry
demonstrates the presence of the decorin protein product in the
floor plate. These experiments demonstrate that decorin is largely
confined to the floor plate, as no signal above background was
detected in other regions of the spinal cord. It has been suggested
that other proteins expressed in the floor plate may accumulate in
the underlying basal lamina or on passing commissural axons (Klar
et al., 1991).
The retention of decorin protein in the floor plate may be
related to its ability to bind other proteins known to be in the floor
plate. Type II collagen and fibronection, both of which bind decorin
with Kd's of approximately 20 nM in solid phase assays (Hedbom
and Heinegird, 1989; Schmidt et al., 1991; Winnem6ller et al., 1991),
have been reported to be expressed in the floor plate (Cheah et al.,
1991; Shiga and Oppenheim, 1991; Su et al., 1991). We have shown
in this report that decorin binds netrin-1, which is highly expressed
in the floor plate. Other ligands for decorin in the floor plate are
possible. F-spondin, a distant homolog of thrombospondin, is
expressed in the floor plate (Klar et al., 1991); thromobspondin has
been shown to interact with decorin with a Kd of about 5 nM in solid
phase assays (Winnem6ller et al., 1992). Likewise, as discussed
above, BMP-6 is expressed in the floor plate (Jones et al., 1991).
The floor plate expression of decorin is unusual in that decorin
is usually expressed in association with collagen fibrils. While both
type II collagen message and protein, which can bind decorin, is
present in the floor plate (Cheah et al., 1991; Su et al., 1991), no
fibrils have been reported; there is not even much evident
pericellular matrix (Yaginuma et al., 1991). Nevertheless, the
expression of multiple proteins, with known or potential affinities
for decorin, suggests that there may be an organized matrix in the
floor plate, and that decorin may be important for that organization
(Fig. 10). One function of such a matrix could be to influence, by
contact-mediated guidance mechanisms, the growth of commissural
axons as they pass underneath the floor plate and then turn towards
the head (Chang and Lagenaur, 1990; Klar et al., 1991; Yaginuma et
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Figure 10. Interactions of decorin with proteins expressed in the
floor plate. Some of these interactions have been demonstrated;
others are hypothesized by analogy with known decorin-binding
proteins (see text), and are indicated by question marks.
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al., 1993). Such a matrix could play a role analagous to that of
basement membranes, which can support the growth of peripheral
axons.
Decorin may play a role in netrin-mediated neurite outgrowth.
Decorin, either alone or as a component of an organized
extracellular matrix, could also play a role in controlling the
diffusion of factors out of the floor plate. Diffusible factors have
been proposed to guide the growth of commissural axons towards
the floor plate (Tessier-Lavigne et al., 1988; Placzek et al., 1990).
Recently, a floor plate-expressed protein that acts as a
chemoattractant for commissural axons in vitro, netrin-1, has been
identified (Serafini et al., 1994; Kennedy et al., 1994). Decorin can
bind to netrin-1, and both proteins are expressed in the floor plate
at a time when commissural axons are extending. This suggests that
decorin could regulate netrin-1 activity. Such regulation could
involve enhancement or inhibition of axon growth or guidance,
controlling the diffusion of netrin-1, or localization of netrin-1 to the
floor plate.
The existence of netrin synergizing activity (NSA), which can
increase the effect of netrin-1 on axon outgrowth (Serafini et al.,
1994), suggests that netrin-1 interacts with other factors in vivo.
Decorin is one one factor that is likely to bind netrin-1 in vivo, and
there are likely to be others. The high affinity of netrin-1 for
heparin suggests that netrin-1 may also bind to heparan sulfate PGs
in the spinal cord. Interestingly, netrin-1 is found in membrane
fractions of brain homogenates and netrin-1-expressing COS cells.
Netrin-1 can, however, be extracted from the surface of cells with
high salt. Such interactions might occur through PGs on the cell
surface. The binding of netrin-1 to HSPGs, either on cell surfaces or
in the basement membranes surrounding floor plate, may also help
organize the matrix of floor plate.
These interactions are unexpected, given the proposed
function of netrin-1 as a diffusible factor. Characterization of the
effects of decorin on netrin-1 activity will likely be important in
understanding the manner in which netrin-1 affects axon growth
175
and guidance, and how gradients of netrin-1 are established in the
spinal cord.
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Chapter 5: The functions of proteoglycan core proteins in
the development of the nervous system.
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1. Introduction.
PGs, as proteins which bear GAG chains, have the potential to
affect a number of functions involving GAG binding proteins. GAGs
can accelerate reactions, stabilize complexes of proteins and
receptors, act as reservoirs of proteins, induce conformational
changes, and participate in extracellular matrix structure. Binding
of GAGs to proteins in some cases can directly mediate processes
such as cell adhesion.
It is clear as well that PG core proteins are in many cases vital
for PG function. The existence of a large number of proteins, with
diverse structures, that can bear GAGs, and the in vivo regulation of
the expression of these proteins, suggests that these proteins play
important functional roles. If the only function of the PG core
protein is to bear and present GAG chains, one might expect to find
only one or a few cores. The diversity of core proteins may reflect
different functions that core proteins may have; the expression of
different core proteins may thus allow different responses upon
interacting with GAG-binding proteins. The regulated in vivo
expression of core proteins may reflect specific requirements of cells
or tissues for particular PGs, and thus further suggests that PG core
proteins have important functions.
2. Multiple PG core proteins as the basis for diverse PG
functions.
The existence of multiple families of PG core proteins, each
with different structures and properties, and each possessing
multiple homologs, suggests that the PG core proteins play
important roles in PG function. Cell surface HS, for example, can be
provided by two families of cell surface PGs, to each of which belong
four members. One class is the syndecan family of transmembrane
HSPGs; the other is the glypican family of GPI-linked HSPGs. The
existence of these two families raise the question of why eight
distinct gene products falling into two classes are required to
provide cell surface HS.
It is likely, based on an examination of the structures of the
two families, that syndecans and glypicans are involved in different
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functions. Syndecan is a transmembrane protein with a cytoplasmic
domain that, being conserved between family members and
between species, has been predicted to interact with the
cytoskeleton (Bernfield et al., 1992). This prediction has been
supported by colocalization studies of syndecan-1 and syndecan-4
with F-actin, and the localization of syndecan-4 to focal adhesions
(Woods and Couchman, 1992; Carey et al., 1994; Woods and
Couchman, 1994). These properties, likely mediated by the
cytoplasmic domain, may make syndecan a particularly good core
protein for providing cell surface HS for functions involving cell
adhesion.
Glypican, on the other hand, is GPI-linked, and thus is unlikely
to interact directly with the cytoskeleton. The GPI-linkage,
however, is predicted to impart other properties on glypican. These
might include high lateral mobilities in cell membranes (Chan et al.,
1991) localization to specialized membrane domains (Lisanti et al.,
1994), and the ability to directly signal through intracellular protein
tyrosine kinases (Stefanova et al., 1991; Thomas and Samelson,
1992; Rudd et al., 1993). Thus, glypican may induce different
cellular responses than syndecan in response to interactions with
heparin-binding proteins.
The extracellular domains of these two classes also suggest
different functions. The extracellular domain of syndecan is poorly
conserved among other family members and between species (with
the exception of the GAG attachment sites) (Bernfield et al., 1992),
suggesting that the syndecan extracellular domain may have little
function beyond the anchoring of GAGs. Glypican and its family
members, however, are more conserved, both between members
and between species (Stipp et al., 1994). In particular, the
conservation of fourteen extracellular cysteines suggests that
glypican and its family members may have a conserved three
dimensional structure. This conserved structure may in turn reflect
a common function. Such a function could include the binding of the
glypican core protein to other proteins in the membrane; however,
no such interaction has yet been described.
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3. Functional implications of the restricted expression of
PGs.
That core proteins are important is supported by the fact that
PG core proteins are often expressed distinctly in spatially and
temporally restricted patterns. Such restrictions in expression can
suggest possible functional roles for a protein.
For instance, expression studies suggest that glypican may act
as a coreceptor for one or a number of heparin-binding proteins. In
the early developing nervous system glypican expression is
associated with neuroepithelia (Chapter 3). At this time, neural
stem cells are proliferating, and beginning to give rise to
differentiated neurons. These processes are likely to be regulated
by growth factors, and both expression data and in vitro assays
suggest that these growth factors include members of the FGF family
(Walicke, 1988; Murphy et al., 1990). The coexpression of glypican
with members of the FGF family at this time in development, along
with the requirement of HS for the physiological actions of FGF,
suggest that glypican may be acting as a coreceptor at this time. In
fact, glypican could be acting as a coreceptor for FGFs throughout the
lifetime of the nervous system. In adulthood, glypican is highly
expressed in neurons that either express members of the FGF
family, or that require FGF for survival (Elde et al., 1991; G6mez-
Pinilla et al., 1992; Hughes et al., 1993). There is also the possibility
that glypican regulates the function of other heparin-binding
proteins instead or as well.
The pattern of glypican contrasts to that of the homolog
cerebroglycan. While glypican is associated with neural precursors
in the early nervous system, cerebroglycan is associated with
differentiated neurons. It is unclear if this complementary pattern
of expression persists throughout development. While glypican is
expressed in the internal and external granule cell layers of the
developing cerebellum, it is not known whether glypican is
associated with newly differentiated neurons, as is cerebroglycan.
Expression of both PGs seems to overlap in the ventricular zone and
cortical plate of developing cerebral cortex, but it is unclear if the
two PGs are expressed by the same cells--the pattern could be
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explained by a switch in expression or by overlapping expression.
It may in general be that 1) cells express glypican, switch to
cerebroglycan upon differentiation, and then switch back to
glypican, or 2) cells express glypican, leave glypican on after turning
on cerebroglycan following differentiation, and then turn
cerebroglycan off, leaving glypican on or shutting it off depending
upon other factors. In order to address these questions, it will be
necessary to perform careful double-labeling analysis of both PGs.
Despite the differences in expression, localization of the
protein products for these two PGs suggests some commonality.
Both glypican and cerebroglycan are localized to nerve fibers and
axons, and in some cases they may be selectively expressed on
axons. In combination with expression data, these data suggest that
cerebroglycan plays a role in axon outgrowth. Glypican may be
expressed on axons for other reasons; if its role is to act as a growth
factor receptor it may be required on axons in order to allow
neuronal response to target-derived signals.
Protein localization data, in combination with preliminary
results showing that glypican is found in biochemical preparations
of synaptosomes (Kumbasar et al., 1994; Litwack et al., 1994b),
further suggest a possible synaptic role. Other PGs are found at
synapses such as agrin or Cat-301; it may be that PGs are important
for synaptic function or specificity. Further characterization of
glypican's localization, including ultrastructural studies, may shed
more light on glypican's function.
4. Interactions of PG cores with other proteins.
Their complementary patterns of expression in the early
nervous system suggest that glypican and cerebroglycan perform
different functions. The structural similarities between the two
proteins, however, makes it unclear what those functions are. That
there are functional differences, however, is further suggested by
preliminary evidence that glypican and cerebroglycan isolated from
neonatal rat brain have different affinities for fibronectin (which is
also expressed in the neonatal rat brain), presumably as a result of
different GAG structures (Herndon and Lander, 1992). Further
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characterization of the binding affinities of these PGs for various
heparin-binding proteins may elucidate function.
In addition to examining the characteristics of glypican-
associated GAGs, it will also be important to search for proteins that
bind to the glypican core protein. No such proteins are yet known.
Nevertheless, recent evidence suggests that both glypican and
cerebroglycan can associate with protein tyrosine kinases
(Kumbasar et al., 1994; Litwack et al., 1994b). Establishing the
identity of these kinases, and whether they interact directly or
indirectly through other proteins with cerebroglycan and glypican,
may also aid in identifying functions for these cores.
Other PGs are known to be interact with proteins through their
cores. The decorin core proteins binds, likely via its leucine-rich
repeats, to collagen type I. This binding is functionally important, as
it affects both the rate of fibrillogenesis and the final morphology of
collagen fibrils. Other decorin homologs, however, exhibit different
binding properties. Biglycan does not bind to collagen; fibromodulin
does bind to collagen, but at a different site on the fibril than does
decorin (Scott and Haigh, 1988; Hedbom and Heinegird, 1993).
Hence, different cores within the same family can exhibit different
binding abilities, and such differences might be one reason why
multiple family members have evolved.
Testable theories as to the functions of individual PGs can be
formed by investigations of both expression and binding of
individual core proteins. For instance, I have shown in Chapter 4
that decorin binds to netrin-1, a chemoattractant for spinal
commissural axons, and that this interaction is likely to involve the
core protein. The specific expression of decorin in the floor plate at
a time when commissural axons are presumably responding to floor
plate-derived netrin-1 suggests that decorin could affect the activity
of netrin-1. Experiments are currently in progress to test the effect
of decorin on netrin-l's axon outgrowth-promoting activity (in
collaboration with M. Galko and M. Tessier-Lavigne, UCSF).
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5. Conclusion.
It may be that particular functions can be assigned to
individual PG core proteins. The studies presented in this thesis
demonstrate that certain PGs are regulated in their expression in the
nervous system, and suggests that this regulation is likely to reflect
the functional roles of these molecules. Further characterization of
nervous system expression, as well as investigation into the
interactions of these PGs with other proteins, is necessary in order
to further elucidate the functions of the individual PG core.
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Appendix 1: Expression of glypican in myeloma cells leads
to loss of heparan sulfate synthesis on PG core proteins.
184
Introduction.
Many of the functions of proteoglycans (PGs) can be attributed
to the function of the attached glycosaminoglycan (GAG). One
example of this is the attachment of myeloma cells to collagen type I
(Sanderson et al., 1992; Sanderson et al., 1994). Myeloma cell
adhesion to collagen type I is directly related to the affinity of cell
surface HS on each cell type for collagen type I; this cell surface HS
is attached to syndecan-1, which is the major, if not the only, HSPG
in these cells. The higher affinity HS of MPC-11 myeloma cells can
support cell adhesion on collagen type I, while the lower affinity HS
of P3 myeloma cells cannot. These differences in affinity are related
to differences in sulfation position; while HS from both cells has the
same overall levels of O-sulfation, the higher affinity MPC-11 HS has
more 4-O-sulfate, a modification apparently involved in high
affinity interactions with collagen.
Nevertheless, it is possible that the core protein of syndecan-1
play a role in the adhesion of MPC-11 cells. The conservation of the
cytoplasmic domain between members of the syndecan family has
led to the suggestion that syndecan can interact with the
cytoskeleton. Indeed, members of the syndecan family have been
found to colocalize with F-actin, and to participate in focal adhesions
(Woods and Couchman, 1992; Carey et al., 1994; Woods and
Couchman, 1994). It may be that this property supports cell
adhesion via attached HS chains.
Glypican, a GPI-linked HSPG, is likely to have different
properties on the cell surface. GPI-linked proteins are predicted to
have high lateral mobilities in cell membranes (Chan et al., 1991).
They also have been reported to be localized to specialized
membrane domains (Lisanti et al., 1994), and to interact with
protein tyrosine kinases (Stefanova et al., 1991; Thomas and
Samelson, 1992; Rudd et al., 1993). Glypican on cell surfaces, then,
might lead to different effects than syndecan.
It may also be that a role of PG core protein is to specify the
structure of its attached HS. No evidence exists that this occurs,
however. Little difference is seen among different cores in the
affinity of their HS for antithrombin III (Mertens et al., 1992). In
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fact, even the same PG can have attached to it both high and low
affinity chains for antithrombin III (Kojima et al., 1992). While one
report suggests that different cores from the same source have
different affinities for FGF-2, these differences have not been
related to HS structure (Aviezer et al., 1994).
In order to investigate the different functional properties of
glypican and syndecan, both in terms of HS structure and effects on
cell adhesion, cells were infected with a retrovirus possessing a
glypican transgene. Some initial differences were observed in terms
of the type of GAG attached to the protein. Surprisingly, however,
high levels of glypican expression lead to a complete loss of
glycanation with HS, but not CS, in these cells. Analysis of such cells
may give insight into the mechanisms of HS synthesis.
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Materials and Methods.
Infection of P3 cells with glypican. A full length rat glypican cDNA
(Litwack et al., 1994a; Chapter 2, this thesis) was inserted into the
EcoRI site of the retroviral vector pMV7 (Kirschmeier et al., 1988).
This vector uses an LTR promoter for transgene expression, and
contains a selectable neo marker. W2 cells were transfected with the
glypican containing construct using Lipofectamine (Gibco BRL) and
selected in the presence of 1 mg/ml G418 (Gibco BRL). Viral
conditioned medium from these y2 trans cell lines was used to
reinfect W2 cells, thus creating W2 inf cell lines. Viral conditioned
medium from the W2 inf lines were used to infect P3 myeloma cells
(gift of R. Sanderson, U. of Arkansas). Infected P3 cells were grown
in the presence of 0.5 mg/ml G418 and individual lines were cloned
by the method of limiting dilutions on mouse macrophage feeder
layers. The relative levels of glypican expression were determined
by fluorescence-activated cell sorting (FACS) (Cancer Center, M. I. T.)
using the affinity purified anti-glypican polyclonal antiserum 343-1
at 2.5 mg/ml and a 1:500 dilution of fluorescein-conjugated goat
anti-rabbit secondary antibody (Vector).
PG purification. PG purifications and iodinations were performed as
previously described (Herndon and Lander, 1990).
Immunoprecipitations were performed as described in Chapter 2,
except that GAG lyase digestion were performed before
immunoprecipitation, and protein A-antibody complexes were
boiled directly in sample buffer before analysis by SDS/PAGE.
Labeled PGs and immunoprecipitates were analyzed by 9%
SDS/PAGE (Laemmli, 1970).
SDS extracts. 5 x 106 cells were washed two times in cold HBSS.
Cells were resuspended in 50 mM Tris [pH 8 @ 40 C], 1% SDS, and
boiled for 10 minutes. After centrifuging for 5 minutes,
supernatants were removed and saved at -800 C until further use.
In some cases, cells were treated for 30 minutes at 370 C with 0.5
U/ml phosphoinositide-specific phospholipase C (PIPLC; Boehringer
Mannheim) and centrifuged before extraction of cell supernatant
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and cell pellets with SDS. Some samples were reduced by boiling
with 10 mM dithiothreitol and then alkylating with 50 mM
iodoacetamide before Western blotting.
Enzymatic treatments. SDS extracts were diluted 1:10 into 1% Triton
X-100. Heparitinase and chondroitinase digestions were performed
as described previously (Herndon and Lander, 1990). For cleavage
of N-linked sugars, samples in 1% Triton X-100 and 10% 13-
mercaptoethanol were treated with 5 U/ml N-glycosidase F
(Boehringer Mannheim) at 370 C overnight.
Western blots. Western blots were performed as described in
Chapter 3, using 5 mg/ml 343-1.
Cell staining. Cells were washed in 5% goat serum/5% fetal calf
serum in HBSS. Cells were then incubated for 30 minutes in 2.5
mg/ml 343-1, washed again, and incubated in a 1:50 dilution of
rhodamine-conjugated goat anti-rabbit secondary antibody (Vector)
for 30 minutes. After washing extensively, cells were fixed in 10%
formalin for 5 minutes, washed in PBS, and then mounted with 50%
glycerol on glass slides. In some cases, cells were treated with 0.5
U/ml PIPLC, 10 mM phytic acid, or 1 mg/ml heparin for thirty
minutes on ice, or in the case of PIPLC, at 370 C. Mock samples were
treated identically, but these reagents were omitted.
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Results.
In order to create cell lines that coexpress glypican and
syndecan-1, P3 myeloma cells were infected with a retrovirus
containing a glypican transgene. After selecting for successful
infectants, PGs were purified from the initial pool of neo resistant
cells (designated P3inf), as well as from uninfected control cells (P3).
Purified PGs were treated with GAG lyases and subjected to
electrophoresis. In PGs purified from P3inf cells, both the syndecan
and glypican core proteins were present at the molecular weights
expected; only syndecan was detected in PGs purified from control
P3 cells (Fig. 1). Syndecan core protein appeared in response to
chondroitinase alone, while glypican core protein appeared in
response to heparitinase alone. This suggests that there is a fraction
of glypican that possesses only HS, and there is fraction of syndecan
that possesses only CS. Immunoprecipitation from the purified PGs
of infected cells using 343-1 yielded a band the size of glypican in
lanes where sample had been treated with heparitinase; otherwise,
a higher molecular weight smear was seen, typical of intact PG (Fig.
1). It is unclear from these experiments whether glypican in P3
cells possesses any CS.
Clonal lines were isolated from P3inf by the method of limiting
dilutions. 7 independent clones were grown up for analysis. FACS
analysis indicated that all lines had significantly higher glypican
expression than P3inf (Fig. 2).
The line expressing the highest levels of glypican as measured
by FACS, F6, was selected for further analysis. PGs were purified
from F6 and analyzed by immunoprecipitation with 343-1 and
SDS/PAGE. Surprisingly, no glypican was detected, either in lanes
containing total PGs, or in lanes containing 343-1
immunoprecipitates (Fig. 3). Syndecan-1 could still easily be
detected. However, syndecan-1 derived from F6 behaved
differently than syndecan-1 from P3 cells or P3inf cells. In these
last two lines, the amount of syndecan-1 seemed greater when
treated with heparitinase and chondroitinase compare to when
treated with chondroitinase alone (Fig. 1); the amount of syndecan-1
from F6 cells seemed equivalent in the two lanes (Fig. 3). Syndecan-
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Figure 1. Analysis of PGs from P3inf cells. 1, 125I-labeled PGs
purified from uninfected P3 cells. 2, 125I-labeled PGs purified from
P3inf cells. 3, 12 5I-labeled PGs purified from uninfected P3 cells
immunoprecipitated with 343-1. 4, 125 1-labeled PGs purified from
P3inf cells immunoprecipitated with 343-1. Samples were analyzed
on a 9% SDS/polyacrylamide gel. Abbreviations: U, untreated; H,
heparitinase-treated; C, chondroitinase-treated; HC, heparitinase-
and chondroitinase-treated.
190
2I I
- HU
( .:
II
3
I I
4
HC C iu
'I,
*0 a* fl t4o a
• t4
1
IL G H U
206 -
105 -
71 -
44-
Figure 2. FACS analysis of clones derived firom P3inf cells. Cells
were sorted based on fluorescence intensity after staining with 343-
1. Individual clones are labeled C3, G5, F6, etc. "no ab" signifies that
no primary or secondary antibody was added to cells before FACS
analysis. "no pri. ab" signifies that no primary antibody was added
to cells before FACS. "Mean fluorescence" indicates the channel of
average fluorescence for that sample.
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Figure 3. Analysis of PGs from F6 cells. 1, 125I-labeled PGs purified
from F6 cells. 2, 12 5I-labeled PGs purified from F6 cells
immunoprecipitated with 343-1. Analysis and abbreviations as in
Fig. 1.
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1 is normally a hybrid HS/CSPG, but in F6 cells it behaved as a pure
CSPG. If this change was due to a loss of HS synthesis, it followed
that glypican, an HSPG, might be completely unglycanated in these
cells.
To test this hypothesis, F6 cells, as well as C3 cells (the lowest
expressing line obtained by FACS), were extracted with SDS, and
untreated or heparitinase- and chondroitinase-treated samples were
analyzed by Western blotting with 343-1. Significant levels of
immunoreactivity were detected both in the presence and absence
of GAG lyases (Fig. 4A,B). Two bands were detected at roughly the
size of glypican, one of about 66 kD and the other of about 57 kD.
The apparent molecular weights of these bands increased upon
reduction and alkylation, as would be expected for glypican--the
upper band now migrated at about 71 kD, and the lower band
migrated at about 64.5 kD. These two bands represent glypican
species that have been differentially N-glycosylated, as the two
bands are lost and one band of approximately 65 kD appears upon
treatment with N-glycosidase F (as compared to 68 kD for the lower
band of the doublet in this gel) (Fig. 5). Glypican in fact has two
potential N-linked glycosylation sites; this may lead to differential
glycosylation in P3 cells and the appearance of two bands.
Additionally, material from F6 contained a significant amount
of high molecular weight material that disappeared upon reduction.
The C3 line, which expresses less glypican, only had a small amount
of high molecular weight material. It is likely that this high
molecular weight material represents disulfide-bonded aggregates
of glypican. No glypican-like signal is seen in uninfected P3 cells,
although in Western blots of P3 cells with -43-1 there is usually a
faint band at about 150 kD. The presence of this band does not
affect any of the interpretations of data offered in this Appendix.
Thus, a large fraction of glypican from both C3 and F6 is
apparently completely unglycanated. In fact, no glypican was ever
detected in standard PG preparations from F6 cells1 suggesting that
1 As PG purification usually include ion-exchange chromatography, which isolates PGs
based on the high negative charge of their attached PGs, unglycanated glypican would be
expected to be lost at this step.
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Figure 4. Western blots of C3 and F6 extracts with 343-1. 15 mg of
SDS extracts of all cell lines treated as described were analyzed by
Western blotting with 343-1. A, Lanes 1,3,5, nonreduced samples;
lanes 2,4,6, reduced and alkylated samples. Lanes 1,2, uninfected
P3 cells; lanes 3,4 C3 cells; lanes 5,6, F6 cells. B, Lanes 1,3,5,
untreated samples; lanes 2,4, heparitinase- and chondroitinase-
treated samples. Lane 1, uninfected P3 cells; lanes 2,3, F6 cells;
lanes 4,5, P3inf cells.
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Figure 5. Two glypican glycoforms are produced in P3 cells, 1, 15
mg of SDS extract of C3 cells treated with N-glycosidase F. 2, 15 mg
of SDS extract of C3 cells, untreated.
199
1 2
214-
111-
74-
46-
aro
all the glypican in these cells is unglycanated. The lack of
glycanation, however, is not an inherent defect in P3 cells, as P3inf
contained glycanated glypican (Fig. 1). In addition, Western analysis
of SDS extracts of P3inf, as performed above, shows that, while there
is a little unglycanated glypican, GAG lyase treatment results in a
large increase in signal due to glypican core. As P3inf is a
heterogeneous cell population, the glycanated and unglycanated
glypican species are likely arising from different subpopulations of
cells.
The lack of glycanation does not seem to be the result of
improper processing of glypican by P3 cells. A large majority of the
C3 glypican can be collected from medium after treatment of C3
cells with PIPLC. No detectable glypican remains in the SDS extracts
of the treated cells (Fig. 6). Similarly, 343-1 stains the surface of F6
cells, and this staining can be abolished by pretreatment of cells
with PIPLC (Fig. 7) but not heparin or phytic acid (data not shown),
which are reported to remove peripheral membrane HSPGs (Carey
and Evans, 1989). Hence, glypican seems to be properly processed
and sorted to the cell surface in these cells.
It was unclear, however, if the failure to be glycanated was a
glypican-specific defect or if it was a global defect in these cells.
35 S04-labeling experiments indicated that syndecan-1 from F6 cells
is predominantly substituted with CS (R. Sanderson, personal
communication). Thus, it is likely that overexpression of glypican in
P3 cells has resulted in a global defect in HS synthesis.
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Figure 6. Effects of PIPLC on glypican in C3 cells., Western blot of
15 mg C3 fractions with 343-1. Lanes 1,3,5,7,9, untreated; lanes
2,4,6,8, heparitinase- and chondroitinase-treated. Lanes 1,2, SDS
lysate of C3 cells; lanes 3,4, supernatant of C3 cells treated with
PIPLC; lanes 5,6, supernatant of cells mock-treated with PIPLC;
lanes 7,8, SDS extract of C3 cells after PIPLC treatment; lane 9, SDS
extract of F6 cells.
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Figure 7. Staining of F6 cells with 343-1. A,C, F6 cells stained with
343-1. C,D, F6 cells stained with secondary antibody only. E,F, F6
cells mock-treated with PIPLC. G,H, F6 cells treated with PIPLC.
A,B,E,F, fluorescence. C,D,G,H, phase-contrast. Scale bar: 50 ptm.
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Discussion.
I have reported here the surprising finding that the
overexpression of glypican in P3 myeloma cells leads to a loss of
total HS synthesis in the cell. While overexpression of PG cores in
cells can lead to changes in GAG synthesis (Shworak et al., 1994b),
no effect of this magnitude has yet been reported.
It is unclear, however, if the phenotypes observed in these
two lines are the result of some type of clonal aberration, the
general result of overexpression of proteins in P3 cells, or the effect
of threshold levels of PG core protein expression. In order to
demonstrate that this effect is due to the overexpression of a PG
core, and that the levels of core are related to the phenotype, I am
serially infecting P3 cells with glypican in order to create a set of P3
lines with sequentially increasing levels of glypican core protein
expression. An inverse monotonic relationship between the levels
of glycanated glypican and number of rounds of infection the cells
have undergone will serve to establish the role of core protein
expression in this phenotype.
Establishing such a relationship may give insight into the
mechanisms controlling HS synthesis. One interpretation of the
phenotype shown here is that there are multiple factors controlling
HS initiation or elongation, possibly existing as a complex, and that
excess core protein competes these factors away from the complex
by binding them individually. However, overexpression
experiments indicate that, at least in the case of syndecan-
4/ryudocan, GAG synthetic enzymes appear to be in excess
(Shworak et al., 1994b). Nevertheless, some of the HS synthetic
activities, in particular those activities invo';'ing HS modifications,
are likely to be coupled (Bame et al., 1991). Overexpression of
ryudocan can lead to the uncoupling of this reactions, even though
HS synthesis in general proceeds and overall levels of modifications
are not greatly affected (Shworak et al., 1994b). If such an effect is
occurring with this phenotype, it will be necessary to know at what
point HS synthesis is failing. I thus plan to analyze any HS or HS
precursor that may be remaining on glypican.
These cells, particularly the C3 cells, are likely to be useful in
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the study of interactions of the glypican core protein with other
molecules. Such studies can be confounded by the presence of GAG,
and even GAG lyase treatment leaves some fragment of GAG
attached to the core. C3 cells could be used as a source of glypican
core protein that has insignificant quantities of GAG attached, and as
a source of GAG-free glypican for experimental use.
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